



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schwab *et al.*

Confirmation No.: 7264

Application No.: 09/830,972

Group Art Unit: 1647

Filed: September 24, 2001

Examiner: Nichols, Christopher J.

For: NUCLEOTIDE AND PROTEIN  
SEQUENCES OF NOGO GENES  
AND METHODS BASED  
THEREON

Attorney Docket No.: 10200-003-999  
(CAM No. 606518-999002)

DECLARATION OF PROF. DR. MARTIN E. SCHWAB AND  
DR. MAIO S. CHEN UNDER 37 C.F.R. 1.132

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

We, MARTIN E. SCHWAB and MAIO S. CHEN, hereby state and declare as follows:

1. Martin E. Schwab is a citizen of Switzerland residing at Berninastrasse 96, Zurich, Switzerland, CH-8057. Maio S. Chen is a citizen of the United States residing at Langaegertenstr. 25, Zollikberg, Switzerland, CH-8125.
2. We are co-inventors of the subject matter described and claimed in the above-identified patent application.
3. Martin E. Schwab is currently Professor of Neuroscience at the Institute for Brain Research of the University of Zurich, the assignee of the present application.
4. Martin E. Schwab is a co-author of the publication entitled "Identification and Characterization of a Bovine Neurite Growth Inhibitor (bNI-220)" (hereinafter "Spillmann et al."), Journal of Biological Chemistry, 1998, 273(30):19283-19293.

5. The contributions of the other co-authors of Spillmann et al., Adrian A. Spillmann, Christine E. Bandtlow, Friedrich Lottspeich, and Flavio Keller, to the work described in Spillmann et al. was as follows: Adrian Spillmann performed protein extractions from central nervous system myelin material, protein purification of Nogo protein from central nervous system myelin material, and different bioassays, such as 3T3 NIH fibroblasts spreading assays, neurite outgrowth assays, and collapse of growth cone assays. Christine Bandtlow performed the Western blot experiment with the IN-1 antibody. Friedrich Lottspeich performed the microsequencing of bNI-220 derived peptides. Flavio Keller performed initial purification of proteins from central nervous system myelin material using column chromatography. These individuals worked under Martin E. Schwab's direction and, while co-authors of Spillmann et al., are not co-inventors of the subject matter that is described and claimed in the above-identified patent application.

6. We declare further that all statements made in this Declaration of our own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Aug. 17<sup>th</sup>, 2004  
DATE

M. E. Schwab  
MARTIN E. SCHWAB

\_\_\_\_\_  
DATE

\_\_\_\_\_  
MAJO S. CHEN

Express Mail No.: EV 452 773 001 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schwab *et al.*

Confirmation No.: 7264

Application No.: 09/830,972

Group Art Unit: 1647

Filed: September 24, 2001

Examiner: Nichols, Christopher J.

For: NUCLEOTIDE AND PROTEIN  
SEQUENCES OF NOGO GENES  
AND METHODS BASED  
THEREONAttorney Docket No.: 10200-003-999  
(CAM No. 606518-999002)DECLARATION OF PROF. DR. MARTIN E. SCHWAB AND  
DR. MAIO S. CHEN UNDER 37 C.F.R. 1.132Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

We, MARTIN E. SCHWAB and MAIO S. CHEN, hereby state and declare as follows:

1. Martin E. Schwab is a citizen of Switzerland residing at Berninastrasse 96, Zurich, Switzerland, CH-8057. Maio S. Chen is a citizen of the United States residing at Langaegertenstr. 25, Zollikberg, Switzerland, CH-8125.
2. We are co-inventors of the subject matter described and claimed in the above-identified patent application.
3. Martin E. Schwab is currently Professor of Neuroscience at the Institute for Brain Research of the University of Zurich, the assignee of the present application.
4. Martin E. Schwab is a co-author of the publication entitled "Identification and Characterization of a Bovine Neurite Growth Inhibitor (bNI-220)" (hereinafter "Spillmann et al."), Journal of Biological Chemistry, 1998, 273(30):19283-19293.

5. The contributions of the other co-authors of Spillmann et al., Adrian A. Spillmann, Christine E. Bandtlow, Friedrich Lottspeich, and Flavio Keller, to the work described in Spillmann et al. was as follows: Adrian Spillmann performed protein extractions from central nervous system myelin material, protein purification of Nogo protein from central nervous system myelin material, and different bioassays, such as 3T3 NIH fibroblasts spreading assays, neurite outgrowth assays, and collapse of growth cone assays. Christine Bandtlow performed the Western blot experiment with the IN-1 antibody. Friedrich Lottspeich performed the microsequencing of bNI-220 derived peptides. Flavio Keller performed initial purification of proteins from central nervous system myelin material using column chromatography. These individuals worked under Martin E. Schwab's direction and, while co-authors of Spillmann et al., are not co-inventors of the subject matter that is described and claimed in the above-identified patent application.

6. We declare further that all statements made in this Declaration of our own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

\_\_\_\_\_  
DATE

\_\_\_\_\_  
MARTIN E. SCHWAB

*Aug. 17-2004*  
\_\_\_\_\_  
DATE

*Maio S. Chen*  
\_\_\_\_\_  
MAIO S. CHEN

Express Mail No.: EV 452 773 001 US  
POWER OF ATTORNEY

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schwab *et al.*

Confirmation No.: 7264

Application No.: 09/830,972

Group Art Unit: 1647

Filed: September 24, 2001

Examiner: Nichols, Christopher J.

For: NUCLEOTIDE AND PROTEIN  
SEQUENCES OF NOGO GENES AND  
METHODS BASED THEREON

Attorney Docket No.: 10200-003-999

REVOCATION AND POWER OF ATTORNEYCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The University of Zurich hereby revokes any and all previous powers and appoints:

☐ Practitioners at Customer Number 20583

as their attorneys or agents to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

☐ The above mentioned Customer Number.☐ Firm or Individual Name:Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 326-3939

I am the:

- ☐ Applicant/Inventor  
☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
(Statement under 37 CFR 3.73(b) is applicable)

**Statement Under 37 C.F.R. 3.73(b)**

The University of Zurich states that it is:

- ☒ the assignee of the entire right, title, and interest; or  
☐ an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:

- ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office on September 24, 2001; Reel 012208; Frame 0503.

ASSIGNEE: University of Zurich

Date: August 18, 2004

Signature: 

Typed Name: Prof. Dr. A. Borbély

Vice President Research

Position/Title: \_\_\_\_\_

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

- ☒ Total of 1 form is submitted.

05/19/99  
13639 U.S. PRO  
1000

BROWDY AND NEIMARK, P.L.L.C.  
ATTORNEYS AT LAW  
PATENT AND TRADEMARK CAUSES  
SUITE 300  
419 SEVENTH STREET, N W  
WASHINGTON, D. C. 20004-2299  
TELEPHONE (202)-628-5197

ALVIN BROWDY (1917-1998)  
SHERIDAN NEIMARK  
ROGER L. BROWDY  
ANNE M. KORNBAU  
NORMAN J. LATKER  
NICK BROMER\*  
(\*PA BAR ONLY)

OF COUNSEL  
IVER P. COOPER

May 19, 1999

05/19/99  
13639 U.S. PRO  
1000  
TEL (202) 737-1128  
(202) 393-1012

E MAIL  
BrwdyNmrk@digizen.net  
PATENT AGENT  
ALLEN C. YUN, PH.D.

Hon. Assistant Commissioner for Patents  
Box Patent Appln  
Washington, D.C. 20231

RE: New Patent Application in U.S.  
Applicant(s): Michal EISENBACH-SCHWARTZ et al.  
Title: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC  
ANTIGENS AND THEIR USES  
Atty's Docket: EIS-SCHWARTZ=2

Sir:

Attached herewith is the above-identified application for Letters Patent including:

- [X] Specification (75 pages), claims (6 pages) and abstract (1 page)
- [X] 31 Sheets Drawings (Figures 1-23)
- [X] Formal [ ] Informal
- [X] The inventors of this application are:  
Michal EISENBACH-SCHWARTZ, an Israeli citizen of 5 Rupin Street,  
Rehovot 76353, Israel;  
Irun R. COHEN, a U.S. citizen of 11 Hankin Street,  
Rehovot 76354, Israel;  
Pierre BESKREMAN, an Israeli citizen of Moshav Sitriya 76834, Israel;  
Alon MOSONEGO, an Israeli citizen care of Ben-Yosef,  
Kfar Hanoar Ben-Shemen 73112, Israel; and  
Gila MOALEM, an Israeli citizen of 27 Bosel Street,  
Rehovot 76405, Israel.
- [X] Return Receipt Postcard (in duplicate)

The following statements are applicable:

- [X] The benefit under 35 USC §119 is claimed of the filing date of: Israel Application No. 124550 in Israel on May 19, 1998. A certified copy of said priority document is attached.
- [X] The present application is a continuation-in-part of prior application no. PCT/US98/14715, filed July 21, 1998, and is also a continuation-in-part of prior application no. 09/218,277, filed December 22, 1998.
- [ ] Incorporation By Reference. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied herewith, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- [ ] The undersigned attorney of record hereby appoints associate power of attorney, to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith to:

- [X] In accordance with 37 CFR 1.53(a) and (b), it is respectfully requested that a serial number and filing date be assigned to this application as of the date of receipt of the present papers. In accordance with the present procedures of the U.S. Patent and Trademark Office, an executed Declaration and the filing fee for the present application will be filed in due course.
- [X] No authorization is given for charging the filing fee at the present time. However, at such time that the declaration is filed, but not before, you are authorized to charge whatever excess fees are necessary (including the filing fee and any extension of time fees then due) to Deposit Account 02-4035, if any such fees due are not fully covered by check filed at that time.
- [X] The attorneys of record in this application will be Sheridan Neimark, Reg. No. 20,520; Roger L. Browdy, Reg. No. 25,618; Anne M. Kornbau, Reg. No. 25,884; Norman J. Latker, Reg. 19,963; Iver P. Cooper, Reg. No. 28,005; \*Allen C. Yun, Reg. No. 37,971 and Nick Bromer, Reg. No. 33,478 (\*Patent Agent). Please send all correspondence with respect to this case to:

BROWDY AND NEIMARK, P.L.L.C.  
419 Seventh Street, N.W.  
Washington, D.C. 20004

Please direct all telephone calls to Browdy and Neimark at (202) 628-5197.

- [X] The Commissioner is hereby authorized to credit any overpayment of fees accompanying this paper to Deposit Account No. 02-4035.

Respectfully submitted,  
BROWDY AND NEIMARK, P.L.L.C.

By: Anne M. Kornbau Reg. No. 25,884  
Roger L. Browdy  
Registration No. 25,618

RLB:bcs

f:\user3\99may\ens253



# ACTIVATED T CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES

## Cross-Reference to Related Applications

The present application is a continuation in part of application Serial No. 09/218,277, filed December 22, 1998, the entire contents of which are hereby incorporated by reference.

## Field of the Invention

The present invention relates to compositions and methods for the promotion of nerve regeneration or prevention or inhibition of neuronal degeneration to ameliorate the effects of injury or disease of the nervous system (NS). In certain embodiments, activated antiself T cells, an NS-specific antigen or peptide derived therefrom or a nucleotide sequence encoding an NS-specific antigen or peptide derived therefrom can be used to promote nerve regeneration or to prevent or inhibit neuronal degeneration caused by injury or disease of nerves within the central nervous system or peripheral nervous system of a human subject. The compositions of the present invention may be administered alone or may be optionally administered in any desired combination.

## Background of the Invention

The nervous system comprises the central (CNS) and the peripheral (PNS) nervous system. The central nervous system is composed of the brain and spinal cord; the peripheral nervous system consists of all of the other neural elements,

namely the nerves and ganglia outside of the brain and spinal cord.

Damage to the nervous system may result from a traumatic injury, such as penetrating trauma or blunt trauma, or a disease or disorder, including but not limited to Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis (ALS), diabetic neuropathy, senile dementia, and ischemia.

Maintenance of central nervous system integrity is a complex "balancing act" in which compromises are struck with the immune system. In most tissues, the immune system plays an essential part in protection, repair, and healing. In the central nervous system, because of its unique immune privilege, immunological reactions are relatively limited (Streilein, J.W., 1993, Curr. Opin. Immunol. 5:428-423; Streilein, J.W., Science 270:1158-1159). A growing body of evidence indicates that the failure of the mammalian central nervous system to achieve functional recovery after injury is a reflection of an ineffective dialog between the damaged tissue and the immune system. For example, the restricted communication between the central nervous system and blood-borne macrophages affects the capacity of axotomized axons to regrow; transplants of activated macrophages can promote central nervous system regrowth (Lazarov Spiegler, O., et al, 1996, FASEB J. 19:1296-1302; Rapalino, O. et al., 1998, Nature Med. 4:814-821).

Activated T cells have been shown to enter the central nervous system parenchyma, irrespective of their antigen specificity, but only T cells capable of reacting with a central nervous system antigen seem to persist there (Hickey,

W.F. et al., 1991, J. Neurosci. Res. 28:254-260; Werkele, H., 1993, In The Blood-Brain Barrier, Pardridge, Ed., Raven Press, Ltd. New York, 67-85; Kramer, R. et al., 1995, Nature Med. 1(11):1162-1166)). T cells reactive to antigens of central nervous system white matter, such as myelin basic protein (MBP), can induce the paralytic disease experimental autoimmune encephalomyelitis (EAE) within several days of their inoculation into naive recipient rats (Ben Nun, A., et al., 1981, Eur. J. Immunol. 11:195-199). Anti-MBP T cells may also be involved in the human disease multiple sclerosis (Ota, K. et al., 1990 Nature 346:183-187; Martin, R. 1997, J. Neural Transm. Suppl. 49:53-67). However, despite their pathogenic potential, anti-MBP T cell clones are present in the immune systems of healthy subjects (Burns, J., et al. 1983, Cell Immunol. 81:435-440; Pette, M. et al., 1990, Proc. Natl. Acad. Sci. USA 87:7968-7972; Martin, R. et al., 1990, J. Immunol. 145:540-548; Schiuesener, H.J, et al., 1985, J. Immunol. 135:3128-3133). Activated T cells, which normally patrol the intact central nervous system, transiently accumulate at sites of central nervous system white matter lesions (Hirschberg, D.L., et al., 1998, J. Neuroimmunol. 89:88-96).

A catastrophic consequence of central nervous system injury is that the primary damage is often compounded by the gradual secondary loss of adjacent neurons that apparently were undamaged, or only marginally damaged, by the initial injury (Faden, A. I., et al., 1992, Trends Pharmacol. Sci. 13:29-35; Faden, A.I., 1993, Crit. Rev. Neurobiol. 7:175-186; McIntosh,



insult, the better the functional outcome. The extent of recovery is a function of the amount of undamaged tissue minus the loss due to secondary degeneration. Recovery from injury would be improved by neuroprotective treatment that could reduce secondary degeneration.

Citation or identification of any reference in this section or any other part of this application shall not be construed as an admission that such reference is available as prior art to the invention.

#### SUMMARY OF THE INVENTION

The present invention is directed to methods and compositions for the promotion of nerve regeneration or prevention or inhibition of neuronal degeneration to ameliorate the effects of injury to or disease of the nervous system (NS). The present invention is based in part on the applicants' unexpected discovery that activated T cells that recognize an antigen of the NS of the patient promote nerve regeneration or confer neuroprotection. As used herein, "neuroprotection" refers to the prevention or inhibition of degenerative effects of injury or disease in the NS. Until recently, it was thought that the immune system excluded immune cells from participating in nervous system repair. It was quite surprising to discover that NS-specific activated T cells can be used to promote nerve regeneration or to protect nervous system tissue from secondary degeneration which may follow damage caused by injury or disease of the CNS or PNS.

"Activated T cell" as used herein includes (i) T cells that have been activated by exposure to a cognate antigen or peptide derived therefrom or derivative thereof and (ii) progeny of such activated T cells. As used herein, a cognate antigen is an antigen that is specifically recognized by the T cell antigen receptor of a T cell that has been previously exposed to the antigen. Alternatively, the T cell which has been previously exposed to the antigen may be activated by a mitogen, such as phytohemagglutinin (PHA) or concanavalin A.

In one embodiment, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of NS-specific activated T cells and methods for using such compositions to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the CNS or PNS, in an amount which is effective to ameliorate the effects of an injury or disease of the NS. "NS-specific activated T cell" as used herein refers to an activated T cell having specificity for an antigen of the NS of a patient. The antigen used to confer the specificity to the T cells may be a self NS-antigen of the patient, a peptide derived therefrom, or an NS-antigen of another individual or even another species, or a peptide derived therefrom, as long as the activated T cell recognizes an antigen in the NS of the patient.

The NS-specific activated T cells are used to promote nerve regeneration or to prevent or inhibit the effects of disease. If the disease being treated is an autoimmune disease, in which the autoimmune antigen is an NS antigen, the T cells which are used in accordance with the present invention for the treatment of neural damage or degeneration caused by



effective to activate T cells *in vivo* or *in vitro*, wherein the activated T cells inhibit or ameliorate the effects of an injury or disease of the NS. "NS-specific antigen" as used herein refers to an antigen that specifically activates T cells such that following activation the activated T cells accumulate at a site of injury or disease in the NS of the patient. In one embodiment, the peptide derived from an NS-specific antigen is a "cryptic epitope" of the antigen. A cryptic epitope activates specific T cells after an animal is immunized with the particular peptide, but not with the whole antigen. In another embodiment, the peptide derived from an NS-specific antigen is an immunogenic epitope of the antigen.

"Derivatives" of NS-specific antigens or peptides derived therefrom as used herein refers to analogs or chemical derivatives of such antigens or peptides as described below, see Section 5.2.

The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a nucleotide sequence encoding an NS-specific antigen or peptide derived therefrom or derivative thereof and methods of use of such compositions to promote nerve regeneration or for preventing or inhibiting neuronal degeneration in the CNS or PNS in which the amount is effective to ameliorate the effects of an injury or disease of the NS.

In the practice of the invention, therapy for amelioration of effects of injury or disease comprising administration of NS-specific activated T cells may optionally be in combination with an NS-specific antigen or peptide derived therefrom.



Additionally, oral administration of NS-specific antigen or a peptide derived therefrom, can be combined with active immunization to build up a critical T cell response immediately after injury.

In another embodiment cell banks can be established to store NS sensitized T cells for neuroprotective treatment of individuals at a later time, as needed. In this case, autologous T cells may be obtained from an individual. Alternatively, allogeneic or semi-allogeneic T cells may be stored such that a bank of T cells of each of the most common MHC-class II types are present. In case an individual is to be treated for an injury, preferably autologous stored T cells are used, but, if autologous T cells are not available, then cells should be used which share an MHC type II molecule with the patient, and these would be expected to be operable in that individual. The cells are preferably stored in an activated state after exposure to an NS antigen or peptide derived therefrom. However, the cells may also be stored in a resting state and activated once they are thawed and prepared for use. The cell lines of the bank are preferably cryopreserved. The cell lines are prepared in any way which is well known in the art. Once the cells are thawed, they are preferably cultured prior to injection in order to eliminate non-viable cells. During this culturing, the cells can be activated or reactivated using the same NS antigen or peptide as used in the original activation. Alternatively, activation may be achieved by culturing in the presence of a mitogen, such as phytohemagglutinin (PHA) or concanavalin A (preferably the former). This will place the cells into an even higher state

of activation. The few days that it takes to culture the cells should not be detrimental to the patient as the treatment in accordance with the present invention may occur any time up to a week or more after the injury in order to still be effective. Alternatively, if time is of the essence, the stored cells may be administered immediately after thawing.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 is a bar graph showing the presence of T cells in uninjured optic nerve or in injured optic nerve one week after injury. Adult Lewis rats were injected with activated T cells of the anti-MBP ( $T_{MBP}$ ), anti-OVA ( $T_{OVA}$ ), anti-p277 ( $T_{p277}$ ) lines, or with PBS, immediately after unilateral crush injury of the optic nerve. Seven days later, both the injured and uninjured optic nerves were removed, cryosectioned and analyzed immunohistochemically for the presence of immunolabeled T cells. T cells were counted at the site of injury and at randomly selected areas in the uninjured optic nerves. The histogram shows the mean number of T cells per  $mm^2 \pm$  s.e.m., counted in two to three sections of each nerve. Each group contained three to four rats. The number of T cells was considerably higher in injured nerves of rats injected with anti-MBP, anti-OVA or anti-p277 T cells; statistical analysis (one-way ANOVA) showed significant differences between T cell numbers in injured optic nerves of rats injected with anti-MBP, anti-OVA, or anti-p277 T cells and the T cell numbers in injured optic nerves of rats injected with PBS ( $P < 0.001$ ); and between injured optic nerves and uninjured optic nerves of rats

injected with anti-MBP, anti-OVA, or anti-p277 T cells  
( $P < 0.001$ ).

Fig. 2 is a bar graph illustrating that T cells specific to MBP, but not of OVA or p277 or hsp60, protect neurons from secondary degeneration. Immediately after optic nerve injury, rats were injected with anti-MBP, anti-OVA or anti-p277 T cells, or with PBS. The neurotracer dye 4-Di-10-Asp was applied to optic nerves distal to the site of the injury, immediately after injury (for assessment of primary damage) or two weeks later (for assessment of secondary degeneration). Five days after dye application, the retinas were excised and flat-mounted. Labeled retinal ganglion cells (RGCs) from three to five randomly selected fields in each retina (all located at approximately the same distance from the optic disk) were counted by fluorescence microscopy. RGC survival in each group of injured nerves was expressed as the percentage of the total number of neurons spared after the primary injury (42% of neurons remained undamaged after the primary injury). The neuroprotective effect of anti-MBP T cells compared with that of PBS was significant ( $P < 0.001$ , one-way ANOVA). Anti-OVA T cells or anti-p277 T cells did not differ significantly from PBS in their effects on the protection of neurons that had escaped primary injury ( $P > 0.05$ , one-way ANOVA). The results are a summary of five experiments. Each group contained five to ten rats.

Figs. 3 (A-C) present photomicrographs of retrogradely labeled retinas of injured optic nerves of rats. Immediately after unilateral crush injury of their optic nerves, rats were injected with PBS (Fig. 3A) or with activated

anti-p277 T cells (Fig. 3B) or activated anti-MBP T cells (Fig. 3C). Two weeks later, the neurotracer dye 4-Di-10-Asp was applied to the optic nerves, distal to the site of injury. After 5 days, the retinas were excised and flat-mounted. Labeled (surviving) RGCs, located at approximately the same distance from the optic disk in each retina, were photographed.

Figs. 4(A-B) are graphs showing that clinical severity of EAE is not influenced by an optic nerve crush injury. For the results presented in Fig. 4A, Lewis rats, either uninjured (dash line) or immediately after optic nerve crush injury (solid line), were injected with activated anti-MBP T cells. EAE was evaluated according to a neurological paralysis scale. [Data points represent  $\pm$  s.e.m.] These results represent a summary of three experiments. Each group contained five to nine rats. Fig. 4B shows that the number of RGCs in the uninjured optic nerve is not influenced by injection of anti-MBP T cells. Two weeks after the injection of anti-MBP T cells or PBS, 4-Di-10Asp was applied to the optic nerves. After 5 days the retinas were excised and flat-mounted. Labeled RGCs from five fields (located at approximately the same distance from the optic disk) in each retina were counted and the average number per mm<sup>2</sup> was calculated. There was no difference between the numbers of labeled RGCs in rats injected with anti-MBP T cells ( $T_{MBP}$ ) and in PBS-injected control rats.

Fig. 5 is a bar graph showing that T cells specific to p51-70 of MBP protect neurons from secondary degeneration. Immediately after optic nerve injury, rats were injected with anti-MBP T cells, anti-p51-70 T cells, or PBS. The

neurotracer dye 4-Di-10-Asp was applied to optic nerves distal to the site of the injury, immediately after injury (for assessment of primary damage) or two weeks later (for assessment of secondary degeneration). Five days after dye application, the retinas were excised and flat-mounted. Labeled retinal ganglion cells (RGCs) from three to five randomly selected fields in each retina (all located at approximately the same distance from the optic disk) were counted by fluorescence microscopy. RGC survival in each group of injured nerves was expressed as the percentage of the total number of neurons spared after primary injury. Compared with that of PBS treatment, the neuroprotective effects of anti-MBP anti-p51-70 T cells were significant ( $P < 0.001$ , one-way ANOVA).

Figs. 6(A-B) are graphs showing that anti-MBP T cells increase the compound action potential (CAP) amplitudes of injured optic nerves. Immediately after optic nerve injury, rats were injected with either PBS or activated anti-MBP T cells ( $T_{MBP}$ ). Two weeks later, the CAPs of injured (Fig. 6A) and uninjured (Fig. 6B) nerves were recorded. There were no significant differences in mean CAP amplitudes between uninjured nerves obtained from PBS-injected and T cell-injected rats ( $n=8$ ;  $p=0.8$ , Student's t-test). The neuroprotective effect of anti-MBP T cells (relative to PBS) on the injured nerve on day 14 after injury was significant ( $n=8$ ,  $p=0.009$ , Student's t-test).

Figs. 7(A-B) are graphs showing recovery of voluntary motor activity as a function of time after contusion, with and without injection of autoimmune anti-MBP T cells. (7A) Twelve rats were deeply anesthetized and laminectomized, and then

subjected to a contusion insult produced by a 10 gram weight dropped from a height of 50 mm. Six of the rats, selected at random, were then inoculated i.p. with  $10^7$  anti-MBP T cells and the other six were inoculated with PBS. At the indicated time points, locomotor behavior in an open field was scored by observers blinded to the treatment received by the rats. Results are expressed as the mean values for each group. The vertical bars indicate SEM. Differences tested by repeated ANOVA, including all time points, were significant ( $p < 0.05$ ).

(7B) A similar experiment using five PBS-treated animals and six animals treated with anti-MBP T cells were all subjected to a more severe contusion. At the indicated time points, locomotor behavior in an open field was scored. The results are expressed as the mean values for each group. The vertical bars indicate S.E.M. Rats in the treated group are represented by open circles and rats in the control group are represented by black circles. Horizontal bars show the median values. The inset shows the median plateau values of the two groups.

Figs 8(A-C) show retrograde labeling of cell bodies at the red nucleus in rats treated with autoimmune anti-MBP T cells (8A) and in control injured (8B) rats. Three months after contusion and treatment with anti-MBP T cells, some rats from both the treated and the control groups were re-anesthetized and a dye was applied below the site of the contusion. After five to seven days the rats were again deeply anesthetized and their brains were excised, processed, and cryosectioned. Sections taken through the red nucleus were inspected and analyzed qualitatively and quantitatively under fluorescent and confocal microscopes. Significantly, more

labelled nuclei were seen in the red nuclei of rats treated with anti-MBP T cells (8A) than in the red nuclei of PBS-treated rats (8B). The quantitative differences are shown in the bar graph (8C) and were obtained from animals with scores of 10 and 11 in the T cell treated group and scores of 6 in the control group. The bar graph shows mean  $\pm$  SD.

Fig. 9 is a series of photographs showing diffusion-weighted imaging of contused spinal cord treated with anti-MBP T cells. Spinal cords of MBP-T cell-treated and PBS-treated animals (with locomotion scores of 10 and 8, respectively) were excised under deep anesthesia, immediately fixed in 4% paraformaldehyde solution, and placed into 5 mm NMR tubes. Diffusion anisotropy was measured in a Bruker DMX 400 widebore spectrometer using a microscopy probe with a 5-mm Helmholtz coil and actively shielded magnetic field gradients. A multislice pulsed gradient spin echo experiment was performed with 9 axial slices, with the central slice positioned at the center of the spinal injury. Images were acquired with TE of 31 ms, TR of 2000 ms, a diffusion time of 15 ms, a diffusion gradient duration of 3 ms, field of view 0.6 mm, matrix size 128 x 128, slice thickness 0.5 mm, and slice separation of 1.18 mm. Four diffusion gradient values of 0, 28, 49, and 71 g/cm were applied along the read direction (transverse diffusion) or along the slice direction (longitudinal diffusion). Diffusion anisotropy is manifested by increased signal intensity in the images with the highest transverse diffusion gradient relative to the longitudinal diffusion gradient. The excised spinal cords of a PBS-treated rat and in the rat treated with MBP-T cells were subjected to diffusion-weighted MRI analysis. In

the PBS-treated injured control, diffusion anisotropy was seen mainly in sections near the proximal and distal stumps of the cord, with low anisotropy in sections taken through the site of injury. In contrast, in the treated rat, higher levels of diffusion anisotropy can be seen in sections taken through the site of injury.

Fig. 10 is a graph illustrating inhibition of secondary degeneration after optic nerve crush injury in adult rats. See text, Section 8, for experimental details. Rats were injected intradermally through the footpads with a 21-mer peptide based on amino acid residues 35-55 (MOG p35-55) of myelin/oligodendrocyte glycoprotein (chemically synthesized at the Weizmann Institute, Israel) ( $50\mu$ /animal) or PBS ten days prior to optic nerve crush injury or MOG p35-55 in the absence of crush injury. MOG p35-55 was administered with Incomplete Freund's Adjuvant. Surviving optic nerve fibers were monitored by retrograde labeling of retinal ganglion cells (RGCs). The number of RGCs in rats injected with PBS or MOG p35-55 was expressed as a percentage of the total number of neurons in rats injected with MOG p35-55 in the absence of crush injury.

Fig. 11 is a graph illustrating inhibition in adult rats of secondary degeneration after optic nerve crush injury by MBP. See text, Section 9, for experimental details. MBP (Sigma, Israel) (1 mg in 0.5 ml saline) was administered orally to adult rats by gavage using a blunt needle. MBP was administered 5 times, i.e., every third day beginning two weeks prior to optic nerve crush injury. Surviving optic nerve fibers were monitored by retrograde labeling of retinal ganglion cells (RGCs). The number of RGCs in treated rats was



expressed as a percentage of the total number of neurons in untreated rats following the injury.

Figs. 12 (A-F) show expression of B7 costimulatory molecules in intact and injured rat optic nerve. Optic nerves were excised from adult Lewis rats before (12A, 12B) and three days after injury (12C, 12D, 12E) and analyzed immunohistochemically for expression of the B7 costimulatory molecule. The site of injury was delineated by GFAP staining. Using calibrated cross-action forceps, the right optic nerve was subjected to a mild crush injury 1-2 mm from the eye. The uninjured contralateral nerve was left undisturbed. Immunohistochemical analysis of optic nerve antigens was performed as follows. Briefly, longitudinal cryosections of the excised nerves (20  $\mu$ m thick) were picked up onto gelatin-coated glass and fixed with ethanol for ten minutes at room temperature. The sections were washed and incubated for one hour at room temperature with mouse monoclonal antibody to rat GFAP (BioMakor, Israel), diluted 1:100, and with antibodies to B7.2 costimulatory molecule and the B7.1 costimulatory molecule (PHARMINGEN, San Diego, CA), diluted 1:25. The sections were washed again and incubated with rhodamine isothiocyanate-conjugated goat anti-mouse IgG (with minimal cross-reaction to rat, human, bovine and horse serum protein) (Jackson ImmunoResearch, West Grove, PA), for one hour at room temperature. All washing solutions contained PBS and 0.05% Tween-20. All diluting solutions contained PBS containing 3% fetal calf serum and 2% bovine serum albumin. The sections were treated with glycerol containing 1,4-diazobicyclo-(2,2,2)-octane and were then viewed with a Zeiss microscope. Note the

morphological changes of the B7.2 positive cells after injury, from a rounded (12A, 12B) to a star-like shape (12C, 12D). The B7.2 positive cells were present at a higher density closer to the injury site (12E). Expression of B7.1 was detectable only from day seven and only at the injured site (12F).

Figs. 13 A-C show immunohistochemical analysis of T cells, macrophages or microglia, and B7.2 costimulatory molecules in the injured optic nerves of rats fed MBP. Lewis rats aged 6-8 weeks were fed 1 mg of bovine MBP (Sigma, Israel) (2 mg MBP/ml PBS) or 0.5 ml PBS only every other day by gastric intubation using a stainless steel feeding needle (Thomas Scientific, Swedesboro, NJ) (Chen, Y., Kuchroo, V.K., Inobe, J. Hafler, D.A. & Weiner, H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237-1240, 1994). Ten days after starting MBP the right optic nerves were subjected to calibrated crush injury, as described for Figure 12. Three days later the nerves were excised and prepared for immunohistochemical analysis of T cells using mouse monoclonal antibodies to T cell receptor 11, diluted 1:25, macrophages or microglia using anti-ED1 antibodies (Serotek, Oxford, U.K) diluted 1:250, astrocytes using anti-GFAP antibodies and B7.2 costimulatory molecules as described for Fig. 12. There were no significant quantitative differences in T cells or in ED-1 positive cells between injured optic nerves of PBS-fed (13A) and MBP-fed (13B) rats. The number of B7.2 positive cells at the site of injury of MBP-fed rats (13C) should be noted, as compared with injured controls (Fig. 12E).

Fig. 14 is a graph showing the slowing of neuronal degeneration in rats with orally induced tolerance to MBP. Lewis rats were fed 1 mg MBP daily, or every other day, or 4 times a day at two hour intervals for five consecutive days. Control animals were given PBS or the non-self antigen OVA (Sigma, Israel). Ten days after the start of MBP ingestion, the right optic nerves were subjected to a calibrated mild crush injury. Two weeks later the RGCs were retrogradely labelled by application of the fluorescent lipophilic dye, 4-(4-didecylamino)styryl)-N-methylpyridinium iodide (4-Di-10-Asp) (Molecular Probes Europe BV, Netherlands), distally to the site of injury, as described. Briefly, complete axotomy was performed 1-2 mm from the distal border to the injury site, and solid crystals (0.2-0.4 mm in diameter) of 4-Di-10-Asp were immediately deposited at the site of the lesion. Retrograde labelling of RGCs by the dye gives a reliable indication of the number of still-functioning neurons, as only intact axons can transport the dye to their cell bodies in the retina. Six days after dye application, the retina was detached from the eye, prepared as a flattened whole mount in 4% paraformaldehyde solution, and examined for labelled ganglion cells by fluorescence microscopy. RGCs were counted from three different regions in the retina. The results are expressed as normalized percentage of each retina to untreated injured animal mean of the same experiment. The median of each group is shown as a bar (Control vs. MBP OTx4 \*\*  $P < 0.01$ ; Control vs. MBP OT \*\*  $P, 0.01$ ; Control vs. OVA OT ns  $P > 0.05$ ).

Fig. 15 shows the nucleotide sequence of rat myelin basic protein gene, SEQ ID NO:1, Genbank accession number M25889 (Schaich et al., Biol. Chem. 367:825-834, 1986).

Fig. 16 shows the nucleotide sequence of human myelin basic protein gene, SEQ ID NO:2, Genbank accession number M13577 (Kamholz et al., Proc. Natl. Acad. Sci. U.S.A. 83(13): 4962-4966, 1986).

Figs 17 (A-F) show the nucleotide sequences of human myelin proteolipid protein gene exons 1-7, SEQ ID NOS:3-8, respectively, Genbank accession number M15026-M15032 respectively (Diehl et al., Proc. Natl. Acad. Sci. U.S.A. 83(24):9807-9811, 1986; published erratum appears in Proc Natl Acad Sci U.S.A. 86(6):617-8, 1991).

Fig. 18 shows the nucleotide sequence of human myelin oligodendrocyte glycoprotein gene, SEQ ID NO:9, Genbank accession number Z48051 (Roth et al., submitted (17-Jan-1995) Roth, CNRS UPR 8291, CIGH, CHU Purpan, Toulouse, France, 31300; Gonzalez et al., Mol. Phylogent. Evol. 6:63-71, 1996).

Fig. 19 shows the nucleotide sequence of rat proteolipid protein and variant, SEQ ID NO:10, Genbank accession number M16471 (Nave et al, Proc. Natl. Acad. Sci. U.S.A 84:600-604, 1987).

Fig. 20 shows the nucleotide sequence of rat myelin-associated glycoprotein, SEQ ID NO:11, Genbank accession number M14871 (Arquint et al, Proc. Natl. Acad. Sci. USA 84:600-604, 1987).

Fig. 21 shows the amino acid sequence of human myelin basic protein, SEQ ID NO:12, Genbank accession number 307160

(Kamholz et al., 1986, Proc. Natl. Acad. Sci. U.S.A.  
83(13):4962-4966, 1986).

Fig. 22 shows the amino acid sequence of human  
proteolipid protein, SEQ ID NO:13, Genbank accession number  
387028.

Fig. 23 shows the amino acid sequence of human myelin  
oligodendrocyte glycoprotein, SEQ ID NO:14, Genbank accession  
number 793839 (Roth et al., Genomics 28(2):241-250, 1995; Roth  
Submitted (17-JAN-1995) Roth CNRS UPR 8291, CIGH, CHU Purpan,  
Toulouse, France, 31300; Gonzalez et al., Mol. Phylogent. Evol.  
6:63-71, 1996).

#### DETAILED DESCRIPTION OF THE INVENTION

Merely for ease of explanation, the detailed  
description of the present invention is divided into the  
following subsections: (1) NS-specific activated T cells; (2)  
NS-specific antigens, peptides derived therefrom and  
derivatives thereof; (3) nucleotide sequences encoding NS-  
specific antigens and peptides derived therefrom; (4)  
therapeutic uses of non-recombinant, NS-specific activated T  
cells, NS-specific antigens, peptides derived therefrom and  
derivatives thereof, and nucleotide sequences encoding NS-  
specific antigens and peptides derived therefrom; and (5)  
formulations and modes of administration of nonrecombinant, NS-  
specific activated T cells, NS-specific antigens, peptides  
derived therefrom and derivatives thereof, and nucleotide  
sequences encoding NS-specific antigens and peptides derived  
therefrom.

### 5.1 NS-SPECIFIC ACTIVATED T CELLS

NS-specific activated T cells (ATCs) can be used for ameliorating or inhibiting the effects of injury or disease of the CNS or PNS that result in NS degeneration or for promoting regeneration in the NS, in particular the CNS.

The NS-specific activated T cells are preferably autologous, most preferably of the CD4 and/or CD8 phenotypes, but they may also be allogeneic T cells from related donors, e.g., siblings, parents, children, or HLA-matched or partially matched, semi-allogeneic or fully allogeneic donors.

In addition to the use of autologous T cells isolated from the subject, the present invention also comprehends the use of semi-allogeneic T cells for neuroprotection. These T cells may be prepared as short- or long-term lines and stored by conventional cryopreservation methods for thawing and administration, either immediately or after culturing for 1-3 days, to a subject suffering from injury to the central nervous system and in need of T cell neuroprotection.

The use of semi-allogeneic T cells is based on the fact that T cells can recognize a specific antigen epitope presented by foreign antigen presenting cells (APC), provided that the APC express the MHC molecule, class I or class II, to which the specific responding T cell population is restricted, along with the antigen epitope recognized by the T cells. Thus, a semi-allogeneic population of T cells that can recognize at least one allelic product of the subject's MHC molecules, preferably an HLA-DR or an HLA-DQ or other HLA molecule, and that is specific for a NS-associated antigen epitope, will be able to recognize the NS antigen in the

subject's area of NS damage and produce the needed neuroprotective effect. There is little or no polymorphism in the adhesion molecules, leukocyte migration molecules, and accessory molecules needed for the T cells to migrate to the area of damage, accumulate there, and undergo activation. Thus, the semi-allogeneic T cells will be able to migrate and accumulate at the CNS site in need of neuroprotection and will be activated to produce the desired effect.

It is known that semi-allogeneic T cells will be rejected by the subject's immune system, but that rejection requires about two weeks to develop. Hence, the semi-allogeneic T cells will have the two week window of opportunity needed to exert neuroprotection. After two weeks, the semi-allogeneic T cells will be rejected from the body of the subject, but that rejection is advantageous to the subject because it will rid the subject of the foreign T cells and prevent any untoward consequences of the activated T cells. The semi-allogeneic T cells thus provide an important safety factor and are a preferred embodiment.

It is known that a relatively small number of HLA class II molecules are shared by most individuals in a population. For example, about 50% of the Jewish population express the HLA-DR5 gene. Thus, a bank of specific T cells reactive to NS antigen epitopes that are restricted to HLA-DR5 would be useful in 50% of that population. The entire population can be covered essentially by a small number of additional T cell lines restricted to a few other prevalent HLA molecules, such as DR1, DR4, DR2, etc. Thus, a functional bank of uniform T cell lines can be prepared and stored for

immediate use in almost any individual in a given population. Such a bank of T cells would overcome any technical problems in obtaining a sufficient number of specific T cells from the subject in need of neuroprotection during the open window of treatment opportunity. The semi-allogeneic T cells will be safely rejected after accomplishing their role of neuroprotection. This aspect of the invention does not contradict, and is in addition to the use of autologous T cells as described herein.

The NS-specific activated T cells are preferably non-attenuated, although attenuated NS-specific activated T cells may be used. T cells may be attenuated using methods well known in the art, including but not limited to, by gamma-irradiation, e.g., 1.5-10.0 Rads (Ben-Nun, A., Wekerle, H. and Cohen, I.R., Nature 292:60-61 (1981); Ben-Nun, A. and Cohen, I.R., J. Immunol. 129:303-308 (1982)); and/or by pressure treatment, for example as described in U.S. Patent No. 4,996,194 (Cohen et al.); and/or by chemical cross-linking with an agent such as formaldehyde, glutaraldehyde and the like, for example as described in U.S. Patent No. 4,996,194 (Cohen et al.); and/or by cross-linking and photoactivation with light with a photoactivatable psoralen compound, for example as described in U.S. Patent No. 5,114,721 (Cohen et al.); and/or by a cytoskeletal disrupting agent such as cytochalsin and colchicine, for example as described in U.S. Patent No. 4,996,194 (Cohen et al.). In a preferred embodiment the NS-specific activated T cells are isolated as described below. T cells can be isolated and purified according to methods known



in the art (Mor and Cohen, 1995, J. Immunol. 155:3693-3699). For an illustrative example, see Section 6.1.

Circulating T cells of a subject which recognize myelin basic protein or another NS antigen, such as the amyloid precursor protein, are isolated and expanded using known procedures. In order to obtain NS-specific activated T cells, T cells are isolated and the NS-specific ATCs are then expanded by a known procedure (Burns et al., Cell Immunol. 81:435, 1983; Pette et al., Proc. Natl. Acad. Sci. USA 87:7968, 1990; Mortin et al., J. Immunol. 145:540, 1990; Schluesener et al., J. Immunol. 135:3128, 1985; Suruhan-Dires Keneli et al., Euro. J. Immunol. 23:530, 1993, which are incorporated herein by reference in their entirety).

The isolated T cells may be activated by exposure of the cells to one or more of a variety of natural or synthetic NS-specific antigens or epitopes, including but not limited to, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP), myelin-associated glycoprotein (MAG), S-100,  $\beta$ -amyloid, Thy-1, P0, P2 and neurotransmitter receptors. In a preferred embodiment, the isolated T cells are activated by one or more cryptic epitopes, including but limited to the following MBP peptides: p11-30, p51-70, p91-110, p131-150, and p-151-170.

During ex vivo activation of the T cells, the T cells may be activated by culturing them in medium to which at least one suitable growth promoting factor has been added. Growth promoting factors suitable for this purpose include,

without limitation, cytokines, for instance tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), interleukin 2 (IL-2), and interleukin 4 (IL-4).

In one embodiment, the activated T cells endogenously produce a substance that ameliorates the effects of injury or disease in the NS.

In another embodiment, the activated T cells endogenously produce a substance that stimulates other cells, including, but not limited to, transforming growth factor- $\beta$  (TGF- $\beta$ ), nerve growth factor (NGF), neurotrophic factor 3 (NT-3), neurotrophic factor 4/5 (NT-4/5), brain derived neurotrophic factor (BDNF); interferon- $\gamma$  (IFN- $\gamma$ ), and interleukin-6 (IL-6), wherein the other cells, directly or indirectly, ameliorate the effects of injury or disease.

Following their proliferation *in vitro*, the T cells are administered to a mammalian subject. In a preferred embodiment, the T cells are administered to a human subject. T cell expansion is preferably performed using peptides corresponding to sequences in a non-pathogenic, NS-specific, self protein.

A subject can initially be immunized with an NS-specific antigen using a non-pathogenic peptide of the self protein. A T cell preparation can be prepared from the blood of such immunized subjects, preferably from T cells selected for their specificity towards the NS-specific antigen. The selected T cells can then be stimulated to produce a T cell line specific to the self-antigen (Ben-Nun et al., J. Immunol. 129:303, 1982).

The NS-specific antigen may be a purified antigen or a crude NS preparation, as will be described below. NS-specific antigen activated T cells, obtained as described above, can be used immediately or may be preserved for later use, e.g., by cryopreservation as described below. NS-specific activated T cells may also be obtained using previously cryopreserved T cells, i.e., after thawing the cells, the T cells may be incubated with NS-specific antigen, optimally together with thymocytes, to obtain a preparation of NS-specific ATCs.

As will be evident to those skilled in the art, the T cells can be preserved, e.g., by cryopreservation, either before or after culture.

Cryopreservation agents which can be used include but are not limited to dimethyl sulfoxide (DMSO) (Lovelock and Bishop, Nature 183:1394-1395, 1959; Ashwood-Smith, Nature 190:1204-1205, 1961), glycerol, polyvinylpyrrolidone (Rinfret, Ann. N.Y. Acad. Sci. 85:576, 1960), polyethylene glycol (Sloviter and Ravdin, Nature 196:548, 1962), albumin, dextran, sucrose, ethylene glycol, i-erythritol, D-ribitol, D-mannitol (Rowe et al., Fed. Proc. 21:157, 1962), D-sorbitol, i-inositol, D-lactose, choline chloride (Bender et al., J. Appl. Physiol. 15:520, 1960), amino acids (Phan The Tran and Bender, Exp. Cell Res. 20:651, 1960), methanol, acetamide, glycerol monoacetate (Lovelock, Biochem. J. 56:265, 1954), inorganic salts (Phan The Tran and Bender, Proc. Soc. Exp. Biol. Med. 104:388, 1960; Phan The Tran and Bender, 1961, in Radiobiology, Proceedings of the

Third Australian Conference on Radiobiology, Ilbery, P.L.T., ed., Butterworth, London, p. 59), and DMSO combined with hydroxyethyl starch and human serum albumin (Zaroulis and Leiderman, Cryobiology 17:311-317, 1980).

A controlled cooling rate is critical. Different cryoprotective agents (Rapatz et al., Cryobiology 5(1):18-25, 1968) and different cell types have different optimal cooling rates. See, e.g., Rowe and Rinfret, Blood 20:636 (1962); Rowe, Cryobiology 3(1):12-18 (1966); Lewis et al., Transfusion 7(1):17-32 (1967); and Mazur, Science 168:939-949 (1970) for effects of cooling velocity on survival of cells and on their transplantation potential. The heat of fusion phase where water turns to ice should be minimal. The cooling procedure can be carried out by use of, e.g., a programmable freezing device or a methanol bath procedure.

Programmable freezing apparatuses allow determination of optimal cooling rates and facilitate standard reproducible cooling. Programmable controlled-rate freezers such as Cryomed or Planar permit tuning of the freezing regimen to the desired cooling rate curve.

After thorough freezing, cells can be rapidly transferred to a long-term cryogenic storage vessel. In one embodiment, samples can be cryogenically stored in mechanical freezers, such as freezers that maintain a temperature of about -80°C or about -20°C. In a preferred embodiment, samples can be cryogenically stored in liquid nitrogen (-196°C) or its vapor. Such storage is greatly facilitated by the availability of highly efficient liquid nitrogen refrigerators, which resemble large Thermos containers with an extremely low vacuum

and internal super insulation, such that heat leakage and nitrogen losses are kept to an absolute minimum.

Considerations and procedures for the manipulation, cryopreservation, and long term storage of T cells can be found, for example, in the following references, incorporated by reference herein: Gorin, Clinics in Haematology 15(1):19-48 (1986); Bone-Marrow Conservation, Culture and Transplantation, Proceedings of a Panel, Moscow, July 22-26, 1968, International Atomic Energy Agency, Vienna, pp. 107-186.

Other methods of cryopreservation of viable cells, or modifications thereof, are available and envisioned for use, e.g., cold metal-mirror techniques. See Livesey and Linner, Nature 327:255 (1987); Linner et al., J. Histochem. Cytochem. 34(9):1123-1135 (1986); see also U.S. Patent No. 4,199,022 by Senken et al., U.S. Patent No. 3,753,357 by Schwartz, U.S. Patent No. 4,559,298 by Fahy.

Frozen cells are preferably thawed quickly (e.g., in a water bath maintained at 37-47°C) and chilled immediately upon thawing. It may be desirable to treat the cells in order to prevent cellular clumping upon thawing. To prevent clumping, various procedures can be used, including but not limited to the addition before or after freezing of DNase (Spitzer et al., Cancer 45:3075-3085, 1980), low molecular weight dextran and citrate, citrate, hydroxyethyl starch (Stiff et al., Cryobiology 20:17-24, 1983), or acid citrate dextrose (Zaroulis and Leiderman, Cryobiology 17:311-317, 1980), etc.

The cryoprotective agent, if toxic in humans, should be removed prior to therapeutic use of the thawed T cells. One

way in which to remove the cryoprotective agent is by dilution to an insignificant concentration.

Once frozen T cells have been thawed and recovered, they are used to promote neuronal regeneration as described herein with respect to non-frozen T cells. Once thawed, the T cells may be used immediately, assuming that they were activated prior to freezing. Preferably, however, the thawed cells are cultured before injection to the patient in order to eliminate non-viable cells. Furthermore, in the course of this culturing over a period of about one to three days, an appropriate activating agent can be added so as to activate the cells, if the frozen cells were resting T cells, or to help the cells achieve a higher rate of activation if they were activated prior to freezing. Usually, time is available to allow such a culturing step prior to administration as the T cells may be administered as long as a week after injury, and possibly longer, and still maintain their neuroregenerative and neuroprotective effect.

## 5.2 NS-SPECIFIC ANTIGENS AND PEPTIDES DERIVED

### THEREFROM

Pharmaceutical compositions comprising an NS-specific antigen or peptide derived therefrom or derivative thereof can be used for preventing or inhibiting the effects of injury or disease that result in NS degeneration or for promoting nerve regeneration in the NS, particularly in the CNS. Additionally, NS-specific antigens or peptides derived therefrom or derivatives thereof may be used for *in vivo* or *in vitro* activation of T cells. In one embodiment, the NS-specific

antigen is an isolated or purified antigen. In another embodiment, methods of promoting nerve regeneration or of preventing or inhibiting the effects of CNS or PNS injury or disease comprise administering NS-specific antigen or a peptide derived therefrom or derivative thereof to a mammal wherein the NS-specific antigen or peptide derived therefrom or derivative thereof activates T cells *in vivo* to produce a population of T cells that accumulate at a site of injury or disease of the CNS or PNS.

The NS-specific antigen may be an antigen obtained from NS tissue, preferably from tissue at a site of CNS injury or disease. The NS-specific antigen may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of antigens. The functional properties may be evaluated using any suitable assay. In the practice of the invention, natural or synthetic NS-specific antigens or epitopes include, but are not limited to, MBP, MOG, PLP, MAG, S-100,  $\beta$ -amyloid, Thy-1, P0, P2 and a neurotransmitter receptor.

Specific illustrative examples of useful NS-specific antigens include but are not limited to, human MBP, depicted in Fig. 21, (SEQ ID NO:12); human proteolipid protein, depicted in Fig. 22 (SEQ ID NO:13); and human oligodendrocyte glycoprotein, depicted in Fig. 23 (SEQ ID NO:14).

In a preferred embodiment, peptides derived from NS-specific, self-antigens or derivatives of NS-specific antigens activate T cells, but do not induce an autoimmune disease. An

example of such peptide is a peptide comprising amino acids 51-70 of myelin basic protein (residues 51-70 of SEQ ID NO:12).

In addition, an NS-specific antigen may be a crude NS-tissue preparation, e.g., derived from NS tissue obtained from mammalian NS. Such a preparation may include cells, both living or dead cells, membrane fractions of such cells or tissue, etc.

an NS-specific antigen may be obtained by an NS biopsy or necropsy from a mammal including, but not limited to, from a site of CNS injury; from cadavers; from cell lines grown in culture. Additionally, an NS-specific antigen may be a protein obtained by genetic engineering, chemically synthesized, etc.

In addition to NS-specific antigens, the invention also relates to peptides derived from NS-specific antigens or derivatives including chemical derivatives and analogs of NS-specific antigens which are functionally active, i.e., they are capable of displaying one or more known functional activities associated with a full-length NS-specific antigen. Such functional activities include but are not limited to antigenicity (ability to bind (or compete with an NS-antigen for binding) to an anti-NS-specific antibody), immunogenicity (ability to generate antibody which binds to an NS-specific protein), and ability to interact with T cells, resulting in activation comparable to that obtained using the corresponding full-length antigen. The crucial test is that the antigen which is used for activating the T cells causes the T cells to be capable of recognizing an antigen in the NS of the mammal (patient) being treated.



SECRET

A peptide derived from a CNS-specific or PNS-specific antigen preferably has a sequence comprised within the antigen sequence and is either: (1) an immunogenic peptide, i.e., a peptide that can elicit a human T cell response detected by a T cell proliferation or by cytokine (e.g. interferon (IFN)- $\gamma$ , interleukin (IL)-2, IL-4 or IL-10) production or (2) a "cryptic epitope" (also designated herein as "immunosilent" or "nonimmunodominant" epitope), i.e., a peptide that by itself can induce a T cell immune response that is not induced by the whole antigen protein (see Moalem et al., Nature Med. 5(1), 1999). Cryptic epitopes for use in the present invention include, but are not limited to, peptides of the myelin basic protein sequence: peptide p11-30, p51-70, p91-110, p131-150, and p151-170. Other peptides can be identified by their capacity to elicit a human T cell response detected by T cell proliferation or by cytokine (e.g. IFN- $\gamma$ , IL-2, IL-4, or IL-10) production. Such cryptic epitopes are particularly preferred as T cells activated thereby will accumulate at the injury site, in accordance with the present invention, but are particularly weak in autoimmunity. Thus, they would be expected to have fewer side effects.

In one specific embodiment of the invention, peptides consisting of or comprising a fragment of an NS-specific antigen consisting of at least 10 (contiguous) amino acids of the NS-specific antigen are provided. In other embodiments, the fragment consists of at least 20 contiguous amino acids or 50 contiguous amino acids of the NS-specific antigen. Derivatives of an NS-specific antigen also include but are not limited to those molecules comprising regions that are substantially

homologous to the full-length antigen or fragments thereof (e.g., in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art) or whose encoding nucleic acid is capable of hybridizing to a coding nucleotide sequence of the full-length NS-specific antigen, under high stringency, moderate stringency, or low stringency conditions.

Computer programs for determining homology may include but are not limited to TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8):2444-8, 1988; Altschul et al., J. Mol. Biol. 215(3):40310, 1990; Thompson, et al., Nucleic Acids Res. 22(22):4673-80, 1994; Higgins, et al., Methods Enzymol 266:383-402, 1996; Altschul, et al., 1990, J. Mol. Biol. 215(3):403-410, 1990).

The NS-specific antigen derivatives of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, a cloned gene sequence can be modified by any of numerous strategies known in the art (Maniatis, T., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*.

Additionally, the coding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy

translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., J. Biol. Chem 253:6551, 1978), etc.

Manipulations may also be made at the protein level. Included within the scope of the invention are derivatives which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

In addition, derivatives of an NS-specific antigen can be chemically synthesized. For example, a peptide corresponding to a portion of an antigen which comprises the desired domain or which mediates the desired activity can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acids analogs can be introduced as a substitution or addition into the amino acid sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid; 4-aminobutyric acid, Abu; 2-amino

butyric acid,  $\gamma$ -Abu;  $\epsilon$ -Ahx, 6-amino hexanoic acid; Aib, 2-amino isobutyric acid; 3-amino propionic acid; ornithine; norleucine; novaline; hydroxyproline; sarcosine; citrulline; cysteic acid; t-butylglycine; t-butylalanine; phenylglycine; cyclohexylalanine;  $\beta$ -alanine; fluoro-amino acids; designer amino acids such as  $\beta$ -methyl amino acids,  $C\alpha$ -methyl amino acids,  $N\alpha$ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The functional activity of NS-specific antigens and peptides derived therefrom and derivatives thereof can be assayed by various methods known in the art, including, but not limited to, T cell proliferation assays (Mor and Cohen, J. Immunol. 155:3693-3699, 1995).

An NS-specific antigen or peptide derived therefrom or derivative thereof may be kept in solution or may be provided in a dry form, e.g. as a powder or lyophilizate, to be mixed with appropriate solution prior to use.

### 5.3 NUCLEOTIDE SEQUENCES ENCODING NS-ANTIGENS AND PEPTIDES DERIVED THEREFROM

Compositions comprising a nucleotide sequence encoding an NS-specific antigen or peptide derived therefrom can be used for preventing or inhibiting the effects of injury or disease that result in CNS or PNS degeneration or for promoting nerve regeneration in the CNS or PNS. Specific illustrative examples of useful nucleotide sequences encoding NS-specific antigens or peptides derived from an NS-specific antigen, include but are not limited to nucleotide sequences

encoding rat myelin basic protein (MBP) peptides, depicted in Fig. 15 (SEQ ID NO:1); human MBP, depicted in Fig. 16 (SEQ ID NO:2); human myelin PLP, depicted in Figs. 17(A-F) (SEQ ID NOs:3-8); human MOG, depicted in Fig. 18 (SEQ ID NO:9); rat PLP and variant, depicted in Fig. 19 (SEQ ID NO:10); and rat MAG, depicted in Fig. 20 (SEQ ID NO:11).

#### 5.4 THERAPEUTIC USES

The compositions described in Sections 5.1 through 5.3 may be used to promote nerve regeneration or to prevent or inhibit secondary degeneration which may otherwise follow primary NS injury, e.g., blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke or damages caused by surgery such as tumor excision. In addition, such compositions may be used to ameliorate the effects of disease that result in a degenerative process, e.g., degeneration occurring in either grey or white matter (or both) as a result of various diseases or disorders, including, without limitation: diabetic neuropathy, senile dementias, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS), non-arteritic optic neuropathy, intervertebral disc herniation, vitamin deficiency, prion diseases such as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral neuropathies associated with various diseases, including but not limited to, uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, IgA and

IgG gammopathies, complications of various drugs (e.g., metronidazole) and toxins (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia telangiectasia, Friedreich's ataxia, amyloid polyneuropathies, adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's disease, lipoproteinemia, etc.

In a preferred embodiment, the NS-specific activated T cells, the NS-specific antigens, peptides derived therefrom, derivatives thereof or the nucleotides encoding said antigens, or peptides or any combination thereof of the present invention are used to treat diseases or disorders where promotion of nerve regeneration or prevention or inhibition of secondary neural degeneration is indicated, which are not autoimmune diseases or neoplasias. In a preferred embodiment, the compositions of the present invention are administered to a human subject.

While activated NS-specific T cells may have been used in the prior art in the course of treatment to develop tolerance to autoimmune antigens in the treatment of autoimmune diseases, or in the course of immunotherapy in the treatment of NS neoplasms, the present invention can also be used to ameliorate the degenerative process caused by autoimmune diseases or neoplasms as long as it is used in a manner not suggested by such prior art methods. Thus, for example, T cells activated by an autoimmune antigen have been suggested for use to create tolerance to the autoimmune antigen and, thus, ameliorate the autoimmune disease. Such treatment, however, would not have suggested the use of T cells directed to other NS antigens or NS antigens which will not induce

tolerance to the autoimmune antigen or T cells which are administered in such a way as to avoid creation of tolerance. Similarly, for neoplasms, the effects of the present invention can be obtained without using immunotherapy processes suggested in the prior art by, for example, using an NS antigen which does not appear in the neoplasm. T cells activated with such an antigen will still accumulate at the site of neural degeneration and facilitate inhibition of this degeneration, even though it will not serve as immunotherapy for the tumor *per se*.

#### 5.5 FORMULATIONS AND ADMINISTRATION

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. The carriers in the pharmaceutical composition may comprise a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or lactose monohydrate; a disintegrating agent, such as alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin; and/or a flavoring agent, such as peppermint,

methyl salicylate, or orange flavoring.

Methods of administration include, but are not limited to, parenteral, e.g., intravenous, intraperitoneal, intramuscular, subcutaneous, mucosal (e.g., oral, intranasal, buccal, vaginal, rectal, intraocular), intrathecal, topical and intradermal routes. Administration can be systemic or local.

For oral administration, the pharmaceutical preparation may be in liquid form, for example, solutions, syrups or suspensions, or may be presented as a drug product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well-known in the art.



Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compositions may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen free water, before use.

The compositions may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

For administration by inhalation, the compositions for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g.,

gelatin, for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

In a preferred embodiment, compositions comprising NS-specific activated T cells, an NS-specific antigen or peptide derived therefrom, or derivative thereof, or a nucleotide sequence encoding such antigen or peptide, are formulated in accordance with routine procedures as pharmaceutical compositions adapted for intravenous or intraperitoneal administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water or saline for injection can be provided so that the ingredients may be mixed prior to administration.

Pharmaceutical compositions comprising NS-specific antigen or peptide derived therefrom or derivative thereof may optionally be administered with an adjuvant, such as Incomplete Freund's Adjuvant.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.

In a preferred embodiment, the pharmaceutical compositions of the invention are administered to a mammal, preferably a human, shortly after injury or detection of a degenerative lesion in the NS. The therapeutic methods of the invention may comprise administration of an NS-specific activated T cell or an NS-specific antigen or peptide derived therefrom or derivative thereof, or a nucleotide sequence encoding such antigen or peptide, or any combination thereof. When using combination therapy, the NS-specific antigen may be administered before, concurrently or after administration of NS-specific activated T cells, a peptide derived from an NS-specific antigen or derivative thereof or a a nucleotide sequence encoding such antigen or peptide.

In one embodiment, the compositions of the invention are administered in combination with one or more of the following (a) mononuclear phagocytes, preferably cultured monocytes (as described in PCT publication No. WO 97/09985, which is incorporated herein by reference in its entirety), that have been stimulated to enhance their capacity to promote neuronal regeneration; (b) a neurotrophic factor such as acidic fibroblast growth factor; and (c) an anti-inflammatory therapeutic substance (i.e., an anti-inflammatory steroid, such as dexamethasone or methylprednisolone, or a non-steroidal anti-inflammatory peptide, such as Thr-Lys-Pro (TKP)).

In another embodiment, mononuclear phagocyte cells according to PCT Publication No. WO 97/09985 and U.S. patent application Serial No. 09/041,280, filed March 11, 1998, are injected into the site of injury or lesion within the CNS, either concurrently, prior to, or following parenteral

administration of NS-specific activated T cells, an NS-specific antigen or peptide derived therefrom or derivative thereof, or a nucleotide sequence encoding such antigen or peptide

In another embodiment, administration of NS-specific activated T cells, NS-specific antigen or peptide sequence encoding such antigen or peptide, may be administered as a single dose or may be repeated, preferably at 2 week intervals and then at successively longer intervals once a month, once a quarter, once every six months, etc. The course of treatment may last several months, several years or occasionally also through the life-time of the individual, depending on the condition or disease which is being treated. In the case of a CNS injury, the treatment may range between several days to months or even years, until the condition has stabilized and there is no or only a limited risk of development of secondary degeneration. In chronic human disease or Parkinson's disease, the therapeutic treatment in accordance with the invention may be for life.

As will be evident to those skilled in the art, the therapeutic effect depends at times on the condition or disease to be treated, on the individual's age and health condition, on other physical parameters (e.g. gender, weight, etc.) of the individual, as well as on various other factors, e.g., whether the individual is taking other drugs, etc.

The optimal dose of the therapeutic compositions comprising NS-specific activated T cells of the invention is proportional to the number of nerve fibers affected by NS injury or disease at the site being treated. In a preferred embodiment, the dose ranges from about  $5 \times 10^6$  to about  $10^7$  for

treating a lesion affecting about  $10^5$  nerve fibers, such as a complete transection of a rat optic nerve, and ranges from about  $10^7$  to about  $10^8$  for treating a lesion affecting about  $10^6$  -  $10^7$  nerve fibers, such as a complete transection of a human optic nerve. As will be evident to those skilled in the art, the dose of T cells can be scaled up or down in proportion to the number of nerve fibers thought to be affected at the lesion or site of injury being treated.

#### 5.6 ESTABLISHMENT OF AUTOLOGOUS CELL BANKS FOR T LYMPHOCYTES

To minimize secondary damage after nerve injury, patients can be treated by administering autologous or semi-allogeneic T lymphocytes sensitized to at least one appropriate NS antigen. As the window of opportunity has not yet been precisely defined, therapy should be administered as soon as possible after the primary injury to maximize the chances of success, preferably within about one week.

To bridge the gap between the time required for activation and the time needed for treatment, a bank can be established with personal vaults of autologous T lymphocytes prepared for future use for neuroprotective therapy against secondary degeneration in case of NS injury. T lymphocytes are isolated from the blood and then sensitized to a NS antigen. The cells are then frozen and suitably stored under the person's name, identity number, and blood group, in a cell bank until needed.

Additionally, autologous stem cells of the CNS can be processed and stored for potential use by an individual patient

in the event of traumatic disorders of the NS such as ischemia or mechanical injury, as well as for treated neurodegenerative conditions such as Alzheimer's disease or Parkinson's disease. Alternatively, semi-allogeneic or allogeneic T cells can be stored frozen in banks for use by any individual who shares one MHC type II molecule with the source of the T cells.

The following examples illustrate certain features of the present invention but are not intended to limit the scope of the present invention.

**EXAMPLE: ACCUMULATION OF ACTIVATED T CELLS IN INJURED  
OPTIC NERVE**

---

**6.1 MATERIALS AND METHODS**

**6.1.1 ANIMALS**

Female Lewis rats were supplied by the Animal Breeding Center of the Weizmann Institute of Science (Rehovot, IL), matched for age (8-12 weeks) and housed four to a cage in a light and temperature-controlled room.

**6.1.2 MEDIA**

The T cell proliferation medium contained the following: Dulbecco's modified Eagle's medium (DMEM, Biological 15 Industries, Israel) supplemented with 2mM L-glutamine (L-Glu, Sigma, USA),  $5 \times 10^{-5}$  M 2-mercaptoethanol (2-ME, Sigma), penicillin (100 IU/ml; Biological Industries), streptomycin (100  $\mu$ /ml; Biological Industries), sodium pyruvate (1 mM; Biological Industries), non-essential amino acids (1 ml/100 ml;

Biological Industries) and autologous rat serum 1% (vol/vol) (Mor et al., Clin. Invest. 85:1594, 1990). Propagation medium contained: DMEM, 2-ME, L-Glu, sodium pyruvate, non-essential amino acids and antibiotics in the same concentration as above with the addition of 10% fetal calf serum (FCS), and 10% T cell growth factor (TCGF) obtained from the supernatant of concanavalin A-stimulated spleen cells (Mor et al., *supra*, 1990).

#### 6.1.3 ANTIGENS

Myelin basic protein (MBP) from the spinal cords of guinea pigs was prepared as described (Hirshfeld, et al., FEBS Lett. 7:317, 1970). Ovalbumin was purchased from Sigma (St. Louis, Missouri). The p51-70 of the rat 18.5kDa isoform of MBP (sequence: APKRGSGKDSHTRTTHYG) (SEQ ID NO:15) and the p277 peptide of the human hsp60 (sequence: VLGGGCALLRCPALDSLTPANED) (SEQ ID NO:16) (Elias et al., Proc. Natl. Acad. Sci. USA 88:3088-3091, 1991) were synthesized using the 9-fluorenylmethoxycarbonyl technique with an automatic multiple peptide synthesizer (AMS 422, ABIMED, Langenfeld, Germany). The purity of the peptides was analyzed by HPLC and amino acid composition.

#### 6.1.4 T CELL LINES

T cell lines were generated from draining lymph node cells obtained from Lewis rats immunized with an antigen (described above in Section 6.1.3). The antigen was dissolved in PBS (1mg/ml) and emulsified with an equal volume of incomplete Freund's adjuvant (Difco Laboratories, Detroit,

Michigan) supplemented with 4 mg/ml *Mycobacterium tuberculosis* (Difco 15 Laboratories, Detroit, Michigan). The emulsion (0.1 ml) was injected into hind foot pads of the rats. Ten days after the antigen was injected, the rats were killed and draining lymph nodes were surgically removed and dissociated. The cells were washed and activated with the antigen (10 µg/ml) in proliferation medium (described above in Section 6.1.2). After incubation for 72 h at 37°C, 90% relative humidity and 7% CO<sub>2</sub>, the cells were transferred to propagation medium (described above in Section 6.1.2). Cells were grown in propagation medium for 4-10 days before being re-exposed to antigen (10 µg/ml) in the presence of irradiated (2000 red) thymus cells (10<sup>7</sup> cells/ml) in proliferation medium. The T cell lines were expanded by repeated re-exposure and propagation.

#### 6.1.5 CRUSH INJURY OF RAT OPTIC NERVE

Crush injury of the optic nerve was performed as previously described (Duvdevani et al., Neurol. Neurosci. 2:31-38, 1990). Briefly, rats were deeply anesthetized by i.p. injection of Rompum (xylazine, 10 mg/kg; Vitamed, Israel) and Vetaler (ketamine, 50 mg/kg; Fort Dodge Laboratories, Fort Dodge, Iowa). Using a binocular operating microscope, a lateral canthotomy was performed in the right eye and the conjunctiva was incised lateral to the cornea. After separation of the retractor bulbi muscles, the optic nerve was exposed intraorbitally by blunt dissection. Using calibrated cross-action forceps, a moderate crush injury was inflicted on the optic nerve, 2mm from the eye (Duvdevani et al.,



Instructure Neurology and Neuroscience 2:31, 1990). The contralateral nerve was left undisturbed and was used as a control.

#### 6.1.6 IMMUNOCYTOCHEMISTRY OF T CELLS

Longitudinal cryostat nerve sections (20  $\mu$ m thick) were picked up onto gelatin glass slides and frozen until preparation for fluorescent staining. Sections were thawed and fixed in ethanol for 10 minutes at room temperature, washed twice with double-distilled water (ddH<sub>2</sub>O), and incubated for 3 minutes in PBS containing 0.05% polyoxyethylene-sorbitan monolaurate (Tween-20; Sigma, USA). Sections were then incubated for 1 hr at room temperature with a mouse monoclonal antibody directed against rat T cell receptor (TCR) (1:100, Hunig et al., J. Exp. Med., 169:73, 1989), in PBS containing 3% FCS and 2% BSA. After three washes with PBS containing 0.05% Tween-20, the sections were incubated with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (with minimal cross-section to rat, human, bovine and horse serum proteins) (Jackson ImmunoResearch, West Grove, Pennsylvania) for one hour at room temperature. The sections were then washed with PBS containing Tween-20 and treated with glycerol containing 1,4-diazobicyclo-(2,2,2) octane (Sigma), to inhibit quenching of fluorescence. The sections were viewed with a Zeiss microscope and cells were counted. Staining in the absence of first antibody was negative.

## 6.2. RESULTS

Fig. 1 shows accumulation of T cells measured immunohistochemically. The number of T cells was considerably higher in injured nerves rats injected with anti-MBP, anti-OVA or anti-p277 cells; statistical analysis (one-way ANOVA) showed significant differences between T cell numbers in injured optic nerves of rats injected with anti-MBP, anti-OVA, or anti-p277 T cells and in injured optic nerves of rats injected with PBS ( $P < 0.001$ ); and between injured optic nerves and uninjured optic nerves of rats injected with anti-MBP, anti-OVA, or anti-p277 T cells ( $P < 0.001$ ).

**EXAMPLE: NEURPROTECTION BY AUTOIMMUNE ANTI-MBP T CELLS**

## 7.1 MATERIAL AND METHODS

Animals, media, antigens, crush injury of rat optic nerve, sectioning of nerves, T cell lines, and immunolabeling of nerve sections are described in Section 6, *supra*.

### 7.1.1. RETROGRADE LABELING AND MEASUREMENT OF PRIMARY DAMAGE AND SECONDARY DEGENERATION

Primary damage of the optic nerve axons and their attached retinal ganglion cells (RGCs) were measured after the immediate post-injury application of the fluorescent lipophilic dye 4-(4-(didecylamino)styryl)-N-methylpyridinium iodide (4-Di-Asp) (Molecular Probes Europe BV, Netherlands) distal to the site of injury. Only axons that are intact are capable of transporting the dye back to their cell bodies; therefore, the

number of labeled cell bodies is a measure of the number of axons that survived the primary damage. Secondary degeneration was also measured by application of the dye distal to the injury site, but two weeks after the primary lesion was inflicted. Application of the neurotracer dye distal to the site of the primary crush after two weeks ensures that only axons that survived both the primary damage and the secondary degeneration will be counted. This approach makes it possible to differentiate between neurons that are still functionally intact and neurons in which the axons are injured but the cell bodies are still viable, as only those neurons whose fibers are morphologically intact can take up dye applied distally to the site of injury and transport it to their cell bodies. Using this method, the number of labeled ganglion cells reliably reflects the number of still-functioning neurons. Labeling and measurement were done by exposing the right optic nerve for a second time, again without damaging the retinal blood supply. Complete axotomy was done 1-2 mm from the distal border of the injury site and solid crystals (0.2-0.4 mm in diameter) of 4-Di-10-Asp were deposited at the site of the newly formed axotomy. Uninjured optic nerves were similarly labeled at approximately the same distance from the globe. Five days after dye application, the rats were killed. The retina was detached from the eye, prepared as a flattened whole mount in 4% paraformaldehyde solution and examined for labeled ganglion cells by fluorescence microscopy. The percentage of RGCs surviving secondary degeneration was calculated using the

following formula: (Number of spared neurons after secondary degeneration)/(Number of spared neurons after primary damage) x 100.

#### 7.1.2 ELECTROPHYSIOLOGICAL RECORDINGS

Nerves were excised and their compound action potentials (CAPs) were recorded *in vitro* using a suction electrode experimental set-up (Yoles et al., J. Neurotrauma 13:49-57, 1996). At different times after injury and injection of T cells or PBS, rats were killed by intraperitoneal injection of pentobarbitone (170 mg/kg) (CTS Chemical Industries, Israel). Both optic nerves were removed while still attached to the optic chiasma, and were immediately transferred to a vial containing a fresh salt solution consisting of 126 mM NaCl, 3 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 2 mM MgSO<sub>4</sub>, 2 mM CaCl<sub>2</sub>, and 10 mM D-glucose, aerated with 95% O<sub>2</sub> and 5% CO<sub>2</sub> at room temperature. After 1 hour, electrophysiological recordings were made. In the injured nerve, recordings were made in a segment distal to the injury site. This segment contains axons of viable retinal ganglion cells that have escaped both primary and secondary damage, as well as the distal stumps of non-viable retinal ganglion cells that have not yet undergone Wallerian degeneration. The nerve ends were connected to two suction Ag-AgCl electrodes immersed in the bathing solution at 37°C. A stimulating pulse was applied through the electrode, and the CAP was recorded by the distal electrode. A stimulator (SD9; Grass Medical Instruments, Quincy, Massachusetts) was used for supramaximal electrical stimulation at a rate of 1 pps to ensure stimulation

of all propagating axons in the nerve. The measured signal was transmitted to a microelectrode AC amplifier (model 1800; A-M Systems, Everett, Washington). The data were processed using the LabView 2.1.1 data acquisition and management system (National Instruments, Austin, Texas). For each nerve, the difference between the peak amplitude and the mean plateau of eight CAPs was computed and was considered as proportional to the number of propagating axons in the optic nerve. The experiments were done by experimentors "blinded", to sample identity. In each experiment the data were normalized relative to the mean CAP of the uninjured nerves from PBS-injected rats,

#### 7.1.3 CLINICAL EVALUATION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

Clinical disease was scored every 1 to 2 days according to the following neurological scale: 0, no abnormality; 1, tail atony; 2, hind limb paralysis; 3, paralysis extending to thoracic spine; 4, front limb paralysis; 5, moribund state.

### 7.2 RESULTS

#### 7.2.1 NEUROPROTECTION BY AUTOIMMUNE anti-MBP T CELLS

Morphological analyses were done to assess the effect of the T cells on the response of the nerve to injury, and specifically on secondary degeneration. Rats were injected intraperitoneally immediately after optic nerve injury with PBS

or with  $1 \times 10^7$  activated T cells of the various cell lines. The degree of primary damage to the optic nerve axons and their attached RGCs was measured by injecting the dye 4-Di-10-Asp distal to the site of the lesion immediately after the injury. A time lapse of 2 weeks between a moderate crush injury and dye application is optimal for demonstrating the number of still viable labeled neurons as a measure of secondary degeneration, and as the response of secondary degeneration to treatment. Therefore, secondary degeneration was quantified by injecting the dye immediately or 2 weeks after the primary injury, and calculating the additional loss of RGCs between the first and the second injections of the dye. The percentage of RGCs that had survived secondary degeneration was then calculated. The percentage of labeled RGCs (reflecting still-viable neurons) was significantly greater in the retinas of the rats injected with anti-MBP T cells than in the retinas of the PBS-injected control rats (Fig. 2). In contrast, the percentage of labeled 30 RGCs in the retinas of the rats injected with anti-OVA or anti-p277 T cells was not significantly greater than that in the control retinas. Thus, although the three T cell lines accumulated at the site of injury, only the MBP-specific autoimmune T cells had a substantial effect in limiting the extend of secondary degeneration. Labeled RGCs of injured optic nerves of rats injected with PBS (Fig. 3A), with anti-p277 T cells (Fig. 3B) or with anti-MBP T cells (FIG. 3C) were compared morphologically using micrographs.

### 7.2.2 CLINICAL SEVERITY OF EAE

Animals were injected i.p. with  $10^7$   $T_{MBP}$  cells with or without concurrent optic nerve crush injury. The clinical course of the rats injected with the  $T_{MBP}$  cells was evaluated according to the neurological paralysis scale. Each group contained 5-9 rats. The functional autoimmunity of the injected anti-MBP T cells was demonstrated by the development of transient EAE in the recipients of these cells. As can be seen in Fig. 4A, the course and severity of the EAE was not affected by the presence of the optic nerve crush injury.

### 7.2.3 SURVIVAL OF RGCS IN NON-INJURED NERVES

Animals were injected i.p. with  $10^7$   $T_{MBP}$  cells or PBS. Two weeks later, 4-Di-10-Asp was applied to the optic nerves. After five days the retinal were excised and flat mounted. Labeled RGCs from five fields (located at approximately the same distance from the optic disk), in each retina were counted and their average number per area ( $mm^2$ ) was calculated.

As can be seen in Fig. 4B, there is no difference in the number of surviving RGCs per area ( $mm^2$ ) in non-injured optic nerves of rats injected with anti-MBP T cells compared to in rats injected with PBS.

### 7.2.4. NEUROPROTECTION BY T CELLS REACTIVE TO A CRYPTIC EPITOPE

To determine whether the neuroprotective effect of the anti-MBP T cells is correlated with their virulence, the effect of T cells reactive to a "cryptic" epitope of MBP, the

peptide 51-70 (p51-70) was examined. "Cryptic" epitopes activate specific T cells after an animal is immunized with the particular peptide, but not with the whole antigen (Mor et al., J. Immunol. 155:3693-3699. 1995). The T cell line reactive to the whole MBP and the T cell line reactive to the cryptic epitope p51-70 were compared for the severity of the EAE they induced, and for their effects on secondary degeneration. In rats injected with the T cell line reactive to the cryptic epitope, disease severity (as manifested by the maximal EAE score) was significantly lower than that in rats injected with the T cell line reactive to the whole protein (Table 1). Whereas anti-MBP T cells caused clinical paralysis of the limbs, rats injected with the anti-p51-70 T cells developed only tail atony, not hind limb paralysis, and almost none showed weakness of the hind limbs. Despite this difference in EAE severity, the neuroprotective effect of the less virulent (anti-p51-70) T cells was similar to that of the more virulent (anti-MBP) T cells (Fig. 5). The percentage of RGCs surviving secondary degeneration in the retinas of rats injected with either of the lines was significantly higher than in the retinas of the PBS-injected rats. Thus, there was no correlation between the neuroprotective effect of the autoimmune T cells and their virulence. It is possible that the anti-p51-70 T cells encounter little antigen in the intact CNS, and therefore cause only mild EAE. Their target antigen may however become more available after injury, enabling these T cells to exert a neuroprotective effect.



TABLE 1. Anti-MBP and anti-p51-70 T cells  
Vary in Pathogenicity

<u>T Cell Line</u>	<u>Clinical EAE</u>	<u>Mean Max. Score</u>
Whole MBP	Moderate to severe	2.00 + 0.2
p51-70 of MBP	Mild	0.70 + 0.2

Immediately after optic nerve crush injury, Lewis rats were injected with activated anti-MBP T cells or anti-p51-70 T cells. The clinical course of EAE was evaluated according to the neurological paralysis scale. The mean maximal (max.) score  $\pm$  s.e.m. was calculated as the average maximal score of all the diseased rats in each group. The table is a summary of nine experiments. Each group contains five to ten rats. Statistical analysis showed a significant difference between the mean maximal score of rats injected with anti-MBP T cells and that of rats injected with anti-p51-70 T cells ( $P=0.039$ , Student's t-test).

#### 7.2.5 ELECTROPHYSIOLOGICAL ACTIVITY

To confirm the neuroprotective effect of the anti-MBP T cells, electrophysiological studies were done. Immediately after optic nerve injury, the rats were injected intraperitoneally with PBS or with  $1 \times 10^7$  activated anti-MBP or anti-OVA T cells. The optic nerves were excised 7, 11 or 14 days later and the compound action potentials (CAPs), a measure of nerve conduction, were recorded from the injured nerves. On day 14, the mean CAP amplitudes of the distal segments recorded from the injured nerves obtained from the PBS-injected control rats were 33% to 50% of those recorded from the rats injected with the anti-MBP T cells (Fig. 6A, Table 2). As the distal segment of the injured nerve contains both neurons that escaped the primary insult and injured neurons that have not yet degenerated, the observed neuroprotective effect could reflect the rescue of spared neurons, or a delay of Wallerian

degeneration of the injured neurons (which normally occurs in the distal stump), or both. No effect of the injection anti-MBP T cells on the mean CAP amplitudes of uninjured nerves was observed (Fig. 6B, Table 2). It is unlikely that the neuroprotective effect observed on day 14 could have been due to the regrowth of nerve fibers, as the time period was too short for this.

The strong neuroprotective effect of the anti-MBP T cells seen on day 14 was associated with a significantly decreased CAP amplitude recorded on day 7 (Table 2). The anti-MBP T cells manifested no substantial effect on the uninjured nerve on day 7, indicating that the reduction in electrophysiological activity observed in the injured nerve on day 7 might reflect the larger number of T cells present at the injury site relative to the uninjured nerve (Fig. 1). The observed reduction in CAP amplitude in the injured nerve on day 7 reflected a transient resting state in the injured nerve. This transient effect has not only disappeared, but was even reversed by day 14 (Table 2). Early signs of the neuroprotective effect could already be detected on day 11 in the rats injected with anti-OVA T cells, no reduction in CAP amplitude on day 7 could be detected in either the injured or the uninjured nerves, and no neuroprotective effect was observed on day 14 (Table 2). Thus, it seems that the early reduction in CAP and the late neuroprotection shown specifically by the anti-MBP T cells are related.

TABLE 2. Transient reduction in electrophysiological activity of the injured optic nerve induced by anti-MBP T cells, followed by a neuroprotective effect

	<u>Uninjured Optic Nerve</u>		<u>Injured Optic Nerve</u>	
	<u>Day 7</u>	<u>Day 14</u>	<u>Day 7</u>	<u>Day 14</u>
Ratio (%) T <sub>MBP</sub> /PBS	89.9±9.4 (n=22)	101.2±22.7 (n=10)	63.8*±14.9 (n=17)	243.1**±70.8 (n=8)
Ratio (%) T <sub>OVA</sub> /PBS	109.7±13.2 (n=11)	92.5±12.6 (n=3)	125.5±24.4 (n=11)	107.3±38.9 (n=4)

Immediately after optic nerve injury, rats were injected with PBS or with activated anti-MBP or anti-OVA T cells. After 7 or 14 days, the CAPs of injured and uninjured nerves were recorded. Ratios were calculated for uninjured nerves as (mean CAP of uninjured nerves from T cell-injected rats/mean CAP of uninjured nerves from PBS-injected rats) x 100, or for injured nerves as (mean CAP of injured nerves from T cell-injected rats/mean CAP of injured nerves from PBS-injected rats) x 100. The P value was calculated by comparing the logarithms of the normalized CAP amplitudes of nerves from PBS-injected rats and rats injected with T cells, using the unpaired Student's test, \*P<0.05; \*\*P<0.001 n=sample size.

### 7.3 NEUROPROTECTION IN SPINAL CORD INJURY

#### 7.3.1. MATERIALS AND METHODS

Animals, antigens (MBP, OVA) and T cell lines were as described hereinbefore in 6.1.1, 6.1.3 and 6.1.4, respectively

**Contusion.** Adult rats (300 to 350g) were anesthetized and the spinal cord was exposed by laminectomy at the level of T7-T8. One hour after induction of anesthesia, a 10 gram rod was dropped onto the laminectomized cord from a height of 50 mm. The impactor device (designed by Prof. Wise Young) allowed, for each animal, measurement of the trajectory of the rod and its contact with the spinal cord to allow uniform lesion. Within an hour of the contusion, rats were

injected i.p., on a random basis, with either  $10^7$  cells (specific to either MBP or OVA, depending on the experimental design) or with PBS. Bladder expression was done at least twice a day (particularly during the first 48h after injury, when it was done 3 times a day) until the end of the second week, by which time the rats had developed autonomous bladder voidance. Approximately twice a week, locomotor activity (of the trunk, tail and hind limbs) in an open field was evaluated by placing the rat for 4 min in the middle of a circular enclosure made of molded plastic with a smooth, non-slip floor (90 cm diameter, 7 cm wall height).

#### 7.3.2 RESULTS

The present study of spinal cord neuroprotection was prompted by the previous example that partial injury to an optic nerve can be ameliorated administering T cells directed to a CNS self-antigen. The question was whether autoimmune T cells could have a beneficial effect on recovery from traumatic spinal cord injury with its greater mass of injured CNS tissue and the attendant spinal shock.

Adult Lewis rats were subjected to a calibrated spinal cord contusion produced by dropping a 10 gram weight from a height of 50 mm onto the laminectomized cord at the level of T7-T8 (see description included in Basso et al., Exp-Neurol 139, 244-256, 1996). The rats were then injected intraperitoneally with autoimmune T cells specific to MBP. Control rats were similarly injured but received either no T cells or T cells specific to the non-self antigen ovalbumin (OVA). Recovery of the rats was assessed every 3 to 4 days in

terms of their behavior in an open-field locomotion test, in which scores range from 0 (complete paraplegia) to 21 (normal mobility). The locomotor performance of the rats was judged by observers blinded to the identity of the treatment received by the rats. Included in the study was a group of uninjured, sham-operated (laminectomized but not contused) rats which were injected with anti-MBP T cells to verify the activity of the T cells. In all the sham-operated rats, the anti-MBP T cells induced clinical experimental autoimmune encephalomyelitis (EAE), which developed by day 4, reached a peak at day 7 and resolved spontaneously by day 11. Note, therefore, that at the early post-traumatic stage, any effect of the autoimmune T cells on the injured spinal cord, whether positive or negative, would be transiently masked both by spinal shock and by the paralysis of EAE.

Indeed, none of the rats with contused spinal cords showed any locomotor activity in the first few days after the contusion (Fig. 7A). Interestingly, however, the rats treated with anti-MBP T cells recovered earlier from spinal shock; on day 11, for example, when no recovery could be detected in any of the untreated control rats, significant improvement was noted in the T cell-treated rats (Fig. 7A). At all time points thereafter, the rats that had received the autoimmune T cells showed better locomotor recovery than did the untreated injured rats (Fig. 7A). Thus the autoimmune T cells, in spite of being encephalitogenic, did confer significant neuroprotection. Moreover, the phase of neuroprotective activity coincided with the phase of immune paralysis, supporting our suggestion that neuroprotection might be related to transient paralysis.

By one month after trauma the rats in both groups had reached a maximal behavioral score, which then remained at plateau for at least 3 months of follow-up. In the untreated rats, maximal recovery of locomotor behavior, as noted in previous reports of similarly severe contusion (Basso et al., *supra*), was marked by some ineffectual movement of hind-limb joints, but the rats showed no ability support their body weight and walk, and obtained a score of  $7.3 \pm 0.8$  (mean  $\pm$  SEM). In contrast, the average score of the rats that had been treated with the anti-MBP T cells was  $10.2 \pm 0.8$ , and in some rats the value was high as 13. All the rats in the treated group could support their body weight and some could frequently walk in a coordinated fashion. The difference between the two groups, based on 2-factor repeated ANOVA, was statistically significant ( $p < 0.05$ ). The recovery curve based on locomotor activity is nonlinear. The above-described increase in motor activity seen after treatment with the anti-MBP T cells could result from much higher percentage of spared tissue based on a linear regression curve on which the behavioral score is correlated with the amount of neural spinal cord tissue (for example, a difference between 11 and 7) on the locomotion score would be read as a difference between 30% and less than 10% of spared tissue).

In another set of experiments the rats were subjected to a more severe insult, resulting in a functional score of  $1.9 \pm 0.8$  (mean  $\pm$  SEM) in the untreated group and  $7.7 \pm 1.4$  in the treated group (Fig. 7B). This difference of more than 3 fold in behavioral scores was manifested by the almost total lack of motor activity in the control rats as compared with the ability

of the autoimmune T cell-treated rats to move all their joints. The beneficial effect was specific to treatment with anti-MBP T cells; no effect was observed after treatment with T cells specific to the non-self antigen OVA (data not shown). The positive effect of the autoimmune T cells seems to be expressed in the preservation of CNS tissue that escaped the initial lesion, i.e., in neuroprotection. Therefore, the magnitude of the effect would be inherently limited by the severity of the insult; the more severe the lesion, the less the amount of spared tissue amenable to neuroprotection.

To determine whether clinical recovery could be explained in terms of preservation of spinal axons, we performed retrograde labeling of the descending spinal tracts by applying the dye rhodamine dextran amine (Brandt et al, J-Neurosci-Methods 45:35-40, 1992) at T12, below the site of damage. The number of dye-stained cells that could be counted in the red nucleus of the brain constituted a quantitative measure of the number of intact axons traversing the area of contusion. Sections of red nuclei from injured rats treated with anti-MBP T cells (Fig. 8) contained 5-fold more labeled cells than sections taken from the untreated injured rats. Photomicrographs of red nuclei taken from rats treated with anti-MBP T cells (with an open field score of 10) and from PBS-treated rats (with a score of 6) are shown in Fig. 8. These findings indicate that the reduction in injury-induced functional deficit observed in the T cell-treated rats can be attributed to the sparing of spinal tracts, resulting in a higher degree of neuron viability.

After a follow-up of more than 3 months, when the locomotor activity scores had reached a plateau, the site of injury of three of PBS-treated animals and three animals treated with anti-MBP T cells were analyzed by diffusion-weighted MRI. The cords were excised in one piece from top to bottom and were immediately placed in fixative (4% paraformaldehyde). Axial sections along the excised contused cord were analyzed. Fig. 9 shows the diffusion anisotropy in axial sections along the contused cord of a rat treated with autoimmune T cells, as compared with that of PBS-treated control rat. The images show anisotropy in the white matter surrounding the grey matter in the center of the cord. Sections taken from the lesion sites of PBS-treated control rats show limited areas of anisotropy, which were significantly smaller than those seen at comparable sites in the cords of the rats treated with the anti-MBP T cells. Quantitative analysis of the anisotropy, reflecting the number of spared fibers, is shown in Fig. 9. The imaging results show unequivocally that, as a result of the treatment with the autoimmune anti-MBP T cells, some spinal cord tracts had escaped the degeneration that would otherwise have occurred.

### 7.3.3 DISCUSSION OF RESULTS

No cure has yet been found for spinal cord lesions, one of the most common yet devastating traumatic injuries in industrial societies. It has been known for more than 40 years that CNS neurons, unlike neurons of the peripheral nervous system, possess only a limited ability to regenerate after injury. During the last two decades, attempts to promote



regeneration have yielded approaches that lead to partial recovery. In the last few years it has become apparent that, although most of the traumatic injuries sustained by the human spinal cord are partial, the resulting functional loss is nevertheless far worse than could be accounted for by the severity of the initial insult; the self-propagating process of secondary degeneration appears to be decisive.

A substantial research effort has recently been directed to arresting injury-induced secondary degeneration. All attempts up to now have been pharmacologically based, and some have resulted in improved recovery from spinal shock. The present study, in contrast, describes a cell therapy that augments what seems to be a natural mechanism of self-maintenance and leads, after a single treatment, to long-lasting recovery. The extent of this recovery appears to exceed that reported using pharmacological methods.

In most tissues, injury-induced damage triggers a cellular immune response that acts to protect the tissue and preserve its homeostasis. This response has been attributed to macrophages and other cells comprising the innate arm of the immune system. Lymphocytes, which are responsible for adaptive immunity, have not been thought to participate in tissue maintenance. Adaptive immunity, according to traditional teaching, is directed against foreign dangers. Our studies now show, however, that the adaptive T cell immune response can be protective even when there is no invasion by foreign pathogens. In the case of tissue maintenance, the specificity of the T cells is to tissue self-antigens.

Our observation of post-traumatic CNS maintenance by autoimmune T cells suggests that we might do well to reevaluate some basic concepts of autoimmunity. T cells that are specific to CNS self antigens in general, and to MBP in particular, have long been considered to be only detrimental to health. In the present study, however, the same T cell preparation that can produce EAE in the undamaged CNS was found to be neuroprotective in the damaged spinal cord, suggesting that the context of the tissue plays an important part in determining the outcome of its interaction with T cells. It would seem that the tissue deploys specific signals to elicit particular T cell behaviors. Among such signals are costimulatory molecules, particularly members of the B7 family (Lenschow et al., Annu. Rev. Immunol. 14:233-258, 1996). As shown hereinafter, the injured rat optic nerve transiently expresses elevated levels of the costimulatory molecule B7.2, which is constitutively expressed at low levels in the rat CNS white matter and which is thought to be associated with regulation of the cytokine profile of the responding T cells (H. L. Weiner, Annu. Rev. Med. 48:341-51, 1997). The early post-injury availability of the exogenous anti-MBP T cells, coinciding with the observed early post-injury increase in B7.2 would support the idea that signals expressed by the tissue might modulate the T cell response. It is thus conceivable that anti-MBP T cells which cause a monophasic autoimmune disease upon interacting with a healthy CNS nerve, might implement a maintenance program when they interact with damaged CNS tissue expressing increased amounts of B7.2 and probably other costimulatory molecules. The neuroprotective effects of the T

cells may be mediated, at least in part, by antigen-dependent regulation of specific cytokines or neurotrophic factors (M. Kerschensteiner et al., J. Exp. Med. 189:865-870, 1999) produced locally at the site of injury.

Thus, the present invention is also directed to manipulating B7.2 co-stimulatory molecule to prevent or inhibit neuronal degeneration and ameliorate the effects of injury to or disease of the nervous system. B7.2 molecule can be up-regulated for this purpose, using drugs or by genetic manipulation, without undue experimentation.

In a recent study, it was reported that injury to the spinal cord triggers a transient autoimmune response to MBP (Popovich et al., J. Neurosci. Res. 45:349-63, 1996). However, whether that response is detrimental or beneficial remained an open question (Popovich et al., J. Comp. Neurol. 377:443-464, 1997). From our present data, it would appear that the activation of anti-MBP T cells could indeed be beneficial. However, a supplement of exogenous autoimmune T cells may be required to overcome the restrictions on immune reactivity imposed by the immune-privilege of the CNS (J. W. Streilein, Science 270:1158-1159, 1995). The finding that autoimmune response can be advantageous suggests that natural autoimmune T cells may have undergone positive selection during ontogeny, as proposed by the theory of the immunological homunculus (I. R. Cohen, Immunol. Today 13, 490-494 (1992), and are not merely a default resulting from the escape from negative selection of T cells that recognize self antigens (C. A. Janeway, Jr., Immunol. Today 13:11-6, 1992). Such a response could then be

considered as a mechanism of potential physiological CNS self-maintenance, which is, however, not sufficient for the purpose because of the immune-privileged character of the CNS.

A single injection of autoimmune T cells lasted for at least 100 days. Thus, this procedure offers a form of self-maintenance. This specific autoimmune response, when properly controlled, is useful as part of a self-derived remedy for spinal cord injury.

**EXAMPLE: NEUROPROTECTIVE EFFECTS OF NS-SPECIFIC ANTIGEN**

**8.1 MATERIALS AND METHODS**

Animals, crush injury of rat optic nerve, and retrograde labeling are described above in Sections 6 and 7. A peptide based on amino acids 35-55 of myelin/oligodendrocyte glycoprotein (MOG p35-55) was chemically synthesized at the Weizmann Institute, Israel.

**8.1.1 INHIBITION OF SECONDARY DEGENERATION**

Rats were injected intradermally in the footpads with MOG p35-55 (50 µg/animal) and IFA, or PBS ten days prior to optic nerve crush injury. Retinal ganglion cells were assessed two weeks after injury using retrograde labeling as described above. The number of RGCs in rats injected with PBS or MOG p35-55 was expressed as a percentage of the total number of neurons in rats injected with MOG p35-55 in the absence of crush injury.

## 8.2 RESULTS

As shown in Fig. 10, the number of labeled retinal ganglion cells (indicating viable axons) was about 12.5 fold greater in animals injected with MOG p35-55 compared to animals receiving PBS.

### EXAMPLE: NEUROPROTECTIVE EFFECTS OF MBP ADMINISTERED ORALLY

## 9.1 MATERIALS AND METHODS

Animals, crush injury of rat optic nerve, and retrograde labeling of RGCs are described above in Sections 6 and 7.

### 9.1.1 INHIBITION OF SECONDARY DEGENERATION

Bovine MBP (Sigma, Israel) (1 mg/dose) was administered to rats by gavage using a blunt needle. MBP was administered 5 times, every third day, beginning 2 weeks prior to optic nerve crush injury. The number of RGCs in treated animals was expressed as a percentage of the total number of neurons in animals subjected to optic nerve crush injury but which did not receive MBP.

## 9.2 RESULTS

As shown in Fig. 11, the number of labeled RGCs was about 1.3 fold greater in animals treated with MBP compared to untreated animals.

### 9.3 THE B7.2 COSTIMULATORY MOLECULE IS ASSOCIATED WITH POST-TRAUMATIC MAINTENANCE OF THE OPTIC NERVE BY ORAL ADMINISTRATION OF MBP

---

#### 9.3.1 INTRODUCTION

Autoimmune T cells can under under certain conditions be beneficial to traumatized CNS axons. The effect of such T cells on the damaged tissue might be influenced by the nature and amount of the costimulatory molecules it expresses. We show that the B7.2 costimulatory molecule is constitutively expressed in the intact rat optic nerve, and after injury is up-regulated at the margins of the injury site. Pre-injury induction of oral tolerance to MBP resulted in a further post-injury increase in B7.2 at the margins and at the injury site itself, as well as a better preservation of the traumatized nerve. Thus, B7.2 expression in the brain and its up-regulated after trauma seem to be directly related to post-traumatic maintenance displayed by autoimmune T cells.

Neuronal injury in the CNS causes degeneration of directly damaged fibers as well as of fibers that escaped the primary insult. It also triggers a systemic response of autoimmune T cells to MBP, that might affect the course of degeneration of the injured nerve. Whether the effect of these T cells on the nerve is detrimental or beneficial may depend, in part, on the nature and level of the costimulatory molecules expressed by the damaged tissue. Several costimulatory molecules have recently been identified, including the B7 and CD40 molecules (Caux et al., "Activation of Human Dendritic Cells Through CD40 Cross-Linking", J. Exp. Med. 180:1263-1272,

1994; and Lenschow et al., "CD28/B7 System of T Cell Costimulation", Annu. Rev. Immunol. 14:233-258, 1996). CD40 appears to be dominant during cell differentiation in the lymph nodes and B7 during activation of T cells in the target organ (Grewal et al., "Requirement for CD40 Ligand in Costimulation Induction, T Cell Activation, and Experimental Allergic Encephalomyelitis", Science 273:1864-1867, 1996). B7 costimulatory molecules are expressed on antigen-presenting cells (APCs) as B7.1 or B7.2., which might preferentially support activation of the Th1 or the Th2 type of immune response, respectively (Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy", Cell 80:707-718, 1995; and Karandikar et al., "Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease", J. Neuroimmunol. 89:10-18, 1998). We were therefor interested in determining the identity B7 subtype expressed in intact and injured CNS white matter, and its possible influence on the course of the response to the injury.

### 9.3.2 RESULTS

The costimulatory molecule expressed constitutively in the intact optic nerves of adult Lewis rats was identified as B7.2. (Figs. 12A, 12B). To examine the effects of neurotrauma on the expression of B7 costimulatory molecules, we inflicted a mild crush injury on the optic nerves of Lewis rats and assessed the neural expression of B7 by immunohistochemical analysis. The most striking effect of the injury was seen on

B7.2 expression manifested on post-injury day 3 by its elevation at the margins of the injury site (Figs. 12C,D,E). In contrast, expression of B7.1 was not detected in the optic nerve either before or 3 days after injury. On day 7, however, B7.1 was detectable at the site of injury, having pattern reminiscent of that seen for macrophages or microglia (Fig. 12F).

Next, we attempted to determine whether the degenerative response to optic nerve injury could be modified by peripheral manipulation of the immune system. The manipulation chosen was induction of oral tolerance, known to cause a "bystander" T cell immunosuppressive effect (Weiner et al., "Tolerance Immune Mechanisms and Treatment of Autoimmune Diseases", Immunol. Today 18:335-343, 1997). Ingestion of low doses of MBP results in the activation of T cells which, based on antigen recognition, secrete TGF as the dominant cytokine and thus favor an immune response of Th2/3 type (Chen, Y., "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis", Science 265: 1237-1240, 1994).

Lewis rats were fed with food to which 1 mg of bovine MBP had been added five times daily every other day. Ten days after first receiving the supplement, the rats were subjected to mild unilateral optic nerve crush injury. This time interval between initiation of oral tolerance and injury was chosen to allow adequate build-up of the systemic T cell response. As shown in Fig. 13A and B, the numbers of macrophages or active microglia (indicated by ED-1 labeling) and T cells (indicated by immunolabeling for T cell receptor),



assessed 3 days after injury, did not differ from those observed in control injured rats which did receive any treatment or were fed with PBS. In the rats with induced oral tolerance to MBP, however, the amounts B7.2 were further increased at the margins of the site of injury (Fig. 13C) as compared with controls (Fig. 12E). In addition, B7.2 in the rats with induced oral tolerance to MBP was also elevated at the site of injury relative to the control nerves (Fig. 13C). It seems reasonable to assume that the T cells exposed to MBP via intestinal absorption, upon invading the injured CNS, contributed to the increase in expression of B7.2 by the injured nerve.

We then attempted to determine whether the observed changes in B7.2 expression in the injured rats was correlated with the extent of neuronal degeneration. Acute injury of the rat optic nerve is followed by a process of nerve degeneration, which can be quantified by retrograde labeling of the surviving neurons and counting of the corresponding cell bodies. Two weeks after optic nerve injury the number of surviving retinal ganglion cells (RGCs), representing still-viable neurons, in the group of MBP-fed rats was significantly higher than that in the control group, or than in the group of rats with injured nerves that were fed with ovalbumin. Interestingly, the benefit of the induced oral tolerance to MBP was increased by feeding the rats with more intensive schedule (Fig. 14).

## DISCUSSION OF EXPERIMENTAL RESULTS

The results of the experiments described in Sections 6 and 7 show that activated T cells accumulate at a site of injury in the CNS. Furthermore, the results also demonstrate that the accumulation of T cells at the site of injury is a non-specific process, i.e., T cells which accumulated at the site of injury included both T cells which are activated by exposure to an antigen present at the site of injury as well as T cells which are activated by an antigen not normally present in the individual.

The results of experiments described in Section 7 demonstrate that the beneficial effects of T cells in ameliorating damage due to injury in the CNS are associated with an NS-specific self-antigen as illustrated by MBP. More specifically, the administration of non-recombinant T cells which were activated by exposure to an antigen which can cause autoimmune disease ( $T_{MBP}$ ), rather than aggravating the injury, led to a significant degree of protection from secondary degeneration. Thus, activating T cells by exposure to a fragment of an NS-specific antigen was beneficial in limiting the spread of injury in the CNS. The present findings show that secondary degeneration can be inhibited by the transfer into the individual on non-recombinant T cells which recognize an NS-specific self antigen which is present at a site of injury. The T cells may recognize cryptic or non-pathogenic epitopes of NS-self antigens.

In addition, the studies described in Sections 8 and 9 show that activation of T cells by administering an immunogenic antigen (e.g. MBP) or immunogenic epitope of an antigen (e.g.

MOG p35-55), may be used for preventing or inhibiting secondary CNS degeneration following injury.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention. Thus the expressions "means to..." and "means for...", or any method step language, as may be found in the specification above and/or in the claims below, followed by a functional statement, are intended to define and cover whatever structural, physical, chemical or electrical element or structure, or whatever method step, which may now or in the future exist which carries out the recited function, whether or not precisely equivalent to the embodiment or embodiments disclosed in the specification above, i.e., other means or steps for carrying out the same function can be used; and it is intended that such expressions be given their broadest interpretation.

All publications cited herein are incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. A method for preventing or inhibiting neuronal degeneration in the central nervous system or peripheral nervous system for ameliorating the effects of injury or disease, comprising administering to an individual in need thereof at least one active ingredient selected from the group consisting of NS-specific activated T cells; a NS-specific antigen; a peptide derived from a NS-specific antigen; a nucleotide sequence encoding a NS-specific antigen; and a nucleotide sequence encoding a peptide derived from a NS-specific antigen.

2. The method according to claim 1 wherein the injury is selected from the group consisting of spinal cord injury, blunt trauma, penetrating trauma, hemorrhaging stroke, and ischemic stroke.

3. The method according to claim 1 wherein the disease is selected from the group consisting of diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's disease, facial nerve palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency.

4. The method according to claim 1 wherein said NS-specific activated T cells are selected from the group consisting of autologous T cells, allogeneic T cells from related donors, and HLA-matched or partially matched semi-allogeneic or fully allogeneic donors.

5. The method according to claim 4 wherein said autologous T cells have been sensitized to human NS antigen.

6. The method according to claim 5 wherein said T cells have previously been taken from an individual, have been sensitized to human NS antigen, and then have been stored for future use.

7. The method according to claim 4 wherein said T cells are autologous T cells.

8. The method according to claim 4 wherein said T cells are semi-allogeneic T cells.

9. The method according to claim 1 wherein said NS-specific antigen is selected from the group consisting of myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein, myelin-associated glycoprotein, S-100,  $\beta$ -amyloid, Thy-1, P0, P2, and neurotransmitter receptors.

10. The method according to claim 1 wherein said peptide derived from a NS-specific antigen is selected from the group consisting of immunogenic epitopes of said antigen and cryptic epitopes of said antigen.

11. The method according to claim 10 wherein said peptide is an immunogenic epitope or a cryptic epitope derived from myelin basic protein.

12. The method according to claim 10 wherein said peptide corresponds to at least one of the sequences selected from the group consisting of p11-30, p51-70, p91-110, p131-150, and p151-170 of myelin basic protein.

13. The method according to claim 1 wherein the NS-specific antigen or peptide derived therefore is administered intravenously, intraperitoneally, orally, intranasally, intrathecally, intradermally, topically, or buccally.

14. The method according to claim 13 wherein said mucosal administration is selected from the group consisting of oral, intranasal, buccal, vaginal, and rectal administration.

15. The method according to claim 1 wherein myelin basic protein is administered orally.

16. The method according to claim 1 wherein said composition is administered orally and the individual is actively immunized to build up a critical T cell response.

17. A method for preventing or inhibiting neuronal degeneration in the central nervous system or peripheral nervous system comprising administering to an individual in need thereof an effective amount of a composition for up-regulating B7.2 costimulatory molecule or genetically manipulating B7.2 costimulatory molecule in said individual.

18. A cell bank comprising T cells which have been expanded against self central nervous system antigen.

19. A method for providing T cells for inhibiting or preventing neuronal degeneration in the central nervous system or peripheral nervous system for ameliorating the effects of injury or disease comprising:

obtaining T cells from an individual;

activating said T cells against at least one nervous system antigen; and

banking said activated T cells for future use.

20. A composition for preventing or inhibiting neuronal degeneration in the central nervous system or peripheral nervous system for ameliorating the effects of injury or disease, comprising an effective amount of at least one active ingredient selected from the group consisting of

NS-specific activated T cells; a NS-specific antigen; a peptide derived from a NS-specific antigen; a nucleotide sequence encoding a NS-specific antigen; and a nucleotide sequence encoding a peptide derived from a NS-specific antigen.

21. The composition according to claim 20 wherein the injury is selected from the group consisting of spinal cord injury, blunt trauma, penetrating trauma, hemorrhaging stroke, and ischemic stroke.

22. The composition according to claim 20 wherein the disease is selected from the group consisting of diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's disease, facial nerve palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency.

23. The composition according to claim 20 wherein said NS-specific activated T cells are selected from the group consisting of autologous T cells, allogeneic T cells from related donors, and HLA-matched or partially matched semi-allogeneic or fully allogeneic donors.

24. The composition according to claim 23 wherein said autologous T cells have been sensitized to human NS antigen.

25. The composition according to claim 24 wherein said T cells have previously been taken from an individual, have been sensitized to human NS antigen, and then have been stored for future use.

26. The composition according to claim 23 wherein said T cells are autologous T cells.

27. The composition according to claim 23 wherein said T cells are semi-allogeneic T cells.

28. The composition according to claim 20 wherein said NS-specific antigen is selected from the group consisting of myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein, myelin-associated glycoprotein, S-100,  $\beta$ -amyloid, Thy-1, P0, P2, and neurotransmitter receptors.

29. The composition according to claim 20 wherein said peptide derived from a NS-specific antigen is selected from the group consisting of immunogenic epitopes of said antigen and cryptic epitopes of said antigen.

30. The composition according to claim 29 wherein said peptide is an immunogenic epitope or a cryptic epitope derived from myelin basic protein.

31. The composition according to claim 30 wherein said peptide corresponds to at least one of the sequences selected from the group consisting of p11-30, p51-70, p91-110, p131-150, and p151-170 of myelin basic protein.

32. The composition according to claim 20 wherein the NS-specific antigen or peptide derived therefore is administered intravenously, intraperitoneally, orally, intranasally, mucosally, intrathecally, intradermally, topically, or buccally.

33. The composition according to claim 32 wherein said mucosal administration is nasal, intranasal, buccal, vaginal, or rectal.

34. The composition according to claim 20 wherein myelin basic protein is administered orally.



35. The composition according to claim 20 wherein said composition is administered orally and the individual is actively immunized to build up a critical T cell response.

36. A composition according to claim 20 further comprising an effective amount of a composition for up-regulating B7.2 costimulatory molecule or genetically manipulating B7.2 costimulatory molecule in said individual.

37. A cell bank comprising T cells which have been expanded against at least one nervous system antigen.

SECRET

[illegible]

\_\_\_\_\_

# ACTIVATED T CELLS NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES

## TABLE OF CONTENTS

	<u>Page</u>
1. FIELD OF THE INVENTION . . . . .	- 1 -
2. BACKGROUND OF THE INVENTION . . . . .	- 1 -
3. SUMMARY OF INVENTION . . . . .	- 4 -
4. BRIEF DESCRIPTION OF THE FIGURES . . . . .	- 6 -
5. DETAILED DESCRIPTION OF THE INVENTION . . . . .	- 14 -
5.1 NS-SPECIFIC ANTISELF ACTIVATED T cells . . . . .	- 14 -
5.2 NS-SPECIFIC ANTIGENS AND PEPTIDES DERIVED THEREFROM . . . . .	- 21 -
5.3 NUCLEOTIDE SEQUENCES ENCODING NS-ANTIGENS AND PEPTIDES DERIVED THEREFROM . . . . .	- 25 -
5.4 THERAPEUTIC USES . . . . .	- 25 -
5.5 FORMULATIONS AND ADMINISTRATION . . . . .	- 26 -
5.6 ESTABLISHMENT OF AUTOCOGOUS CELL BANKS . . . . .	- 31 -
6. EXAMPLE: ACCUMULATION OF ACTIVATED T cells IN INJURED OPTIC NERVE . . . . .	- 31 -
6.1 MATERIALS AND METHODS . . . . .	- 31 -
6.1.1 ANIMALS . . . . .	- 31 -
6.1.2 MEDIA . . . . .	- 32 -
6.1.3 ANTIGENS . . . . .	- 32 -
6.1.4 T cell LINES . . . . .	- 33 -
6.1.5 CRUSH INJURY OF RAT OPTIC NERVE . . . . .	- 33 -
6.1.6 IMMUNOCYTOCHEMISTRY OF T cells . . . . .	- 33 -
6.2 RESULTS . . . . .	- 34 -
7. EXAMPLE: NEUROPROTECTION BY AUTOIMMUNE ANTI-MBP T cells . . . . .	- 34 -
7.1 MATERIALS AND METHODS . . . . .	- 34 -
7.1.1 RETROGRADE LABELING AND MEASUREMENT OF PRIMARY DAMAGE AND SECONDARY DEGENERATION . . . . .	- 35 -
7.1.2 ELECTROPHYSIOLOGICAL RECORDINGS . . . . .	- 36 -
7.1.3 CLINICAL EVALUATION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS . . . . .	- 37 -

[illegible]

7.2 RESULTS . . . . .	37 -
7.2.1 NEUROPROTECTION BY AUTOIMMUNE ANTI-MBP T cells . . . . .	37 -
7.2.2 CLINICAL SEVERITY OF EAE . . . . .	38 -
7.2.3 SURVIVAL OF RGCS IN NON-INJURED NERVES . . . . .	38 -
7.2.4 NEUROPROTECTION BY T cells REACTIVE TO A CRYPTIC EPITOPE . . . . .	38 -
7.2.5 ELECTROPHYSIOLOGICAL ACTIVITY . . . . .	40 -
7.3 NEUROPROTECTION IN SPINAL CORD INJURY . . . . .	41 -
7.3.1 MATERIALS AND METHODS . . . . .	41 -
7.3.2 RESULTS . . . . .	42 -
7.3.3 DISCUSSION . . . . .	45 -
8. EXAMPLE: NEUROPROTECTIVE EFFECTS OF NS-SPECIFIC ANTIGEN . . . . .	48 -
8.1 MATERIALS AND METHODS . . . . .	48 -
8.1.1 INHIBITION OF SECONDARY DEGENERATION . . . . .	48 -
8.2 RESULTS . . . . .	48 -
9. EXAMPLE: NEUROPROTECTIVE EFFECTS OF MBP ADMINISTERED ORALLY . . . . .	48 -
9.1 MATERIALS AND METHODS . . . . .	48 -
9.1.1 INHIBITION OF SECONDARY DEGENERATION . . . . .	48 -
9.2 RESULTS . . . . .	49 -
9.3 THE B 7.2 COSTIMULATORY MOLECULE IS ASSOCIATED WITH POST-TRAUMATIC MAINTENANCE OF THE OPTIC NERVE . . . . .	49 -
9.3.1 INTRODUCTION . . . . .	49 -
9.3.2 RESULTS . . . . .	50 -
10. DISCUSSION OF EXPERIMENTAL RESULTS . . . . .	52 -




FIG. 1




FIG. 2

666750 1977E60




FIG. 3A




FIG. 3B




FIG. 3C

160  $\mu$ m






FIG. 4A




FIG. 4B




FIG. 5





FIG. 6





FIG. 8





FIG. 9

site of contusion






FIG. 10









FIG. 8/

FIG. 12



0034464 054000



[illegible]

FIG. 14



Experiment Groups

1 ccaagaagat cccacagcag cttccgaagg cctggatgtg atggcatcac agaagagacc  
 61 ctcacagcga cacggatcca agtacttggc cacagcaagt accatggacc atgcccggca  
 121 tggcttcctc ccaaggcaca gagacacggg catccttgac tccatcgggc gcttctttag  
 181 cggtgacagg ggtgcgcca agcggggctc tggcaaggac tcacacacaa gaactacca  
 241 ctacggctcc ctgccccaga agtcgcagag gacccaagat gaaaaccag tagtccactt  
 301 cttcaagaac attgtgacac ctcgtacacc ccctccatcc caaggaaagg ggagaggcct  
 361 gtccctcagc agatttagct ggggaggaag agacagccgc tctggatctc ccatggcaag  
 421 acgctgagag cctccctgct cagccttccc gaatcctgcc ctcggcttct taatataact  
 481 gccttaaacg ttttaattcta cttgcaccaa atagctagtt agagcagacc ctctcttaat  
 541 cccgtggggc tgtgaacgcg gcgggccagc ccacggcacc ctgactggct aaaactgttt  
 601 gtcccttttt at

FIG. 15

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

1 gaaaacagtg cagccacctc cgagagcctg gatgtgatgg cgtcacagaa gagaccctcc  
 61 cagaggcacg gatccaagta cctggccaca gcaagtacca tggaccatgc caggcatggc  
 121 ttcctcccaa ggcacagaga cacgggcac cttgactcca tcgggcgctt ctttggcggg  
 181 gacaggggtg cgccaaagcg gggctctggc aaggactcac accaccggc aagaactgct  
 241 cactatggct ccctgcccc aaggtcacac ggccggaccc aagatgaaaa ccccgtagtc  
 301 cacttcttca agaacattgt gacgcctcgc acaccacccc cgtcgcaggg aaaggggaga  
 361 ggactgtccc tgagcagatt tagctggggg gccgaaggcc agagaccagg atttggtac  
 421 ggaggcagag cgtccgacta taaatcggt cacaagggat tcaaggaggt cgtgcccag  
 481 ggcacgcttt ccaaaatttt taagctggga ggaagagata gtcgctctgg atcaccatg  
 541 gctagacgct gaaaaccac ctgggtccgg aatcctgtcc tcagcttctt aatataactg  
 601 ccttaaaact ttaatccac ttgccctgt tacctaatta gagcagatga cccctcccct  
 661 aatgcctgcg gagttgtgca cgtagtaggg tcaggccacg gcagcctacc ggcaatttcc  
 721 ggccaacagt taaatgagaa catgaaaaca gaaaacggtt aaaaactgtcc ctttctgtgt  
 781 gaagatcacg ttccttcccc cgcaatgtgc ccccagacgc acgtgggtct tcagggggcc  
 841 aggtgcacg acgtccctcc acgttcaccc ctcaccctt ggacttctt ttcgcccgtg  
 901 ctcggcaccc ttgcgctttt gctgggtcact gccatggagg cacacagctg cagagacaga  
 961 gaggacgtgg gcggcagaga ggactgttga catccaagct tcctttgttt ttttttctg  
 1021 tcttctctc acctcctaaa gtagacttca tttttcctaa caggattaga cagtcaagga  
 1081 gtggcttact acatgtggga gctttttggt atgtgacatg cgggctgggc agctgttaga  
 1141 gtccaacgtg gggcagcaaa gagagggggc cacctcccca ggccgtggct gccacacac  
 1201 cccaattagc tgaattcgcg tgtggcagag ggaggaaaag gaggcaaagc tgggctgggc  
 1261 aatggcctca cataggdaac agggctcttc tggagatttg gtgatggaga tgtcaagcag  
 1321 gtggcctctg gacgtcaccg ttgccctgca tgggtggccc agagcagcct ctatgaacaa  
 1381 cctcgtttcc aaaccacagc ccacagccgg agagtccagg aagacttgcg cactcagagc  
 1441 agaagggtag gagtccctca gacagcctcg cagccgcgc cagtcgccc atgacactggc  
 1501 tgtgaccggg cgtgctggca gcggcagtg acagtggcca gcactaacc tccctgagaa  
 1561 gataaccggc tcattcactt cctcccagaa gacgcgtggt agcgagtagg cacaggcgtg  
 1621 cacctgctcc cgaattactc accgagacac acgggctgag cagacggccc ctgtgatgga  
 1681 gacaaagagc tcttctgacc atatccttct taacaccgc tggcatctcc tttcgcgct  
 1741 ccctccctaa cctactgacc caccttttga ttttagcgca cctgtgattg ataggccttc  
 1801 caaagagtcc cagctggca tcaccctccc cgaggacgga gatgaggagt agtcagcgtg  
 1861 atgcaaaaac gcgtcttctt aatccaattc taattctgaa tgtttcgtgt gggcttaata  
 1921 ccatgtctat taatatatag cctcgatgat gagagagtta caaagaacaa aactccagac  
 1981 acaaacctcc aaatttttca gcagaagcac tctgcgtcgc tgagctgagg tcggctctgc  
 2041 gatccatacg tggccgcacc cacacagcac gtgctgtgac gatggctgaa cggaaagtgt  
 2101 acactgttcc tgaatattga aataaaacaa taaactttt

FIG. 16

A.

1	taatatctag	ggktttgact	ctgacccggtg	ttggggctct	cacttcacgg	cttctcacgc
61	ttgtgctgca	tatcccacac	caattagacc	caaggatcag	ttggaagttt	ccaggacatc
121	ttcattttat	ttccaccctc	aatccacatt	tccagatgtc	tctgcagcaa	agcgaaattc
181	caggcaagcc	ttagggaaaa	aaggaaaaac	aaagaaaatg	aaacaattgg	cagtgaagg
241	cagaaagaga	agatggagcc	cttagagaag	ggagtatccc	tgagtaggtg	gggaaaagg
301	gaggagaagg	ggaggaggag	aggaggagga	aagcaggcct	gtccctttaa	gggggttggc
361	tgtcaatcag	aaagcccttt	tcattgcagg	agaagaggac	aaagatactc	agagagaaaa
421	agtaaaagac	cgaagaagga	ggctggagag	accaggatcc	ttccagctga	acaaagtcag
481	ccacaaagca	gactagccag	ccggctacaa	ttggagtcag	agtcccaaag	acatgggtaa
541	gtttcaaaaa	ctttagcatt	gaagattcaa	gaggacacag	g	

B.

1	ctgctttcag	agcctgtgac	ttcttgtgtg	cctctcctgt	ttctcagcaa	catggcatag
61	ggcctgggat	accaggtctg	gggatctcag	ggactcttag	cactttaaga	cacatgtgtt
121	cccaggccct	ggtgtgttcc	tctagtcca	gaaagatgtt	tcatgttttg	ctgactttgt
181	ataaagtctg	tttgtagctg	ttttgacaga	atctcagcgt	ataactgagg	gtggggacat
241	tagccaagct	gcattatagg	aggacaaaac	tgccatacaa	agtgtccaaa	atcattaagc
301	ctgcattttt	attattggga	gtaatatcaa	acctcctatt	ttccaatttt	catttcttgt
361	cctgtgctag	ctccatcctg	tttgactgc	tcctccata	tgtaaaactaa	gaagaatcaa
421	gcattctttg	caacaaatac	acacgatgct	caaaaatgtc	caggagcatc	caatttccaa
481	agtttcctcc	acctggaatg	ctcttcacgc	taaaatcctg	tctgacaata	ccagcatctc
541	tggcctgcac	tcaccccttc	ctggaactcc	aagtgcattt	acctctgtgt	accacttaet
601	tggctgcctg	aattgttagt	tgaaaatatt	aggtctactt	agctaattct	tcctcaggaa
661	attaaagact	cccataatgg	agagtctgtg	tcttttctct	cttcatatcc	cgtataacac
721	ccagcataat	gctgggcata	tagtgagtat	tccataaata	gttgatgaat	gactaaaata
781	agcaagcaaa	caaacagact	agaacaataa	gaaagaagg	actggatttc	ataatctctc
841	tggcttgcta	tttgaattgc	tgaattatta	ttatttttta	aatatttttt	aaattctggc
901	aataaaaagg	aaggatttat	tttcttttct	tctttttttt	tttcttgaga	cagagtctcg
961	ctcttactgc	ccaggctgga	gtacaatggc	gcaatcttgg	ctcacggcaa	cctccgcctc
1021	ctcctgggtt	taacagattc	tcctgtctca	gcctcctgag	tagctgggat	tacaggcata
1081	cgcccatgcc	cggtcaattt	ttgtattttt	agtagagacg	gggttttgcc	atgttggcca
1141	ggctggtctt	gaactcctga	cctcatgtga	tccacctgcc	tcagcctccc	aaagtgtggt
1201	gattacaggc	atgcgccacc	gtgcccgccc	aaagatttat	tttcaagaat	gaaacaaagt
1261	aaggattctg	ggtcaatctc	acatgctgaa	agcctaaaacc	tctagccgct	cctgcttttt
1321	gacttcggag	tgcccactat	ctccgagcct	gtgagcacag	ggcctggcag	aggggtttga
1381	gtggcatgag	ctacctactg	gatgtgcctg	actgtttccc	cttcttcttc	cccaggcttg
1441	ttagagtgtc	gtgcaagatg	tctggtaggg	gccccctttg	cttccctggt	ggccactgga
1501	ttgtgtttct	ttgggtgggc	actgttctgt	ggctgtggac	atgaagccct	cactggcaca
1561	gaaaagctaa	ttgagaccta	tttctccaaa	aactaccaag	actatgagta	tctcatcaat
1621	gtgtaagtac	ctgccctccc	acacagaccc	atcttttttt	tcctctcttc	catcctggag
1681	atagagaact	cttcagtacc	ttagtaacta	gcaggggact	ggggtggagc	cagaccggat
1741	tcccagagtct	tccctctgtg	ca			

FIGS. 17A-B

C.

1	ctagaaaatc	cctagccttg	ttaagggtgct	cgctctgggtg	tatacctcac	ttatgtcggg
61	aaagaagcca	ggtcttcaat	taataagatt	ccctgggtctc	gtttgtctac	ctgtaaatgc
121	aggatccatg	ccttccagta	tgtcatctat	ggaactgcct	ctttcttctt	cctttatggg
181	gccctcctgc	tggtcgaggg	cttctacacc	accggcgag	tcaggcagat	ctttggcgac
241	tacaagacca	ccatctgcgg	caagggcctg	agcgcaacgg	taacaggggg	ccagaagggg
301	aggggttcca	gaggccaaca	tcaagctcat	tctttggagc	gggtgtgtca	ttgtttggga
361	aaatggctag	gacatcccga	caagggtgatc	atcctcagga	ttttgtggca	ataacaaggg
421	gtgggggaaa	attggggcgg	agtctgtggc	ctcgtcccca	cccaaggctg	ggtcctctct
481	aggggcctgg	catttgagtg	aggaagcgat	ggctgcagcc	gaacgagaag	gtcaggaaga
541	acgtgggtgcc	cagctggcct	agcctcacct	ttcaaagggt	ccctaagcaa	atttcttctc
601	aaaacagaaa	gcatgagttt	tgtgggatgc	tttgtacaat	cagaccattt	ctaagccatc
661	tggttggtatc	cctttgttcc	cttccatagta	ggtaccacaa	gagtggatct	aactggacaa
721	gagtctaaaa	tgctgctcat	gtgattgaga	cttgggcacc	tgagctraga	gggaggatgg
781	ataataaaaa	ttaaataata	actccaagg	aaatttacia	tgttctgg	

D.

1	gacccctc	attcttcccc	tacccattcc	ccccaccctc	cgttatactg	gggccagtta
61	tctagtagat	actgccaatt	acccttggca	gaggtgccct	gctcactaat	tttatttggg
121	ggagmgccct	ggaacctggt	tttaatgtct	ggcacacgcc	acttccagga	tctcccaggt
181	tggtgttcta	catctgcagg	ctgatgctga	tttctaacca	acccatgtca	atcatttttag
241	tttgtgggca	tcacpctatgc	cctgaccgtt	gtgtggctcc	tggtgtttgc	ctgctctgct
301	gtgcctgtgt	acattttactt	caacacctgg	accacctgcc	agtctattgc	cttccccagc
361	aagacctctg	ccagtatagg	cagtctctgt	gctgatgcca	gaatgtatgg	tgagttaggg
421	tacgggtgct	ttggctctcc	taccactat	ggaagcacta	tatatttgg	tattttctta
481	gtgtaaggag	ggtgggtgatt	atgagaaaaa	tataagatga	tgaatgattg	ggtcttagtt
541	tattaatcct	tccctactga	aaccagagag	gtttcttccc	ccggaaggga	acttgggaagt
601	ggtggggagtt	ttcttggcca	ttcacattgg	cctactctag	ttgactgctg	ttcacaaccc
661	caaagcagca	catttcaata	acaaacacaa	ggttdsacca	ctgttcaata	ccaccttctc
721	ttttttgtaa	acctgtagaa	aagaggatcc	taattgttgg	tagmatccaa	mtttacagcc
781	aggataatta	gagatggaag	aagggctctg	ggggaaagtc	tccatgtggc	cccgtaactc
841	cataaagctt	accctgcttg	ctttttgtgt	cttacttagg	tggtctccca	tggaatgctt
901	tccctggcaa	ggtttgtggc	tccaaccttc	tgtccatctg	caaaacagct	gaggtgagtg
961	ggttatttgg	gttattttac	aagggagtag	ctaataccat	acaaattaca	cccatggcct
1021	tcaatttttaa	ggactgaaag	tttccctttg	ctggattttg	aattagccga	ttgcttctta
1081	caacatgttg	gctaagtgtg	cctgagccaa	tgagcataga	aggtaaaaca	cctcttttct

E.

1	aattagcaca	cagaaaggat	atccaacaca	tacaaagctg	tnntcatgga	ctacactgga
61	gcatattact	gctgttgcaa	gaaacatttc	ttcttcctct	tttcattttc	ctgcagttcc
121	aatgacctt	ccacctgttt	attgctgcat	ttgtgggggc	tgagctaca	ctgggttccc
181	tggtgagttg	actttgaatg	atcttggcga	gtaaataggc	ctgagatagt	tgtgggtaca
241	gctattctga	aaggcaagaa	ggtagactgc	ttccatcctt	gaaatgctgg	agggga

FIGS. 17C-E





1	atggaaatgt	tctgtatttg	tgttgctctga	tgagataacc	actaactgta	gtgctattga
61	gcatttgaaa	catggctagt	gtaatcaatg	aaccaaattt	ttaattttat	ttaattgtaa
121	ttaatttttaa	gtggccacat	gcagggagtg	actgctgcat	tggaacagcac	ggctctaaat
181	tgagcctttt	ttccttattt	ggtgagggcat	acttgccctta	agattgggaa	gtctattttt
241	ggaacctgct	accaatgctg	gtctcacact	tgcaattctc	agctgagcca	agaggtgaga
301	gaaaggctg	ttccattcc	aagatctcac	tctccctgt	gacactgagg	aaactggcaa
361	gtgatgtgaa	ggctggagag	cgtgtcctgt	atgctggctc	tgtcccttct	gcctgtgttg
421	actgacatag	ttagttgctg	cccttgctgg	tctcccttcc	tccaaccttg	cctctctgag
481	cacacctgac	attcatctca	tgacttccct	aaaaacattc	tttgggaaca	agaaactaac
541	aaatcccaag	tgacctatca	catatacaaa	catacagggc	agagtttgga	ttcgcggtag
601	aagaaaggga	ggtagacat	taagaagaat	ggtctggtga	tgacagttgt	gagataatag
661	aaacaggaaa	aagaaatcta	agttttcttt	ctttttttaa	gaaccaataa	taatttctct
721	cttttgacta	gtcagtaggg	ctggggtgga	ttggaggaag	cttacatatt	ccatgaacaa
781	gcctcttcct	aaggctcctg	aagtgtcctg	gccccactga	ttagccctta	gaagaccctt
841	caaagggttg	atctccagga	gggagtgagg	gaggaaagcc	ctgtaccagg	cagcctctgc
901	tccattgctc	tgggggggtg	gggaagacaa	accctggtca	tccccctcag	tctgtaccct
961	tttgtgtgag	tgccctggcaa	gggtgacgtg	gggctgtttc	tgcgggcaca	gctgcagcaa
1021	ttaccggagt	ggaggcaggg	cccaggcagc	actgccctcc	aagatcttcc	cttgggcttt
1081	tcagcagtaa	ggggacatgc	acccaaggg	cctccacttg	gcctgacctt	gctgcggggg
1141	ctctctgtcc	ccagggaacg	tagagatggc	aagcttatcg	agaccctctc	tgcccagctg
1201	cctctgtctc	ttcctctctc	ttcctctctc	ccaagtgtct	tccagctatg	caggttaagac
1261	atgttttttt	ttcctgccctg	gggagaccct	gaaaacagaa	aggctagtgt	cctggggggt
1321	agctccttca	aacatcctca	agtgtgtata	ttatctttct	aaaacataga	cctactgaca
1381	tgccctccctt	cctcagaaac	cttccgtggg	tggttcttac	agccttcaag	atggagtcca
1441	gactcttttt	tttttttggg	acagagtctc	cctctgttgc	tcaggctgga	gtgcagtggc
1501	atgatctcgg	ctcactgcaa	cctcagcctc	cctggttcaa	gcgattctcc	tgacttggcc
1561	tcccaagtag	cggagactac	aggcgcctgc	caccacaccc	agctaaattt	gttcttttct
1621	ttcttttttt	tttttttggg	gatttttagga	cagacggggg	ttcacatgtt	ggccaggatg
1681	gtctcgatct	cttgacctgc	tgatccggcc	gcctcagctt	cccaaagtac	tgggattatg
1741	ggcgtgagcc	actgcactag	gcctaatttt	tttattttta	gtagagatgg	ggttttacca
1801	tggtggccag	gctggtctgg	aacccctgac	ctcaagtggg	ctgccctcct	cagcctccca
1861	aagttctgag	attacaggca	tgagccattg	cgtctgacct	agactcctta	atgtgactaa
1921	ctccaggctt	tccttggact	acttcttact	tgtctttcca	gctttgtctt	ttcacctctc
1981	caattgagat	aaaataataa	caacctcttg	gagttctcat	caggattaca	tgaatgaga
2041	tatgtaacat	gcttagcagt	gcctgtccat	agtaaatctc	aataaatgtt	tgtggaatta
2101	taatatcttg	tcattgtttga	gactttgtct	tgcataatca	ggcaccagta	ggtttttata
2161	aaggaaccog	tctgtcacgt	gcagaggaga	aataaacaga	aagtttccca	tcctcaggga
2221	gccacctgac	tgacagaggc	acagtgcac	cactctccag	gtctagggga	gaaagcagcc
2281	ttattttctta	gtagctcaga	atctgacttg	agaaacacat	ccacatagaa	aaaaacaagg
2341	aactttttcg	ggtcagggtc	cgggaccac	agtgaggttg	aagatacagg	ggaagggaaga
2401	gggaaataga	gccatcccca	gggtggaaga	tctcagaaga	gaatttgga	aacaagggtat
2461	gaacaaggac	tgaatagtga	gaagtgtatg	agagacagct	aaagttagatg	gagtgtcaaa
2521	accaaaacct	ctaagggtag	aataggcagc	aatttgccca	agtcctaaca	gggaggccca
2581	taggaggatt	caacctcaag	atgctgtgcc	acattccaag	agggaaccta	aaggctgggc
2641	tgaagagtca	gagatggcta	cagctggcaa	aaagatgggc	agatgctgag	aggagatgat
2701	tgctaaaatg	ttctgtccag	gacattcaca	gtatctctat	aaccagagtc	ttttttgtcg
2761	ttgttgttct	caagaaggaa	acttgaggcc	gggtgtgtgtg	gtttatgccc	ataatcccag
2821	cgctttgggg	ccaaggcagg	cggatcacct	gaggtcagga	gttcgagacc	agcctggcca
2881	acagtgtgaa	acctcatctt	tactaaaaat	acaaaaatta	gctggatgcg	gcggtaggtg
2941	cctgtaatgc	cagctactcg	ggaggctgag	gcaggagaat	cacttgaacc	tgggagcgg
3001	aggttgacag	gaggcggagg	ttgcagtga	ccaagattgc	accactgcac	tccagcctgg

FIG. 18

3061	gcgacagaga	gtaagactgt	ctcaaaaaat	aaatgaataa	ataaaaagga	agaagaagaa
3121	gaagaacaat	tgcaatcctc	cctggctcta	gaatgtcatt	taaaagtcga	gtgtcttctt
3181	ccttccctgt	tttgaagcag	cccttctcat	gacaggcttg	cttgccaagg	ttccctctga
3241	ccttaaatct	cttccttttg	gtgtcttggg	cagggcagtt	cagagtata	ggaccaagac
3301	accctatccg	ggctctggtc	ggggatgaag	tgggaattgcc	atgtcgcata	tctctggga
3361	agaacgctac	aggcatggag	gtggggtggt	accgcccccc	cttctctagg	gtgggtcatc
3421	tctacagaaa	tggcaaggac	caagatggag	accaggcacc	tgaatatcgg	ggccggacag
3481	agctgctgaa	agatgctatt	ggtaggggaa	aggtgactct	caggatccgg	aatgtaagg
3541	tctcagatga	aggaggtttc	acctgcttct	tccgagatca	ttcttacc	gaggaggcag
3601	caatggaatt	gaaagtagaa	ggtagtagt	gccatataat	attaggatt	aactgttggg
3661	tggccaagaa	caattattct	ctcaactgag	atgagatccc	tcaacccaaa	catctcagtc
3721	ctgggaatga	tttccataaa	aatgtacaca	tcaataaaca	gaaactcatg	cttagggatg
3781	tctgttgcat	cattattcag	agtagcaagg	aaattgggat	caaaatcaat	gcctttgagt
3841	aggtaagtga	cagaatgaac	aatggtagcc	atactgtgaa	tattatgcag	ggattaaaaa
3901	gattattttta	gcactaggcc	agatgggttg	gggggctcct	ctaaggatt	attgagtgat
3961	aagagcaagc	tgctgtagga	tacaaaaaca	aaaacaaaac	cctagggcat	ggtaggttgc
4021	ctcgagcta	ctcaggagcc	tgagacggga	ggctggcttg	agcccagggg	tttgcagtta
4081	cagtgcagta	actgcactcc	actgcactcc	aacccgggtg	acagagcaaa	gaccttcacc
4141	cccactccct	acccgtctct	aaaaaaaaca	aaaaacaaaa	caaaaaaacc	cttgggcccc
4201	gcgccgtggc	tcacgcctgt	aatcccagca	ctgtgggagg	ccgaggtggg	cagatcacaa
4261	ggtcaggaga	tcgagaccat	cctggctaaa	acggtgaaac	cccgtctcta	ctaaaaat
4321	aaaaaaaaaa	aaaaaattta	gccaggcatg	gtagcaggcg	cctgtagtcc	cagctactcg
4381	ggaggctgag	gcaggagaat	ggcgtgaaac	cggagagcgg	ggttgcagtg	agccaaaatc
4441	cttccactgc	actccagcat	gggggacaca	gcgagactcc	gtctcaaaaa	aaaaaaadaa
4501	accctgtatt	tgtgagcgca	cacacacaca	cacacacaca	cacacctgtg	cttggtccta
4561	gtgaataagc	aagtaaatca	aatgtctaaa	tataattata	gaaaggagat	gtcacctttt
4621	ggctgtacct	ccactatttc	attctgcaga	attgcagaat	ttcttttttt	ttctcttct
4681	ttcttttctt	tttttttttg	acacagagtc	tcgctctgta	acccaggctg	gagtgcgaatg
4741	gcgccctccg	cctcctgggt	tcaagtgatt	ctcctgcctc	agcctcccga	gtagctggga
4801	ttacagggtgc	ccaccaccac	acccagctaa	tttttgtatt	tttagtagag	acagggtttc
4861	accaggttgt	caaggttggt	ctcaaaactcc	tgacctcagg	tgatccactc	gcctcagact
4921	cccaaaagtgc	tgggattaca	ggcatgagcc	atggtgcccg	gcctcagaat	ttcattttca
4981	acatgttttg	catgatgggt	gattttggag	aatatttttt	gctctatcgc	aggatgatta
5041	agatgtggac	aagggtgaagc	cgatggaggg	ggagctttga	aagttaacttg	ctatttaatt
5101	gaggaaactaa	actgctttga	gagcctgggg	gtcagatcct	ctgccttttc	ctcctcccca
5161	cctgcagtg	aaacatcaga	caattgatca	ctattgtatc	ttggagggtg	gagtgaccat
5221	tgacgtgctg	ggaccagaag	atggcattgt	atgtggaaca	acaaagcact	atttctagag
5281	actgcctgca	gggatattga	aatagcttta	tgtgtctcag	aatgttcttc	atacagctgt
5341	ttttattggg	gaaattctac	ttgccgaaaa	gtttgatagt	gagaccctct	ccagtttgca
5401	gattttttctc	cttctctgctc	aacaacttcc	tagctcagta	actgcctctc	ccaacaaact
5461	ccctcagttt	caccacacca	aaaaaggaag	acaagccggt	tgcggtggct	cacacctata
5521	atcccaaaac	tttgggaggc	cgaggcggtg	ggatccacct	gaggtcggga	gttcgagact
5581	agcctgacca	acatggagaa	accctgtctc	tactaaaaac	acaaaattag	cctggcgtgg
5641	tggcgcattc	ctgtaatccc	agctgggagg	ctgaggcagg	agaatcgctt	gaaccccgga
5701	ggcggagggt	gcagtgcagc	aagatcgttc	cattacactc	cagtctgggc	aagaaaagtg
5761	gaactccatc	tccaaaaaaa	aaaaaaaaaa	aacaagggaag	acaaaaagaa	aagcagctaa
5821	agactttgcc	tcagggggaga	aagttctctt	ttgggttgct	atccacattc	caacctctg
5881	ttcccaacctc	ttcgtctgca	tgcctaagaa	actgttttac	aagtaaataa	gggacgcttt
5941	gtctaggctt	tggagccagg	aagttgagac	aaatttagga	atgagatgaa	gtaatggtat
6001	tattgcaagt	ctcagggtga	actacctctg	ctcttctctt	gaagagtttc	taatttctct
6061	tgtttactta	tttttttctt	gtcatttttg	ggattttatt	actagttgtc	tctaactcct

FIG. 18 (cont.)

6121	tcttttaatt	cttcattatg	aaacataaaa	acaaatgcc	ggcgcgag	ctcacgcctg
6181	taatcccagc	actttgggag	gccgaagcgg	gcagatcacc	cgggtcagga	gttcgagacc
6241	agcctgatca	acatggagaa	accccgctctc	tactaaaaaa	tacaaaatta	gctaggcggtg
6301	gtggcacatg	ccagtaatcc	cagctacttg	agagactgag	gcaggagaat	cgcttgaacc
6361	gggaggcaga	ggttgcggtg	agccaagatc	gcgccattgc	actccagcct	gggcaacaag
6421	agcaaaactc	tgtctcaaaa	aaaaaaaaacc	acatacaaac	cagagataat	attataatga
6481	gcctccaagt	gcctaccacc	ttgctgcagc	acttgtcaat	ccaggggacca	cccacctcac
6541	cggctcccca	ctcattacca	ccctccccta	ctcaattact	gaggtaaatc	ctaggcagca
6601	tgatcatttc	ttttttttct	ttttatttat	tttgagacag	gatctgtctc	tgtcaccag
6661	gctggagtgt	agtggcatat	ctctgctcac	tgcagcctct	gcctcccggg	cagaagccat
6721	cctcccacct	cagcctacat	agtagctggg	accacaggca	cacaccacca	cacactgcta
6781	atgttttgta	ttttttgtag	agactgggtt	ttaccatgtt	gatcaggctg	gtctcaaaact
6841	cctaggctca	agcaatcctc	ccacctcggc	ctcccaaagt	gctagaatta	caggcgcgag
6901	ccactgcacc	cagcgaagaa	cactttttta	aaaataaata	ggccggggcg	ggtggctcac
6961	acctgtaatc	ccagtacttt	gggagcccaa	ggaggggcga	tcagtagggtc	aagagattga
7021	gaccatecta	agtaacatgg	tgaaccccca	tttctactac	aaatacaaaa	acaaaattag
7081	cctggcggtg	tggcaggcgc	ctgtagtccc	agctacttgg	gagctgaggc	aggagaatgg
7141	agtgaaccgg	ggaggcgag	cttgagtgga	gctgagatca	tgccactgca	ctccccctg
7201	gggcaacaga	gtgagactcc	caaaaaaaaa	aaaaaaagcc	ccccctcccc	acacacaata
7261	atataaataa	ataaataacc	acaatactat	tatcacatct	tacaaaactca	acaaaaattt
7321	cttaatatca	tcaaatcccc	agtttgtgtt	caaattttcc	tgattgtttc	ataaatatac
7381	tcttacagtt	ggtttctttt	agcgagattc	aaatgagacc	cacctgttga	cctttgcccct
7441	taggggttcc	cagggtctga	attttgttga	cgacattccc	atgttgctat	gtaatacgggt
7501	cctccatgcc	ctgtgttttt	ctgtaaactg	atagatgtgg	aggtgcaatg	acatttgtgt
7561	ttgattttact	ttggcaaata	tagttcatca	gtgatactct	atacttcttg	ttgctttaca
7621	tccggaggct	gataatgtct	gcttttctct	cttttcta	tatttgtgaa	aggaaaaatg
7681	tgggggggtg	ggagaaaaaa	acccttaagt	acatactcgc	taaatcacat	tgctacaggt
7741	aacttccatt	aagaacttga	aagtaaaagt	agctgcattt	tcccctaggg	aacacaatga
7801	tagacaggag	ccttagtcta	cagcttgaag	gattgtaatt	atacctaagc	aaccttctg
7861	gaccagttta	atgtttattag	ctgtgatgta	tccctacctt	tgatgtcatt	atccttactt
7921	agctccctta	aagcagagat	caagatgaaa	agggcttcag	ctgcagcatg	gcacatggag
7981	attagagtgg	ggcttttgga	tgctgaggag	cagacctaga	atgggaaata	gatgggagcc
8041	acagaagtga	aggtccccct	ccctcattgc	tcaacctact	ccacatctcc	aggtctgcac
8101	atctgttcag	ttactgaatc	ctgtgtaagc	taccttcttt	ttcttttttc	ttttatttat
8161	ttatttattt	tttttttgag	atggagtgtt	gctcttggtta	cccaggctgg	agtgcaatgg
8221	tgcaatctcg	gctcactgca	ccctccaact	cccagggttca	tgcaattctc	ctccctcagc
8281	cttccaagta	gctgggatta	caggctgcac	caccatgtct	ggctaatttt	tgaaaaaatca
8341	gtagagagag	ggtttcacca	tggtggccaa	gccggtctcg	aactcctgac	ctcaagtgat
8401	ccaccacact	tggcctccca	aaatgctggg	attacagggtg	tgagccacca	tgcccgctgt
8461	aaactacctt	cttaaaagct	ctagaagagg	gcttttaacc	ttttgttgtg	tgtcatgcac
8521	cttcgcgaag	ctgatgaagt	tgatagaccc	atctcagaat	tttttttttt	tttttgagac
8581	agtgtctcac	tctgtcaccc	aggattgggt	gcagtggcac	gatcatgggt	cattgcagcc
8641	tccacctacc	aggctcaagt	gatcctcctg	actcagcctc	ttgaatagct	gagaccacag
8701	gcttgtgtca	ccatgccccag	gtaattttta	attttttttc	gtagaggcag	ggtctcacat
8761	tatgttgccc	agtctggcct	cgagaactcc	tgggctcaag	caatcttctc	gccttgggct
8821	cccāaagtgg	tgggattaca	ggggagagcc	accacaccta	gpcaggagga	tgttttaaat
8881	acaccaaata	aaacatttat	acccaaatcc	agttatccaa	atattaaatt	aacaagaggtt
8941	agggtgaccc	tatttaattag	tgtaatttcc	aaatagtaat	gaacataagt	gatagtttga
9001	gatttctgtg	acttttctaa	tgtgacgtga	aaatatttgt	gatttttctt	ttcttttttt
9061	tttttttgaga	tggagtctcg	ctcttggtgc	ccaggctgga	gtgcaatggc	aagatctcgg
9121	ctcacctcaa	cctccgcctc	ctgggttcaa	gcgattctcc	tgcctcagcc	tcttgagtag

FIG. 18 (cont.)



actgtatcac	ctgtacttat	atcttctgctt	tacaaactca	ggatgtttcc	atgagtacag
aacatgacta	atcagagaag	acctcataga	ggaatagaaa	agccaccaag	ccccactagg
aattgacccc	tcaaggacat	ggtttctagc	ctttttgttc	actgcagatt	gcccactgcc
taaagataat	ggcaacagaa	gagcacccaa	atatttggtt	gataaatgtt	gcagacacta
gaaggtgtca	ttagggcaca	gatggtacct	tctctgagca	aacttccttc	acagctcctc
ctcccagggc	tgtaggtgac	tctactcttg	tcacctggca	cacagagttc	tatcgtagca
tttaggaaat	tagaccagt	tgtggaccac	acacacacac	atctttacac	acccaaagag
gaggaatagt	atctttgttt	tggaggactt	gactatgaaa	ggctttaact	cctttttgta
ccatgaatct	ctctggcact	ccagtgaagt	ctaaaggacc	cctttgcaga	atgtttttta
atatacacat	aaaatagaac	acataggatt	gcaaaaaaaa	tcattgtact	aaaatacagt
tatcaaccga	taatcacatt	tgtgatata	taacataaat	gtttcttttt	tttttttttg
gaggcagagt	ttggctcttg	tcacccaggc	tggagtgcaa	tggcgcgatc	taggctcact
gaaacctctg	cctcccgggt	tcaagcgatt	ctcagcctcc	tgagtagctg	ggattacagg
ctcccggccac	gagccaggac	taatttttgt	attttttagta	gagactaggt	ttcaccagg
tggccaggct	ggcctcgaa	tctgtgacct	aggtgatcca	cctgccttgg	cctcccaaag
tgtctgggatt	acgggcatga	gccaccgtgc	ccggccataa	atatttcttt	agccaaagta
atacattaag	taatgtagca	gcaagtctaa	taacctgtaa	tttctttctt	tctttctttc
tttctttttt	tttgagatga	agtttttttg	agatggagtg	caatggcaca	atctcggctc
actgcaacct	ccacctcctg	ggttcaagcg	attctcctgc	ctcagcctcc	caagttgctg
gaactacagg	cgcatgccac	catgcccagc	taatttttgt	attttttagta	gagacggggg
ttcaccatgt	tggccagggt	ggctttgaac	ccctgacctc	aggtgatctg	cctgccttgg
ccttccaaag	tgtctgggatt	acagggcatga	gccaccaggc	ccagccpaat	aacctttaat
ttcaacatac	taataaacat	aaacagtatt	tcaagatttc	tgcaataaact	tgcaataaact
tgaaaacatc	tgtggcttcc	attggtaatt	aagtcacagg	tactgctcat	attgtggtta
ggttgtaaaat	gttttggttt	gttttggttt	ttccaagact	tgggggaatg	ggtgttggtg
ggatcaacaa	gagtcttgct	ctgtggccca	ggctggagtg	caggggcagg	atcttggtct
actgcaacct	ccgcctccca	ggttcaagcg	attctcctgc	ctcagcctcc	tgagtagctg
gcattacagg	catgtgccac	cacgcccagc	taatttttac	attttttagta	gagatggggg
ttcaccatgt	tggcctggct	ggtcttgaa	tcttggcctc	atgatccacc	cgctcgggac
tcccagagtg	ttgggattac	aggcatgagc	caccacacct	ggcagttggt	acatttttaa
tgaaagaaaa	tgttaaatcc	agttattgaa	aataaggagg	cagtactttt	ctcatccaag
ttcatggact	ttctgaattt	tgtccccaga	gtccttttgt	gttctaggac	cccaggttaa
ggaacccaaa	aagacagggt	ggtggggcat	gaggggggaa	acatgttaat	ccctgtttgt
tctggtgaac	aattcagatc	cccactttct	gaggggtgcc	tgctggaaga	taaccctgtt
tgtaattgtg	ccggttcttg	gacctttggt	gcctttgatc	atctgctaca	actgggtaca
tcgaagacta	gcaggtgcag	tggctgggca	gcaggcaaga	ccaccaataa	gtgggggacc
aagtcagctc	tgaatgggaa	gccaaaagag	aatagaacca	ggactcaaga	ttaggggagc
tgggatttcc	ttattcctct	gtccccatgc	ccaaccccag	gctcttctga	gaaactgtga
agagaaccac	ttactggatc	tgtgggatcc	cccagtgga	agggcagtg	gggtcactcc
aaatgtccat	agggaggatg	tggggaaggt	gctattcatc	ttccactaat	cacatatttg
tttctttttg	ttttcagggc	aattccttga	agagctacgt	aagtctctct	ctctctggtt
taagcagaga	ataaaaagcc	aggaaaggga	gacagaagca	acaagaggaa	gaggcgggct
attgagggat	cacattccca	gaggaaagga	ggagctggag	agcctgggtg	gagggaagac
tcctcctggg	aggtagaggg	caaagaagcc	agctgttaga	gacacattta	caggtggcag
agaagctgga	ggcactccta	tctgccacct	gatccattcc	tccttcaactg	cccctaagca
ggaatccaac	cctagctggt	ctcattggcc	attccaagagc	aaactgcccag	tgcctcacct
ctcagatcaa	ccattgaggc	aggaatggag	acaaagatgac	cccaagggct	tttcttctcc
ctagtccaat	ggttttatga	tacaaactac	tgacatacgt	ttttcaagtt	ttttctctct
tcttctagga	aatcccttct	gagtgatgtc	acatcttggc	aggggtggag	gagagcctgg
ttgcccaggg	atgtgtcctt	ggggacatct	catccatcaa	gttgacacact	cactggcatc
tttgctatgg	ggacattcca	atgtgcactt	tcagggaacac	tctgaattcc	aagtagaatt

FIG. 18 (cont.)

15301 gatttccctt cttctgtcat ctacctttt tcttcatttt cccattttta ttacctttct  
 15361 ttccattttt ctctccagtc ttccacctgg aagccctctc tggctaagga caggcaggtg  
 15421 cccctctctc catcagagga cacctgtact ggagagcaac acaggatggt ctctgccatg  
 15481 aactggaggc caggaatctc ctactgaaa attacagtat ggtaactttg caaatggtgg  
 15541 ttgtttcttc caagactcca gccctgattg cgcaaaactg aaaggcatgt gaagggaaagg  
 15601 aagaggaaga gtgcaaaaca ttgaagagag agctgagtga gctgaagagt gaggatatga  
 15661 gtagcccaa cccaaacctg gagatgggga gaaacctaca gaatactagc cagagctcct  
 15721 ccttgtcttg gcagcctact agggacctgg ggaagcaaaa acgaaagctg ggcaacatgc  
 15781 ctgctttaga atgttttctt tctacttaca catcttcac aggtctcaga atctttcctt  
 15841 cctctcatcc ttttctccta tctacatatc tatcagagta tccactgttt attcaacaac  
 15901 tactacttga tggtcagaca caaacaaca agctaggtgc taattaataa agatacaggt  
 15961 tttggccggg tgcgggtggc cagcctgta atccagcac tttgggaggc cgaggcgggc  
 16021 gaatcacgag gtcaggagtt caagaccagc ctggccaaca tggtgaaacc ccatctctac  
 16081 taaaaataca aacaattaac tgagcatagt ggtgggcacc tataatacca gctactcggg  
 16141 aggctgaggc aggagaatcg cttgaacca ggaggcagag gttgcagtga gctgagatcg  
 16201 cgccactgca ctctagccgg agtgacagag taagactctg tctcaaaaat aaataaataa  
 16261 ataaataaat aaataaataa ataaataaaa aataataata caagttttca taagcacact  
 16321 tetaacccct tgtcttttat gtatttctt ccttatccac gcacctgtct cctctactc  
 16381 cagcctcatt accccagagg tcagtcctca ggaaaactaa acacaaagaa agagctcagt  
 16441 cagaaaggcc atttatttat gtttcaagat gctcactgcc tcctttgttt tgtctccttt  
 16501 gcaggccttc tctcttaggc ctcttctctt ggggggatgg atcctggggg gagattgatc  
 16561 acctccatgc ttccattcct cccagccat agtggggaca tcatgagaga agccaagcca  
 16621 ctggcccagg atcaccggc atttatggg gctgctctgg cacaggctct tgcctttata  
 16681 gcccctccag tgatccataa ggccctcttt ctcccaaag gagaggtcac agatagggca  
 16741 aaggtagctc ttctgcttcc agtgggtctg ctgggtgtctg accagcctgg aaaatgagct  
 16801 gaaagacttg ctgcaatgga agcagtagtt gggcggtct gtgagtggtg ccttctggtg  
 16861 tctggagaga taggatttct tgctaaaagt caaagaacaa tgggggcaac agaagacatt  
 16921 gagtcttgag ggcttcactg gatgagagtt ggatctggca tcctgacaga gggttccagt  
 16981 gatgggtgcc tgggtcctgg tcacagggtg ttggttctta agtacagatg cctgggtctg  
 17041 ggccatagga cctcagttc taaatatggg ttcttgggac ctggccactg gtgcatggtt  
 17101 cacatccaaa agcccctgga tggacctctg gcttctggcg atgggtgtct ggaattcagc  
 17161 ctgggtgcct ggaatcctca aagtacactc ctgggttcca tccactggct cctggttttg  
 17221 gtgtatcttc tgggtggcgtt tgagctcaga ctggtcccgg aagctcttcc cacacacaga  
 17281 gcatgaatgg ggccggtaac ccagatggac gcggcggtga cgacttagtc cagaagcatc  
 17341 acagtaggtc ttgtcacaga gcgtgcaaca gaagggcctc tcccaagat gcatgcgtct  
 17401 gtgatagctg agggacttgg ggctccgaaa caacttcca cactgactgc agctgttagt  
 17461 cagcttggga ttgtgaacaa actggtggct atagaggtag gagcgcctgc tgaacattt  
 17521 ggcacaggtg tagcaaaa

FIG. 18 (cont.)





1 ctgtatcagt gctcctcgtc gcctcactgt acttcacgga agagacttgg ttgactggcc  
 61 acctggagcg gaatcaggag acattcccaa ctgagagaga ctgagcccta gctcggccac  
 121 ttgctggaca agatgatatt ccttaccacc ctgcctctgt tttggataat gatttcagct  
 181 tctcgagggg ggcactgggg tgccctggatg ccctcgtcca tctcagcctt cgagggcacg  
 241 tgtgtctcca tcccctgccg ttctgacttc ccgatgagc tcagaccggc tgtggtacat  
 301 ggcgtctggt atttcaacag tccctacccc aagaactacc cgccagtggg cttcaagtcc  
 361 cgcacacaag tggtecacga gagcttccag ggccgtagcc gcctgttggg agacctgggc  
 421 ctacgaaact gcaccctgct tctcagcacg ctgagccctg agctgggagg gaaatactat  
 481 ttccgaggtg acctgggagg ctacaaccag tacaccttct cggagcacag cgtcctggac  
 541 atcatcaaca cccccaacat cgtggtgccc ccagaagtgg tggcaggaac ggaagtagag  
 601 gtcagctgca tgggtgccga caactgccca gagctgcgcc ctgagctgag ctggctgggc  
 661 cacgaggggc taggggagcc cactgttctg ggtcggtgc gggaggatga aggcacctgg  
 721 gtgcaggtgt cactgctaca ctctgtgcct actagagagg ccaacggcca ccgtctgggc  
 781 tgtcaggctg ccttcccca caccaccttg cagttcgagg gttacgccag tctggacgtc  
 841 aagtaccccc cgggtgattgt ggagatgaat tcctctgtgg aggccattga gggctccac  
 901 gtcagcctgc tctgtggggc tgacagcaac ccgccaccgc tgctgacttg gatgcgggat  
 961 gggatggtgt tgagggaggc agttgctgag agcctgtacc tggatctgga ggaggtgacc  
 1021 ccagcagagg acggcatcta tgcttgccctg gcagagaatg cctatggcca ggacaaccgc  
 1081 acggtggagc tgagcgtcat gtatgcacct tggaaagcca cagtgaatgg gacggtggtg  
 1141 gcggtagagg gggagacagt ctccatcctg tgttccacac agagcaaccc ggaccctatt  
 1201 ctcaccatct tcaaggagaa gcagatcctg gccacggtca tctatgagag tcagctgacg  
 1261 ctggaaactcc ctgcagtgc gcccaggagc gatggggagt actggtgtgt agctgagaac  
 1321 cagtatggcc agagagccac cgccttcaac ctgtctgtgg agtttgcctc cataatcctt  
 1381 ctggaatcgc actgtgcagc ggccagagac accgtgcagt gcctgtgtgt ggtaaaatcc  
 1441 aacccgggac cctccgtggc ctttgagctg ccttcccgc aactgactgt gaacgagaca  
 1501 gagagggagt ttgtgtactc agagcgcagc ggccctcctg taccagcat cctcacgtc  
 1561 cggggtcagg cccaagcccc accccgcgtc atttgtacct ccaggaacct ctacggcacc  
 1621 cagagcctcg agctgccttt ccaggagca caccgactga tgtgggcca aatcggccct  
 1681 gtgggtgctg tggtcgcctt tgccatcctg attgccattg tctgctacat caccagaca  
 1741 agaagaaaaa agaacgtcac agagagcccc agcttctcag cgggagacaa ccctcatgtc  
 1801 ctgtacagcc ccgaattccg aatctctgga gcacctgata agtatgagag tgagaagcgc  
 1861 ctgggggtccg agaggaggct gctgggcctt aggggggaac cccagaact ggacctcagt  
 1921 tattccactc cagacctggg gaaacgacct accaaggaca gctacacctt gacagaggag  
 1981 ctggctgagt acgcagaaat ccgagtcaag tga

FIG. 20







## END OF JOB SEPARATOR

JOB NUMBER	0000302107
PRINT DATE	03/18/2004
PRIORITY	10

ORDER NUMBER	0001146076
ORDER DATE	03-17-2004
BIN NUMBER	



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/35, 45/00, A01N 63/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/34827</b>  <b>(43) International Publication Date:</b> 15 July 1999 (15.07.99)
<b>(21) International Application Number:</b> PCT/US98/14715  <b>(22) International Filing Date:</b> 21 July 1998 (21.07.98)  <b>(71) Applicant (for all designated States except US):</b> YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, Stone Administration Building, Herzl Street, 76100 Rehovot (IL).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> EISENBACH-SCHWARTZ, Michal [IL/IL]; Rupin Street 5, 76353 Rehovot (IL). COHEN, Irun, R. [US/IL]; Hankin Street 21, 76354 Rehovot (IL). HIRSCHBERG, David, L. [IL/US]; Apartment 3, 919 Fremont Place, Menlo Park, CA 94025 (US).  <b>(74) Agent:</b> BROWDY, Roger, L.; Browdy and Neimark, 419 Seventh Street, Suite 300, N.W., Washington, DC 20004 (US).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>With amended claims.</i> <i>Upon the request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a).</i>
<b>(54) Title:</b> ACTIVATED T-CELLS AND THEIR USES  <b>(57) Abstract</b>  <p>The present invention relates to compositions and methods for the treatment or diagnosis of injury of the central nervous system (CNS). In particular, the invention relates to compositions comprising activated T-cells which are used to deliver (a) a diagnostic substance or (b) a therapeutic substance to a site of damage of the CNS caused by injury or disease. The invention also relates to pharmaceutical compositions comprising antiself T-cells that recognize antigens present in a greater concentration in the CNS compared to the circulation and methods of use thereof to prevent or inhibit degeneration of nerves within the CNS. The invention also relates to pharmaceutical compositions comprising an antigen (or derivative thereof) present in a greater concentration in the CNS compared to the circulation (NS-specific antigen or derivative) and methods of use thereof to prevent or inhibit degeneration of nerves within the CNS. The substance-delivering activated T-cell composition of the present invention may be administered alone or in combination with NS-specific T-cells or NS-specific antigen or in combination with NS-specific T-cells and NS-specific antigen.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ACTIVATED T-CELLS AND THEIR USES

### 1. FIELD OF THE INVENTION

The present invention relates to compositions and  
5 methods for the treatment or diagnosis of injury of the  
central nervous system (CNS). In an embodiment, activated  
T-cells are used to deliver (a) a diagnostic substance for  
detecting a site of injury or disease or (b) a therapeutic  
substance for ameliorating an effect of a disease or injury,  
10 such as, for e.g., promoting axonal regeneration or  
preventing or inhibiting degeneration caused by injury or  
disease. In a preferred embodiment, the activated T-cells  
that are used for delivering a substance do not recognize a  
nervous system (NS) antigen. More preferably, the substance-  
15 delivering activated T-cells recognize a non-self antigen  
(e.g., ovalbumin). In another embodiment, pharmaceutical  
compositions comprising antiseif T-cells that recognize an  
antigen present in a greater concentration in the nervous  
system (NS) compared to the other organs or circulation are  
20 used to prevent or inhibit degeneration of nerves within the  
CNS. In a preferred embodiment the antiseif T-cells of the  
present invention are not genetically-engineered. In another  
embodiment, pharmaceutical compositions comprising an antigen  
(or derivative thereof) present in a greater concentration in  
25 the NS compared to other organs or the circulation (NS-  
specific antigen or derivative) are used to prevent or  
inhibit degeneration of nerves within the CNS. The activated  
T-cell compositions of the present invention may be  
administered alone or in combination with NS-specific  
30 antiseif T-cells or NS-specific antigen or in combination  
with NS-specific antiseif T-cells and NS-specific antigen.

### 2. BACKGROUND OF THE INVENTION

Damage to the CNS may result from a traumatic injury,  
35 such as penetrating trauma or blunt trauma, or a disease or  
disorder, including but not limited to Alzheimer's disease,  
Parkinson's disease, multiple sclerosis, Huntington's  
disease, amyotrophic lateral sclerosis (ALS) and ischemias.



Following traumatic injuries in the peripheral nervous system (PNS), an invasion of blood derived monocytes as well as activation of microglia within the PNS occurs (Stoll, et al., 1989, *Neurosci.*, 9:2327-35; Perry and Gordon, 1991, *Int. Rev. Cytol*, 125:203-44; Perry and Gordon, 1988, *Trends Neurosci.*, 11:273-277; Jordan and Thomas, 1988, *Brain macrophages: Questions of origin and Interrelationships*, 13:165-178; Griffin, et al., 1990, *Ann. Neurol.*, 27:8; Giulian, et al., 1989, *J. Neurosci.*, 9:4416-29; Giulian, 1987, *J. Neurosci. Res.*, 18:155-171; de Groot, et al., 1989, 179:314-27; and Bauer, et al., *J. Neurosci. Res.*, 38:365-75). By contrast, the invasion of blood derived monocytes is delayed and more limited in its scope in traumatic injuries to the CNS (Perry and Gordon, 1991, *Int. Rev. Cytol*, 125:203-44; Andersson, et al., 1991, *Immunol. Lett.*, 30:177-81; and Perry et al., 1987, *J. Exp. Med.*, 165:1218-1223). In addition, the duration of events associated with the acute phase of the injury, though less pronounced, is prolonged in the CNS as compared to the PNS. For example, several weeks after injury, numerous activated macrophages and microglia are found in the CNS, while only a few are detectable in PNS nerves at such time after injury (Perry et al., 1987, *J. Exp. Med.*, 165:1218-1223; Lunn et al., 1990, *Neuroscience* 35:157-165).

Neurons in mammalian CNS do not undergo spontaneous regeneration following an injury. Thus, a CNS injury causes permanent impairment of motor and sensory functions. In contrast, neurons in the PNS have a far greater capacity to regenerate. Studies using allogenic macrophages incubated with a stimulant (e.g. a nerve segment) and subsequently administered into the CNS of a mammal at or near the site of injury have shown regeneration of the impaired motor or sensory function (PCT Publication WO 97/09885 and Spiegler et al., 1996, *FASEB J.* 10:1296).

Another tragic consequence of CNS injury is that the primary injury is often compounded by a degenerative process which results in a secondary loss, over time, of adjacent

neurons that were not damaged by the initial injury. It has been suggested that the secondary degeneration results from diffusion of toxic chemicals produced by damaged neurons (McIntosh, 1993, *J. Neurotrauma* 10:215; Lynch and Dawson, 1994, *Curr. Opin. Neurol.* 7:510; Smith et al., 1995, *New Horiz.* 3:562; Faden, 1996, *Pharmacol. Toxicol.*, 78:12; Faden, 1996, *JAMA*, 276:569).

Popovitch et al. has shown that CNS trauma such as spinal injury triggers a systemic response to self epitopes such as myelin basic proteins (MBP) (Popovitch et al., 1996, *J. Neurosci. Res.*, 45:349). Activated T-cells that recognize a self antigen as well as activated T-cells that recognize a non-self antigen have been shown to enter the CNS parenchyma. Only T-cells capable of recognizing a CNS antigen appear to persist in the nervous tissue (Hickey et al., 1991, *J. Neurosci. Res.* 28, 254-60). Although activated T-cells that recognize a self antigen (antiself T-cells) apparently persist in nervous tissue, use of activated T-cells that recognize a non-self antigen (non-self T-cells) for administration to an individual have advantages such as no risk of induction of autoimmune disease. Further, use of non-self activated T-cells eliminates the necessity of activating autologous or syngeneric T-cells; therefore, non-self T-cells may be activated and stored for use in any individual.

T-cells reactive to antigens of CNS white matter, such as myelin basic protein (MBP), can induce the paralytic disease experimental autoimmune encephalomyelitis (EAE) within several days of their inoculation into naive recipient rats (Ben Nun et al., 1981, *Eur. J. Immunol.* 11, 195-9). Studies have suggested a role for anti-MBP T-cells in the human disease multiple sclerosis (Ota et al., 1990, *Nature* 346, 183-7; Martin, 1997, *J. Neural. Transm. Suppl.* 49, 53-67; Sun, 1993, *Acta Neurol. Scand. Suppl.* 142:1-56). Despite their pathogenic potential, anti-MBP T cell clones are present in the immune systems of healthy subjects (Burns et al., 1983, *Cell. Immunol.* 81, 435-40; Schluesener and

Wekerle, 1985, *J. Immunol.* 135, 3128-33). However, little is known about the possible physiological functions of antiself T-cells.

Citation or identification of any reference shall not be construed as an admission that such reference is available as prior art to the present invention.

### 3. SUMMARY OF THE INVENTION

The present invention is directed to methods and compositions for the treatment or diagnosis of injury of the central nervous system (CNS). The present invention provides methods for delivering a therapeutic or detectable substance to a site of injury or disease of the CNS, comprising administering an effective amount of activated T-cells that contain or express a therapeutic or detectable substance to a mammal wherein the amount is effective to detect, diagnose, or monitor a site of injury or disease in the CNS or is effective to ameliorate the effects of an injury or disease of the CNS. The activated T-cells used for delivery of a substance preferably do not recognize a nervous system specific antigen (NS-specific antigen); more preferably the activated T-cells recognize a non-self antigen. "Activated T-cell" as used herein includes (i) T-cells that have been activated by (a) exposure to a cognate antigen or derivative thereof or (b) exposure to an appropriate mitogen such as a lectin (e.g. concanavalin A (Con A) or phytohemagglutinin (PHA)), and (ii) progeny of such activated T-cells. As used herein, a cognate antigen is an antigen that is specifically recognized by the T-cell antigen receptor of a T-cell that has been previously exposed to the antigen. As used herein, a derivative of an antigen is a fragment or amino acid variant (e.g., an insertion, substitution and/or deletion derivative) of the corresponding full-length antigen so long as the fragment or amino acid variant is capable of displaying one or more functional activities of the corresponding full-length antigen. Such functional activities include but are not limited to antigenicity

[ability to bind (or compete with the antigen for binding) to an anti-antigen-specific antibody], immunogenicity (ability to generate antibody which binds to the antigen), and ability to interact with T-cells resulting in activation comparable  
5 to that obtained using the corresponding full-length antigen.

The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of non-recombinant, NS-specific antiseif T-cells and methods of use of such compositions for prevention or inhibition of CNS  
10 nerve degeneration in which the amount is effective to ameliorate the effects of an injury or disease of the CNS. "NS-specific antiseif T-cell" as used herein refers to an activated T-cell which recognizes a self antigen present in a greater concentration in the nervous system (NS) compared to  
15 other organs or the circulation or an antigen that shares an antigenic determinant with an antigen present in a greater concentration in the NS compared to other organs or the circulation.

The present invention also provides pharmaceutical  
20 compositions and methods of use comprising a therapeutically effective amount of NS-specific antigens (or derivatives thereof) for prevention or inhibition of CNS degeneration in which the amount is effective to activate T-cells *in vivo* or *in vitro* wherein the activated T-cells ameliorate the effects  
25 of an injury or disease of the CNS. "NS-specific antigen" as used herein refers to an antigen present in the NS or an antigen that shares an antigenic determinant with an antigen present in a greater concentration in the NS compared to other organs or the circulation.

30 In the practice of the invention, therapy for amelioration of effects of injury or disease comprising administration of activated T-cells may optionally be in combination with NS-specific antiseif T-cells or a NS-specific antigen (or derivative thereof) or NS-specific  
35 antiseif T-cells and a NS-specific antigen.

#### 4. BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 presents low-power epifluorescence micrographs of optic nerve after a controlled crush injury in rats treated with T-cell clones primed with MBP. See text, Section 6, for experimental details.

5 Fig. 2 presents high-power micrographs of the site of optic nerve injury shown in Fig. 1, showing the large concentration of injected cells localized in the site of injury.

Fig. 3 presents a serial section through non-injured  
10 optic nerve.

Fig. 4 is a graphical representation of the number of T-cells at the site of injury of two different T-cell clones primed with antigen MBP or ovalbumin (OVA) ( $T_{MBP}$  or  $T_{OVA}$ , respectively) after injury, at various time intervals  
15 following injury.  $T_{MBP}$  and  $T_{OVA}$  cells were injected into animals at the time of optic nerve crush, ipsilateral and contralateral nerves were then removed and prepared for microscopy at days 3, 7, 14 and 21. The figure shows that T-cells accumulated at the site of injury, independent of the  
20 antigen with which they were primed (each result is an average of 5 different experiments; the bar shows the standard deviation). See text, Section 6, for experimental details.

Fig. 5 shows accumulation of T-cells primed with MBP or  
25 OVA ( $T_{MBP}$  and  $T_{OVA}$ , respectively) measured immunochemically using antibodies to T-cell receptors. A comparison of the number of accumulated cells in injured optic nerve (ON) and in non-injured optic nerve is illustrated. See text, Section 6, for experimental details.

30 Fig. 6 shows accumulation of T-cells in injured and non-injured optic nerve after various treatment protocols. T-cells specific to MBP ( $T_{MBP}$ ) were injected either immediately after nerve injury ( $T_{MBP}$  Cell Injection = 0) or 14 days after injury ( $T_{MBP}$  Cell Injection = 14). Their accumulation at the  
35 optic nerve was analyzed either 7 days (nerve excision - day 7) or 21 days (nerve excision = day 21) after injury.

Fig. 7 shows T-cell accumulation in injured optic nerve 1 week after injury. See text, Section 6, for experimental details. Anti-MBP or anti-OVA or anti-hsp60 T cell lines were raised, maintained, and activated by incubation with MBP from the spinal cords of guinea pigs, or with OVA (Sigma), or with the 51-70 peptide of MBP, respectively, in the presence of irradiated (2000 rad) syngeneic thymus cells. See text, Section 7, for experimental details. Activated T-cells ( $1 \times 10^7$  cells) of the anti-MBP or anti-OVA lines or PBS were injected intraperitoneally into adult Lewis rats immediately after unilateral crush injury of the optic nerve. Seven days after injury both optic nerves were removed, cryosectioned, and analyzed immunohistochemically for the presence of labeled T-cells. Bars shows the mean total numbers of T-cells counted in 2 or 3 sections of each nerve. Each group contained 3 or 4 rats.

Fig. 8 illustrates inhibition of secondary degeneration after partial optic nerve crush injury in adult rats. See text, Section 7, for experimental details. Surviving optic nerve fibers were monitored by retrograde labeling of retinal ganglion cells immediately after injury and 2 weeks later. Five days after dye application retinas were excised, and labeled retinal ganglion cells (RGCs) were counted under the fluorescence microscope. Counting was performed in 5 randomly selected fields in each retina (all located at approximately the same distance from the optic disc). The number of RGCs in each group of injured nerves in rats injected with PBS only or injected with anti-MBP, anti-OVA, or anti-hsp60 T-cells was expressed as percentages of the total numbers of spared neurons following the primary injury (42% of the axons remained viable after the primary injury).

Fig. 9 presents photomicrographs showing retrograde labeled retinas of injured optic nerves of rats injected with (A) PBS, (B) anti-hsp60 T-cells, or (C) anti-MBP T-cells. See text. Section 7, for experimental details.

Fig. 10 shows number of surviving RGCs of injured optic nerves of rats injected with anti-MBP T-cells ( $T_{MBP}$ ), T-cells

generated against a peptide comprising amino acids 51-70 of MBP (T<sub>p</sub> 51-70), or PBS. See text, Section 7, for experimental details.

Fig. 11 presents clinical course of rats injected with 5 anti-MBP T-cells. Results were evaluated according to the neurological paralysis scale (EAE score). Rats were injected i.p. with  $1 \times 10^7$  activated anti-MBP T-cells either immediately after optic nerve crush injury (-■-) or without optic nerve crush injury (--o--). Each group contained 5 to 9 rats. 10 Data points represents means  $\pm$  SEM. See text, Section 7, for experimental details.

Fig. 12 shows the survival of neurons in uninjured nerves in rats injected i.p. with  $1 \times 10^7$  activated anti-MBP T-cells or PBS. See text. Section 7, for experimental details.

15 Fig. 13 illustrates inhibition of secondary degeneration after optic nerve crush injury in adult rats. See text, Section 8, for experimental details. Rats were injected intradermally into footpads with a 21-mer peptide based on amino acid residues 35-55 (MOG p35-55) of 20 myelin/oligodendrocyte glycoprotein (chemically synthesized at the Weizmann Institute, Israel) ( $50 \mu\text{g}/\text{animal}$ ) or PBS ten days prior to optic nerve crush injury or MOG p35-55 in the absence of crush injury. MOG p35-55 was administered with Incomplete Freund's Adjuvant. Surviving optic nerve fiber 25 were monitored by retrograde labeling of retinal ganglion cells (RGCs). The number of RGCs in rats injected with PBS or MOG p35-55 was expressed as a percentage of the total number of neurons in rats injected with MOG p35-55 in the absence of crush injury.

30 Fig. 14 illustrates inhibition of secondary degeneration after optic nerve crush injury in adult rats. See text, Section 9, for experimental details. MBP (Sigma, Israel) (1 mg in 0.5 ml saline) was administered to adult rats by gavage using a blunt needle MBP was administered 5 times, i.e., 35 every third day beginning 2 weeks prior to optic nerve crush injury. Surviving optic nerve fibers were monitored by retrograde labeling of retinal ganglion cells (RGCs). The

number of RGCs in treated rats was expressed as a percentage of the total number of neurons in untreated rats following the injury.

5 5. DETAILED DESCRIPTION OF THE INVENTION

In the practice of the invention, compositions comprising activated T-cells are used for delivery of (a) a diagnostic substance or (b) a therapeutic substance to a site of injury or disease of the CNS in a mammal.

10 Generally, T-cells of the present invention are T-cells which recognize an antigen not normally present or present in small quantities in the circulation. Such antigens include but are not limited to NS-specific antigens, cryptic antigens or "non-self" antigens (i.e., antigens not normally present  
15 in an individual). Non-self antigens may be, without limitation, viral, bacterial, etc., including tissue-specific antigens from a different species or individual.

In an embodiment, T-cells are activated *in vitro* by exposure to an antigen and administered to a mammal.

20 The present invention provides methods for delivering a therapeutic or detectable substance to a site of injury or disease of the CNS, comprising administering an effective amount of activated T-cells that contain or express a therapeutic or detectable substance to a mammal wherein the  
25 amount is effective to detect, diagnose, or monitor a site of injury or disease in the CNS or is effective to ameliorate the effects of an injury or disease of the CNS.

Pharmaceutical compositions comprising NS-specific antiself T-cells and methods of use of such compositions for  
30 prevention or inhibition of CNS degeneration are provided. In a preferred embodiment, the NS-specific antiself T-cells are non-recombinant.

Pharmaceutical compositions and method of use thereof comprising a NS-specific antigen (or derivative thereof) are  
35 used for preventing or inhibiting degeneration of nerves within the CNS.



The present invention provides methods for (a) delivery of substances to a site of CNS injury or disease comprising administration of activated T-cells and (b) amelioration of degeneration comprising administration of (i) NS-specific  
5 antiseif T-cells or (ii) an NS-specific antigen or derivative thereof or both (i) and (ii). In the practice of the invention, substance-delivering activated T-cells may optionally be administered in combination with (a) NS-specific antiseif T-cells or (b) an NS-specific antigen (or  
10 derivative thereof) or both (a) and (b).

If desired, the methods of the present invention may optionally be combined concurrently with one or more of the following: (a) administration into the CNS of mononuclear phagocytes (preferably cultured monocytes) that have been  
15 stimulated to enhance their capacity to promote axonal regeneration; (b) administration into the CNS of a neurotrophic factor such as acidic fibroblast growth factor; and (c) administration of an anti-inflammatory therapeutic substance (i.e., an anti-inflammatory steroid, such as  
20 dexamethasone or methylprednisolone, or a non-steroidal anti-inflammatory agent or drug, such as aspirin, indomethacin, ibuprofen, fenoprofen, ketoprofen or haproxen, or an anti-inflammatory peptide, such as Thr-Lys-Pro (TKP)).

## 25        5.1 DELIVERY OF SUBSTANCES

Described herein are activated T-cells capable of delivering a diagnostic or therapeutic substance to a site of injury or disease in the CNS. In a preferred embodiment the activated T-cells do not recognize a NS-specific antigen;  
30 more preferably, the activated T-cells recognize a non-self antigen. In one embodiment, such activated T-cells may be used as part of a diagnostic technique for the detection of a site of damage in the CNS caused by injury or disease. In another embodiment, the activated T-cells may be used as part  
35 of a therapeutic regimen for ameliorating the effects of injury or disease of the CNS by promoting axonal regeneration or inhibiting or preventing CNS degeneration.

### 5.1.1 DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS

Activated T-cells of the present invention can be used for the delivery of various therapeutic and detectable substances to a site of injury or disease within the CNS. In a preferred embodiment, the activated T-cells of the present invention are activated by exposure to an antigen that is not NS-specific, more preferably by exposure to a non-self antigen. The detectable substances may be used for detecting, diagnosing or monitoring a site of injury or disease of the CNS.

In an embodiment, the T-cells are allogeneic T-cells, e.g. a pooled T-cell preparation obtained from a blood bank. The use of allogeneic T-cells is applicable for various treatments comprising limited administrations, including but not limited to, delivery of T-cells to a site of CNS injury for diagnostic purposes; for an acute single administration or one-dose therapy, etc. In another embodiment, the T-cells are syngeneic T-cells, preferably autologous T-cells (i.e., from the same individual).

T-cells can be isolated and purified according to methods known in the art (Mor and Cohen, 1995, J. Immunol. 155:3693-3699). For an illustrative example, see Section 6.1.

For use in the diagnostic methods of the invention, T-cells which preferentially localize to a site of injury or disease in the CNS can be detectably labeled.

The T-cells can be detectably labeled with a contrast agent including, without limitation, metals such as gold particles, gadolinium complexes, etc. Alternatively, the T-cells can be labeled detectably with a radioisotope, including but not limited to: <sup>125</sup>Iodine, <sup>131</sup>Iodine, <sup>99m</sup>Technecium. The T-cells can also be detectably labeled using a fluorescence emitting metal such as <sup>152</sup>Eu, or others of the lanthanide series.

Methods for detectably labeling T-cells may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory

Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York) and Current Protocols in Immunology (Current Protocols in Immunology, 1997, Eds., Coligan et al., John Wiley & Sons, Inc., NIH) which are incorporated herein  
5 by reference in their entirety. Labeling of T-cells with metal particles may be achieved by incubating cells in a suspension comprising the metal particles wherein the T-cells spontaneously internalize such particles into the cell's cytosol. Such substances may also be introduced into the  
10 cells by a variety of electroporetic techniques (Current Protocols in Immunology, 1997, Eds. Coligan et al., John Wiley & Sons, Inc., NIH). Fluorescence emitting metals or radioactive metals can be attached to the T-cells using such metal chelating agents as diethylenetriaminepentacetic acid  
15 (DTPA) or ethylenediaminetetraacetic acid (EDTA). Labeling of T-cells with a radioisotope can be achieved by incubating cells with a radioactive metabolic precursor.

Presence of labeled, activated T-cells can be detected in the patient using methods known in the art for *in vivo*  
20 scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include but are not limited to: computed tomography (CT),  
25 whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), sonography, radiation responsive surgical instrument (Thurston et al., U.S. Patent 5,441,050), and fluorescence responsive scanning instrument.

After labeling, the T-cells of the present invention are  
30 activated. The T-cells may be activated by exposure of the cells to one or more of a variety of natural and synthetic antigens and epitopes, including but not limited to, lipopolysaccharide (LPS), myelin basic protein (MBP), myelin/oligodendrocyte glycoprotein (MOG), myelin proteolipid  
35 protein (PLP), myelin associated protein (MAG), S-100,  $\beta$ -amyloid, Thy-1, neurotransmitter receptors. Preferably, T-

cells are activated by an antigen that is not specific to the NS, more preferably by a non-self antigen.

During *ex vivo* activation of the T-cells, the T-cells may be activated by culturing them in medium to which at least one suitable growth promoting factor has been added. Growth promoting factors suitable for this purpose include, without limitation, cytokines, for instance tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), interleukin 2 (IL-2), and interleukin 4 (IL-4).

10 In an embodiment, the activated T-cells endogenously produced a substance that ameliorates the effects of injury or disease in the CNS.

In another embodiment, the activated T-cells endogenously produce a substance that stimulates other cells, including, but not limited to, transforming growth factor- $\beta$  (TGF- $\beta$ ), nerve growth factor (NGF), neurotrophic factor 3 (NT-3), neurotrophic factor 4/5 (NT-4/5), brain-derived neurotrophic factor (BDNF), interferon- $\delta$  (IFN- $\delta$ ), interleukin-6 (IL-6), wherein the other cells, directly or  
20 indirectly, ameliorate the effects of injury or disease.

In another embodiment, the T-cells may be genetically engineered *in vitro* to insert therein a nucleotide sequence as described in Kramer et al., 1995, Nature Medicine, 1(11):1162-1166. The nucleotide sequence is under the  
25 control of necessary elements for transcription and translation such that a biologically active protein encoded by the nucleotide sequence can be either expressed continuously or induced to expression as a result of exposure of the T-cells to a microenvironment of a kind present at the  
30 site of injury.

Due to the inherent degeneracy of the genetic code, other nucleotide sequences that encode substantially the same or a functionally equivalent amino acid sequence of a protein, are within the scope of the invention. Preferably,  
35 the expression product of said nucleotide sequence is a secretory protein.

The recombinant T-cells which contain a coding sequence and which express a biologically active gene product may be identified by at least four general approaches: (a) DNA-DNA or DNA-RNA hybridization; (b) the presence or absence of  
5 "marker" gene functions; (c) assessing the level of transcription as measured by the expression of mRNA transcripts in the cell; and (d) detection of the product encoded by the nucleotide sequence as measured by immunoassay or by its biological activity.

10 In the first approach, the presence of the coding sequence inserted in the expression vector can be detected by DNA-DNA or DNA-RNA hybridization using probes comprising nucleotide sequences that are homologous to the coding sequence or portions or derivatives thereof.

15 In the second approach, the recombinant expression system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, resistance to methotrexate, transformation phenotype,  
20 occlusion body formation in baculovirus, etc.). For example, if the coding sequence is inserted within a marker gene sequence of a vector, recombinant cells containing the coding sequence can be identified by the absence of the marker gene function. Alternatively, a marker gene can be placed in  
25 tandem with a sequence under the control of the same or different promoter used to control the expression of the coding sequence. Expression of the marker in response to induction or selection indicates expression of the coding sequence.

30 In the third approach, transcriptional activity of a nucleotide sequence can be assessed by hybridization assays. For example, RNA can be isolated and analyzed by Northern blot using a probe having sequence homology to a coding sequence or transcribed noncoding sequence or particular  
35 portions thereof. Alternatively, total nucleic acid of the host cell may be extracted and quantitatively assayed for hybridization to such probes.

In the fourth approach, the levels of a protein product can be assessed immunologically, for example by Western blots, immunoassays such as radioimmuno-precipitation, enzyme-linked immunoassays and the like.

5       The T-cells may be stably transfected with said nucleotide sequences or may be transiently transfected. Transient transfection may be applicable for acute one-dose therapeutic regimens.

Such nucleotide sequences may encode various substances including, without limitation, therapeutic substances; enzymes which catalyze a therapeutic substance; a regulatory product which stimulates expression of a therapeutic substance in the T-cells, etc. Examples include: nucleotide sequences encoding neurotrophic factors such as NGF;  
15 nucleotide sequences encoding enzymes which play a role in CNS nerve regeneration such as the enzyme transglutaminase; nucleotide sequences encoding enzymes which catalyze the production of a neurotransmitter, e.g. enzymes involved in the catalysis of acetylcholine or dopamine, etc. As a  
20 result, T-cells which localize at the site of CNS injury or disease produce and secrete the needed substances at the site.

As will be evident to those skilled in the art, the T-cells can be preserved, e.g. by cryopreservation, either  
25 before or after culture.

Cryopreservation agents which can be used include but are not limited to dimethyl sulfoxide (DMSO) (Lovelock and Bishop, 1959, Nature 183:1394-1395; Ashwood-Smith, 1961, Nature 190:1204-1205), glycerol, polyvinylpyrrolidone  
30 (Rinfret, 1960, Ann. N.Y. Acad. Sci. 85:576), polyethylene glycol (Sloviter and Ravdin, 1962, Nature 196:548), albumin, dextran, sucrose, ethylene glycol, i-erythritol, D-ribitol, D-mannitol (Rowe et al., 1962, Fed. Proc. 21:157), D-sorbitol, i-inositol, D-lactose, choline chloride (Bender  
35 et al., 1960, J. Appl. Physiol. 15:520), amino acids (Phan The Tran and Bender, 1960, Exp. Cell Res. 20:651), methanol, acetamide, glycerol monoacetate (Lovelock, 1954, Biochem. J.

56:265), inorganic salts (Phan The Tran and Bender, 1960, Proc. Soc. Exp. Biol. Med. 104:388; Phan The Tran and Bender, 1961, in Radiobiology, Proceedings of the Third Australian Conference on Radiobiology, Ilbery, P.L.T., ed., Butterworth, 5 London, p. 59), and DMSO combined with hydroxyethyl starch and human serum albumin (Zaroulis and Leiderman, 1980, Cryobiology 17:311-317).

A controlled cooling rate is critical. Different cryoprotective agents (Rapatz et al., 1968, Cryobiology 10 5(1):18-25) and different cell types have different optimal cooling rates. See, e.g., Rowe and Rinfret, 1962, Blood 20:636; Rowe, 1966, Cryobiology 3(1):12-18; Lewis et al., 1967, Transfusion 7(1):17-32; and Mazur, 1970, Science 168:939-949 for effects of cooling velocity on survival of 15 cells and on their transplantation potential. The heat of fusion phase where water turns to ice should be minimal. The cooling procedure can be carried out by use of, e.g., a programmable freezing device or a methanol bath procedure.

Programmable freezing apparatuses allow determination of 20 optimal cooling rates and facilitate standard reproducible cooling. Programmable controlled-rate freezers such as Cryomed or Planar permit tuning of the freezing regimen to the desired cooling rate curve.

After thorough freezing, cells can be rapidly 25 transferred to a long-term cryogenic storage vessel. In one embodiment, samples can be cryogenically stored in mechanical freezers, such as freezers that maintain a temperature of about -80°C or about -20°C. In a preferred embodiment, samples can be cryogenically stored in liquid nitrogen 30 (-196°C) or its vapor. Such storage is greatly facilitated by the availability of highly efficient liquid nitrogen refrigerators, which resemble large Thermos containers with an extremely low vacuum and internal super insulation, such that heat leakage and nitrogen losses are kept to an absolute 35 minimum.

Considerations and procedures for the manipulation, cryopreservation, and long term storage of T-cells can be

found, for example, in the following references, incorporated by reference herein: Gorin, 1986, Clinics in Haematology 15(1):19-48; Bone-Marrow Conservation, Culture and Transplantation, Proceedings of a Panel, Moscow, July 22-26, 1968, International Atomic Energy Agency, Vienna, pp. 107-186.

Other methods of cryopreservation of viable cells, or modifications thereof, are available and envisioned for use, e.g., cold metal-mirror techniques. See Livesey and Linner, 1987, Nature 327:255; Linner et al., 1986, J. Histochem. Cytochem. 34(9):1123-1135; see also U.S. Patent No. 4,199,022 by Senken et al., U.S. Patent No. 3,753,357 by Schwartz, U.S. Patent No. 4,559,298 by Fahy.

Frozen cells are preferably thawed quickly (e.g., in a water bath maintained at 37-41°C) and chilled immediately upon thawing. It may be desirable to treat the cells in order to prevent cellular clumping upon thawing. To prevent clumping, various procedures can be used, including but not limited to the addition before or after freezing of DNase (Spitzer et al., 1980, Cancer 45:3075-3085), low molecular weight dextran and citrate, hydroxyethyl starch (Stiff et al., 1983, Cryobiology 20:17-24), or acid citrate dextrose (Zaroulis and Leiderman, 1980, Cryobiology 17:311-317), etc.

The cryoprotective agent, if toxic in humans, should be removed prior to therapeutic use of the thawed T-cells. One way in which to remove the cryoprotective agent is by dilution to an insignificant concentration.

Once frozen T-cells have been thawed and recovered, they are used to promote axonal regeneration as described herein with respect to non-frozen T-cells.

#### 5.1.2 USES

The compositions and methods of the present invention comprising activated, substance-delivering T-cells are useful for treating or detecting a site of damage in the CNS caused by injury or disease.



Methods for detecting a site of injury or disease of the CNS in a mammal comprise: (a) administering to a mammal an effective amount of labeled activated T-cells; and (b) detecting in the mammal the labeled activated T-cells that have accumulated at said site of injury or disease, in which step (b) is performed after an interval sufficient to permit said labeled activated T-cells administered to step (a) to accumulate at said site of injury or disease.

For use in the therapeutic methods of the invention, activated T-cells can be used to deliver substances for ameliorating the effects of injury or disease by, for example, promoting axonal regeneration or inhibiting or preventing degeneration of the CNS. Such substances include, without limitation, growth factors which promote nerve regeneration such as nerve growth factor (NGF); substances lacking at the site of injury, e.g. neurotransmitters such as acetylcholine, dopamine; anti-inflammatory substances, etc. Further, activated T-cells may endogenously produce a substance that has a therapeutic effect on the CNS injury, including, without limitation, interleukins and growth factors.

In a preferred embodiment, the activated T-cells do not recognize a NS-specific antigen; more preferably, the labeled activated T-cells recognize a non-self antigen.

The injury or disease may be situated in any portion of the CNS, including the brain, spinal cord, or optic nerve. One example of such injury or disease is trauma, including blunt trauma, penetrating trauma, and trauma sustained during a neurosurgical operation or other procedure. Another example of such injury or disease is stroke, including hemorrhagic stroke and ischemic stroke. Other examples of disease are Alzheimer's disease, multiple sclerosis, Huntington's disease, ALS, and Parkinson's disease. Yet another example of such injury or disease is optic nerve injury accompanying optic neuropathy or glaucoma. Still further examples of CNS injury or disease will be evident to those skilled in the art from this description and are

encompassed by the present invention. The compositions and methods of the present invention are useful for treating CNS injury or disease that results in axonal damage whether or not the subject also suffers from another disease of the central or peripheral nervous system, such as neurological disease of genetic, metabolic, toxic, nutritional, infective or autoimmune origin.

## 5.2 AMELIORATION OF CNS DAMAGE

### 10 5.2.1 THERAPEUTIC COMPOSITIONS AND USES

The invention also provides methods of preventing or inhibiting CNS degeneration by administering a composition comprising an effective amount of NS-specific antiseif T-cells. In a preferred embodiment the NS-specific antiseif T-  
15 cells are non-recombinant cells.

The invention also provides methods of preventing or inhibiting CNS degeneration by administering a composition comprising an effective amount of a NS-specific antigen.

The activated, substance-delivering T-cells described,  
20 *supra*, in Section 5.1 may be used alone or in combination with NS-specific antiseif T-cells or a NS-specific antigen or NS-specific antiseif T-cells and a NS-specific antigen for ameliorating the effects of injury or disease, e.g., for promoting axonal regeneration and preventing or inhibiting  
25 CNS degeneration.

#### 5.2.1.1 NS-SPECIFIC ANTISEIF T-CELLS

NS-specific antiseif T-cells (ATCs) can be used for ameliorating the effects of injury or disease of the CNS that  
30 result in CNS degeneration. In a preferred embodiment the NS-specific antiseif T-cells are isolated.

Circulating T-cells of a subject which recognize myelin basic protein or another NS antigen such as the amyloid precursor protein are isolated and expanded using known  
35 procedures. In order to obtain NS-specific antiseif T-cells, T-cells are isolated and the NS-specific ATCs are then expanded by known procedures (Burns et al., *Cell Immunol.*

81:435 (1983); Pette et al., *Proc. Natl. Acad. Sci. USA*  
87:7968 (1990); Mortin et al., *J. Immunol.* 145:540 (1990);  
Schluesener et al., *J. Immunol.* 135:3128 (1985); Suruhan-  
Dires Keneli et al., *Euro. J. Immunol.* 23:530 (1993) which  
5 are incorporated herein by reference in their entirety.

Following their proliferation *in vitro*, the T-cells are  
administered to a mammalian subject. In a preferred  
embodiment, the T-cells are administered to a human subject.  
T-cell expansion is preferably performed using peptides  
10 corresponding to sequences in a non-pathogenic, NS-specific,  
self protein.

A subject can initially be immunized with a NS-specific  
antigen using a non-pathogenic peptide of the self protein.  
A T-cell preparation can be prepared from the blood of such  
15 immunized subjects, preferably from T-cells selected for  
their specificity towards the NS-specific antigen. The  
selected T-cells can then be stimulated to produce a T-cell  
line specific to the self-antigen (Ben-Nun et al., *J.*  
*Immunol.* 129:303 (1982)).

20 The NS-specific antigen may be a purified antigen, a  
crude NS preparation, or a peptide derived from a NS-antigen,  
as will be described below.

NS-specific ATCs, obtained as described above, can be  
used immediately or may be preserved for later use, e.g. by  
25 cryopreservation as described in Section 5.1, *supra*. NS-  
specific ATCs may also be obtained using previously  
cryopreserved T-cells, i.e., after thawing the cells, the  
T-cells may be incubated with NS-specific antigen, optimally  
together with thymocytes, to obtain a preparation of NS-  
30 specific ATCs.

#### 5.2.1.2 NS-SPECIFIC ANTIGENS

Pharmaceutical compositions comprising a NS-specific  
antigen are used for ameliorating the effects of injury or  
35 disease that result in CNS degeneration. Additionally, NS-  
specific antigens may be used for *in vivo* or *in vitro*  
activation of antiself T-cells. In an embodiment, the NS-

specific antigen is an isolated antigen. In an embodiment, methods of ameliorating the effects of CNS injury or disease comprise administering NS-specific antigen to a mammal wherein the NS-specific Ag activates T-cells *in vivo* to  
5 produce a population of T-cells that accumulate at a site of injury or disease of the CNS.

The NS-specific antigen may be an antigen obtained from NS tissue, preferably from tissue at a site of CNS injury or disease. The NS-specific antigen may be isolated and  
10 purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of antigens. The functional properties may be evaluated using any suitable  
15 assay.

In a preferred embodiment, peptides derived from NS-specific, self antigens activate T-cells, but do not induce an autoimmune disease. An example of such a antigen fragment is a peptide comprising amino acids 51-70 of myelin basic  
20 protein. SEQ ID NO:1 (Kamholz et al., 1986, Proc. Natl. Acad. Sci. USA 83:4962-4966, GenBank accession number M13577; Roth et al., 1987, J. Neurosci. Res. 17(4):321-328, GenBank accession number M30516).

In addition, a NS-specific antigen may be a crude NS-tissue preparation, e.g., derived from tissue obtained at the  
25 site of CNS injury. Such a preparation may include cells, both living or dead cells, membrane fractions of such cells or tissue, etc.

A NS-specific antigen may be obtained by a NS biopsy  
30 from a mammal including, but not limited to, from a site of CNS injury; from cadavers; from cell lines grown in culture. Additionally, a NS-specific antigen may be a protein obtained by genetic engineering, chemically synthesized, etc.

In addition to purified antigen, the invention also  
35 relates to derivatives (e.g., fragments) or analogs of NS-specific antigens which are functionally active, i.e., they are capable of displaying one or more known functional

activities associated with a full-length NS-specific antigen. Such functional activities include but are not limited to antigenicity [ability to bind (or compete with a CNS-antigen for binding) to an anti-NS-specific antibody], immunogenicity  
5 (ability to generate antibody which binds to a NS-specific protein), and ability to interact with T-cells, resulting in activation comparable to that obtained using the corresponding full-length antigen.

In a specific embodiment of the invention, proteins  
10 consisting of or comprising a fragment of a NS-specific antigen consisting of at least 10 (contiguous) amino acids of the CNS-specific antigen is provided. In other embodiments, the fragment consists of at least 20 contiguous amino acids or 50 contiguous amino acids of the NS-specific antigen.  
15 Derivatives or analogs of a NS-specific antigen include but are not limited to those molecules comprising regions that are substantially homologous to the full-length antigen or fragments thereof (e.g., in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid  
20 sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art) or whose encoding nucleic acid is capable of hybridizing to a coding nucleotide sequence of the full-length NS-specific antigen, under  
25 stringent, moderately stringent, or nonstringent conditions.

The NS-specific antigen derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, a cloned  
30 gene sequence can be modified by any of numerous strategies known in the art (Maniatis, T., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate sites with restriction endonuclease(s),  
35 followed by further enzymatic modification if desired, isolated, and ligated in vitro.

Additionally, the coding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new  
5 restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem  
10 253:6551), etc.

Manipulations may also be made at the protein level. Included within the scope of the invention are fragments or other derivatives or analogs which are differentially modified during or after translation, e.g., by glycosylation,  
15 acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to  
20 specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

In addition, analogs and derivatives of a NS-specific  
25 antigen can be chemically synthesized. For example, a peptide corresponding to a portion of an antigen which comprises the desired domain or which mediates the desired activity can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical  
30 amino acid analogs can be introduced as a substitution or addition into the amino acid sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino  
35 hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-

butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids,  $\alpha$ -methyl amino acids,  $N\alpha$ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The functional activity of NS-specific antigens and derivatives thereof can be assayed by various methods known in the art, including, but not limited to T-cell proliferation assays (Mor and Cohen, 1995, J. Immunol. 155:3693-3699).

A NS-specific antigen or derivative thereof may be kept in solution or may be provided in a dry form, e.g. as a powder or lyophilizate, to be mixed with appropriate solution prior to use.

#### 5.2.2 USES

The compositions described in Section 5.2 may be used to prevent or inhibit secondary degeneration which may otherwise follow primary CNS injury, e.g. a cut or a crush in a CNS tissue. In addition, such compositions may be used to ameliorate the effects of disease that results in degenerative processes, e.g. degeneration occurring in either grey or white matter (or both) as a result of various diseases or disorders including, without limitation: senile dementias, Alzheimer's disease, Parkinson's Disease, glaucoma, multiple sclerosis, Huntington's disease, ALS, prion diseases such as Creutzfeldt-Jakob disease, etc.

#### 30 5.3 FORMULATIONS AND ADMINISTRATION

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. The carriers in the pharmaceutical composition may comprise a binder, such as microcrystalline cellulose, 5 polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatine, starch, lactose or lactose monohydrate; a disintegrating agent, such as alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; a glidant, such as 10 colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin; and/or a flavoring agent, such as peppermint, methyl salicylate, or orange flavoring.

Methods of administration include, but are not limited to, parenteral e.g. intravenous, intraperitoneal, 15 intramuscular, subcutaneous, and mucosal e.g., oral, nasal, buccal, vaginal, rectal, intraocular) routes. Administration can be systemic or local.

For oral administration, the pharmaceutical preparation may be in liquid form, for example, solutions, syrups or 20 suspensions, or may be presented as a drug product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose 25 derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The pharmaceutical compositions may take the 30 form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline 35 cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents



(e.g., sodium lauryl sulphate). The tablets may be coated by methods well-known in the art.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

- 5 For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

- The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or  
10 continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain  
15 formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

- The compounds may also be formulated in rectal  
20 compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

- For administration by inhalation, the compositions for use according to the present invention are conveniently  
25 delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized  
30 aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

- 35 In a preferred embodiment, compositions comprising substance-delivering activated T-cells or NS-specific antiself T-cells are formulated in accordance with routine

procedures as pharmaceutical compositions adapted for intravenous or intraperitoneal administration to human beings.

Typically, compositions for intravenous administration  
5 are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together. Where the  
10 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water or saline for injection can be provided so that the ingredients  
15 may be mixed prior to administration.

In an embodiment, pharmaceutical compositions comprising NS-specific antigen are administered with an adjuvant, such as Incomplete Freund's Adjuvant.

The invention also provides a pharmaceutical pack or kit  
20 comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.

In a preferred embodiment, the pharmaceutical compositions of the invention are administered to a mammal  
25 shortly after injury or detection of a degenerative lesion in the CNS. The therapeutic methods of the invention may comprise administration of activated T-cells or NS-specific ATCs or a NS-specific antigen or any combination thereof.

In an embodiment, the NS-specific ATCs or a NS-specific  
30 antigen of the invention are administered in combination with a therapeutic composition which promotes regeneration of axons within the CNS; the latter therapeutic composition may comprise for example, the activated, substance-delivering T-cells of the present invention wherein the said substance  
35 promotes nerve regeneration. Alternatively, the therapeutic composition may comprise mononuclear phagocytes as described in PCT Publication No. WO 97/09985, which is incorporated

herein by reference in its entirety. Briefly, mononuclear phagocytes which are cultured *ex vivo* together with a stimulatory tissue, such as dermis or a nerve segment, are administered into the central nervous system of a mammal at  
5 or near the site of injury or disease-inflicted lesion. In an embodiment, the mononuclear phagocytes are allogeneic. In a preferred embodiment, the mononuclear phagocytes are autologous.

In an embodiment, mononuclear phagocyte cells according  
10 PCT Publication No. WO 97/09985 and U.S. patent application Serial No. 09/041,280, filed March 11, 1998, are injected into the site of injury or lesion within the CNS, either concurrently, prior to, or following parenteral administration of NS-specific ATCs or NS-specific antigen.  
15 In an embodiment, administration of substance-delivering activated T-cells, or NS-specific ATCs, a NS-specific antigen, may be administered as a single dose or may be repeated, preferably at 2 week intervals and then successively longer intervals once a month, once a quarter,  
20 once every six months, etc. The course of treatment may last several months, several years or occasionally also through the life-time of the individual, depending on the condition or disease which is being treated. In the case of a CNS injury, the treatment may range between several days to  
25 months or even years, until the condition has stabilized and there is no or only a limited risk of development of secondary degeneration. In chronic human diseases or conditions such as Alzheimer's disease or Parkinson's disease, the therapeutic treatment in accordance with the  
30 invention may be for life.

As will be evident to those of skill in the art, the therapeutic effect depends at times on the condition or disease to be treated, on the individual's age and health condition, on other physical parameters (e.g. gender, weight,  
35 etc.) of the individual, as well as on various other factors, e.g. whether the individual is taking other drugs, etc.

The optimal dose of the therapeutic compositions comprising activated T-cells or NS-specific antiself T-cells of the invention is proportional to the number of nerve fibers affected by CNS injury or disease at the site being treated. In a preferred embodiment, the dose ranges from about  $5 \times 10^6$  to about  $10^7$  for treating a lesion affecting about  $10^5$  nerve fibers, such as a complete transection of a rat optic nerve, and ranges from about  $10^7$  to about  $10^8$  for treating a lesion affecting about  $10^5$  nerve fibers, such as a complete transection of a human optic nerve. As will be evident to those of skill in the art, the dose of T-cells can be scaled up or down in proportion to the number of nerve fibers affected at the lesion or site of injury being treated.

15

6. **EXAMPLE: ACCUMULATION OF ACTIVATED T-CELLS IN INJURED CNS**

6.1 **MATERIALS AND METHODS**

6.1.1 **ANIMALS**

20

Female Lewis rats were obtained from Harlan Olac (Bicester, UK), matched for age (8-12 weeks) and housed four to a cage in a light and temperature-controlled room.

6.1.2 **PROTEINS USED FOR T-CELL ACTIVATION**

25

Myelin basic protein (MBP) was prepared from guinea pig spinal cord as previously described (Ben-Nun et al., *supra* (1982)). Chick ovalbumin (OVA) was purchased from Sigma (Israel). Heat-inactivated *Mycobacterium tuberculosis* H37RA (*M. tuberculosis*) and Incomplete Freund's adjuvant (IFA) were purchased from Difco Laboratories (Detroit, MI, USA).

30

6.1.3 **MEDIA**

The proliferation medium of the T-cells contained the following: Dulbecco's modified Eagle's medium (DMEM, Biological Industries, Israel) supplemented with 2mM L-glutamine (L-Glu, Sigma, USA),  $5 \times 10^{-5}$ M 2-mercaptoethanol (2-

35

ME, Sigma), penicillin (100 IU/ml; Biological Industries), streptomycin (100 µg/ml; Biological Industries), sodium pyruvate (1 mM; Biological Industries), non-essential amino acids (1 ml/100 ml; Biological Industries) and autologous rat serum 1% (vol/vol) (Mor et al., *Clin. Invest.*, **85**:1594 (1990)). Propagation medium contained: DMEM, 2-ME, L-Glu, sodium pyruvate, non-essential amino acids and antibiotics in the same concentration as above and also 10% fetal calf serum (FCS), and 10% T-cell growth factor (TCGF) obtained from the supernatant of concanavalin A-stimulated spleen cells (Mor et al., *supra*, 1990).

#### 6.1.4 ANTIGENS

MBP from the spinal cords of guinea pigs was prepared as described (Hirshfeld, et al., 1970, *FEBS Lett.* **7**:317). OVA was purchased from Sigma (St. Louis, Missouri). The p51-70 of the rat 18.5kDa isoform of MBP (sequence: APKRGSGKDSHTRTTHYG) SEQ ID NO:2 and the p277 of the human hsp60 (sequence: VLGGGCALLRCPALDSLTPANED) SEQ ID NO:3 (Elias, et al., 1991, *Proc. Natl. Acad. Sci. USA* **88**, 3088-91) were synthesized using the 9-fluorenylmethoxycarbonyl technique with an automatic multiple peptide synthesizer (AMS 422, ABIMED, Langenfeld, Germany). The purity of the peptides was analyzed by HPLC and amino acid composition.

25

#### 6.1.5 T CELL LINES

T-cell lines were generated from draining lymph node cells obtained from Lewis rats immunized with an antigen. The antigen was dissolved in PBS (1mg/ml) and emulsified with an equal volume of incomplete Freund's adjuvant (Difco Laboratories, Detroit, Michigan) supplemented with 4 mg/ml *Mycobacterium tuberculosis* (Difco). The emulsion (0.1 ml) was injected into hind foot pads of the rats. Ten days after the antigen was injected, the rats were killed and draining lymph nodes were surgically removed and dissociated. The cells were washed and activated with the antigen (10µg/ml) in proliferation medium containing Dulbecco's modified Eagle's

35

medium (DMEM) supplemented with L-glutamine (2mM), 2-mercaptoethanol ( $5 \times 10^{-5}$ M), sodium pyruvate (1mM), penicillin (100 IU/ml), streptomycin (100  $\mu$ g/ml), nonessential amino acids (1 ml/100 ml) and autologous rat serum 1% (volume/volume). After incubation for 72 h at 37°C, 90% relative humidity and 7% CO<sub>2</sub>, the cells were transferred to propagation medium which additionally contained 10% fetal calf serum (FCS) (volume/volume) and 10% T cell growth factor derived from the supernatant of concanavalin A-stimulated spleen cells. Cells were grown in propagation medium for 4-10 days before being re-exposed to antigen (10 $\mu$ g/ml) in the presence of irradiated (2000 rad) thymus cells (10<sup>7</sup> cells/ml) in proliferation medium. The T-cell lines were expanded by repeated re-exposure and propagation.

15

#### 6.1.6 LABELING OF T-CELLS

T-cells were washed and suspended in 10.7 $\mu$ m Hoechst 33342 Stain (Molecular Probes, USA) for 10 minutes at 37°C. The cells were washed twice with 50 ml volumes of PBS and then resuspended at  $5 \times 10^6$  cells/ml on ice until injection.

#### 6.1.7 CRUSH INJURY OF RAT OPTIC NERVE

Crush injuries were performed as previously described (Hirschberg et al., 1994, J. Neuroimmunol. 50:9-16). Briefly, rats were deeply anesthetized by i.p. injection of xylazine (10 mg/kg; Rompun) and ketamine (50 mg/kg; Velalar). Under a binocular operating microscope, a lateral canthotomy was performed in the right eye and the conjunctiva was incised lateral to the cornea. After separation of the retractor bulbi muscles, the optic nerve was exposed intraorbitally by blunt dissection. A moderate crush injury was inflicted on the optic nerve, 2 mm from the eye, using a calibrated cross-action forceps (Duvdevani et al., *Instructure Neurology and Neuroscience*, 2:31, 1990). The contralateral nerve was left undisturbed and was used as a control.

#### 6.1.8 SECTIONING OF NERVES

At specified time points, rats were euthanized by over-anesthesia with ether and their optic nerves were surgically removed, immersed in Tissue-Tek (Miles Inc., USA), and frozen in liquid nitrogen cooled in iso-pentane (BDH, UK). The nerves were then transferred to dry ice and stored at -70°C until sectioning. Longitudinal cryostat nerve sections (20 µm thick) were picked up onto gelatin-coated glass slides (four sections per slide) and frozen at -20°C until viewed or prepared for fluorescence staining.

#### 6.1.9 DATA ANALYSIS OF T-CELLS IN NERVE SECTIONS

Nerves excised at various time periods after injury were prepared and sectioned. Hoechst-labeled nuclei or immunostained cells in each section were counted using the fluorescence microscope. For each time point five sections were counted, and the numbers were averaged.

#### 6.1.10 IMMUNOLABELING OF NERVE SECTIONS

Longitudinal cryostat nerve sections (20 µm thick) were picked up onto gelatin glass slides and frozen until preparation for fluorescent staining. Sections were thawed and fixed in ethanol for 10 minutes at room temperature, washed twice with double-distilled water (ddH<sub>2</sub>O), and incubated for 3 minutes in PBS containing 0.05% polyoxyethylene-sorbitan monolaurate (Tween-20; Sigma, USA). They were then incubated overnight at 4°C with a mouse monoclonal antibody directed against rat macrophages (ED1; 1:400; Serotec, UK) and antibody against rat glial fibrillary acidic protein (GFAP; 1:100; BioMakor), all diluted in PBS containing 3% FCS. Staining of T-cells was accomplished by incubating nerve sections for 1 hr at room temperature with a mouse monoclonal antibody directed against rat T-cell receptor (TCR) (1:100, Hunig et al., *J. Exp. Med.*, 169:73, 1989), in PBS containing 3% FCS and 2% BSA. After three washes with PBS containing 0.05% Tween-20, the sections were incubated with goat anti-mouse F(ab')<sub>2</sub> conjugated to either

fluorescein isothiocyanate (FITC; BioMakor) or tetramethyl rhodamine isothiocyanate (TRITC; BioMakor) at a dilution of 1:100 and 1:50 respectively, for 1 hr at room temperature. They were then washed with PBS containing Tween-20 and 5 treated with glycerol containing 1,4-diazobicyclo-(2,2,2) octane (Sigma), to inhibit quenching of fluorescence. The sections were viewed with a Zeiss Universal fluorescence microscope using filters that detect TRITC, FITC and Hoechst stains (Blaugrund et al., *Exp. Neurol.*, 118:105, 1992, 10 Blaugrund et al., *Brain Res.*, 574:244, 1992).

## 6.2 RESULTS

### 6.2.1 ACCUMULATION OF ACTIVATED T-CELLS

T-cell clones primed to MBP ( $T_{MBP}$ ) were activated with 15 MBP for 2 days before being labeled with Hoechst stain and injected into animals i.p. at the time of injury. At 3, 7, 14 and 21 days after injury, the nerves were excised, cryosectioned and analyzed microscopically for the presence of labeled T-cells.

20  $T_{MBP}$  cells were detected in the injured optic nerves at day 3 and accumulated until a peak at day 14 (Fig. 1). Large clusters of  $T_{MBP}$  cells were observed at the injury site and fewer individual cells were seen proximal and distal (Fig. 2). Four weeks after injury, labeled T-cells were still 25 detectable in the degenerating optic nerves. No T-cells were found in the non-injured optic nerves (Fig. 3), non-injured sciatic nerve or injured sciatic nerve at any time after injury. Labeled T-cells were occasionally found in capillaries and in connective tissue but were not 30 concentrated or localized into any specific areas. T-cells that were not prestimulated with antigen did not accumulate in any of the nerves, including damaged nerves.

The accumulation of  $T_{MBP}$  cells in injured CNS, but not in injured PNS, suggests that there might be some specific 35 interaction between the primed T-cells and the CNS tissue from which the MBP antigen was originally derived. To determine whether the injured CNS interacted with T-cells in



general, or specifically with T-cells primed with a CNS antigen, the previous experiments were repeated using a clone that responds to chick ovalbumin ( $T_{OVA}$ ). Rats were injected with a labeled  $T_{OVA}$  clone prestimulated with ovalbumin (OVA) using the same protocol as with the  $T_{MBP}$  cells. The labeled  $T_{OVA}$  cells accumulated in injured optic nerve, and the pattern of accumulation was similar to that of the  $T_{MBP}$  cells. Labeled  $T_{OVA}$  and  $T_{MBP}$  cells were counted in longitudinal sections of optic nerve prepared, 3, 7, 14 and 21 days after injury. No significant different was observed in numbers of  $T_{MBP}$  and  $T_{OVA}$  cells in injured optic nerve (Fig. 4), indicating that antigen specificity has little to do with the accumulation of T-cells in CNS injury sites.  $T_{MBP}$  cells were detectable slightly earlier than  $T_{OVA}$  cells in the optic nerve injury site, and antigen specificity may play a role in this but is not sufficient to explain the large accumulation of  $T_{OVA}$  cells in the site of injury.

Fig. 5 shows accumulation of T-cells measured immunocytochemically using antibodies to T-cell receptors. This detection technique rules out the possibility that the observed labeling is due to phagocytic cells which had phagocytized the pre-labeled T-cells shown in Fig. 1. The graph shows a striking elevation in T-cell accumulation following injury, regardless of whether the systematically injected T-cells are specific to a self-epitope (MBP) or to a non-self epitope (OVA).

Fig. 6 shows that accumulation of T-cells is dependent on the lesion and not the breakdown of the blood-brain barrier. T-cells specific to either MBP or OVA were injected 2 weeks after injury and their accumulation analyzed a week later, namely 21 days following the primary lesion. Their accumulation was compared to that of T-cells injected immediately after injury and detected either 7 or 21 days later. It appears that the time elapsed between the injury and the injection of T-cells, which is a factor in the sealing of the blood-brain barrier, is not a factor in the T-cell accumulation.

## 7. EXAMPLE: USES OF ACTIVATED T-CELLS AND NS-SPECIFIC ATCS

### 7.1 MATERIALS AND METHODS

Animals, proteins used for T-cell stimulation, media, crush injury of rat optic nerve, sectioning of nerves, immunolabeling of nerve sections, and data analysis of T-cells in nerve sections are described in Section 6, *supra*.

#### 7.1.1 ESTABLISHMENT OF T-CELL LINES WITH ACTIVE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE)

10 MBP and OVA were dissolved in PBS (1 mg/ml) and emulsified with an equal volume of Incomplete Freund's Adjuvant (IFA) supplemented with 4 mg/ml *M. tuberculosis*. Rats were immunized subcutaneously in the hind footpads with 0.1 ml of the emulsion. At day 9 (1-3 days before clinical onset of disease), animals were euthanized and draining lymph nodes were surgically removed and dissociated under sterile conditions. The cells were washed and placed in proliferation medium with irradiated thymocytes (2000 rads) and either 10 µg/ml of MBP, OVA or *M. tuberculosis* for 3 days. Cells were then washed and placed in propagation medium for 5 to 10 days at which time they were re-exposed to irradiated thymocytes and peptides in proliferation medium. T-cell lines were expanded by re-exposure and propagation and tested for specificity in an antigen specific T cell proliferation assay. Lines were expanded and stocks were frozen in liquid nitrogen. The cells were thawed and stimulated once before being used in experiments.

#### 7.1.2 PASSIVE TRANSFER OF T-CELL LINES

30 T-cell lines were activated by restimulation *in vitro* with their own antigen (10 µg/ml) in proliferation medium. After incubation for 48-72 hrs at 37°C 90% relative humidity and 7.5% CO<sub>2</sub>, the cells were washed. Viable cells were isolated on Percoll and suspended in PBS. Animals were injected with 10 x 10<sup>6</sup> cells/ml i.p. Control animals were injected with 1 ml PBS i.p.

### 7.1.3 CRUSH INJURY OF RAT SCIATIC NERVE

Under deep anesthesia as described in Section 6.1.5, the sciatic nerve was exposed and a similar crush injury was inflicted. At the end of the operation the skin was sutured.

5

### 7.1.4 RETROGRADE LABELING OF RGCs

The optic nerve was exposed, without damaging the retinal blood supply. Solid crystals of the dye, 4-(4-(didecylamino)styryl)-n-methyl-pyridinium iodide (4-Di-10-  
10 Asp) (Molecular Probes, Europe BV), were deposited 1-2 mm from the distal border of the injury site. Non-injured optic nerves were similarly labeled at approximately the same distance from the globe. Five days after dye application, the retinas were excised under deep anesthesia, flat mounted  
15 in 4% paraformaldehyde solution, and labeled retinal ganglion cells (RGCs) were counted by fluorescence microscopy.

### 7.1.5 ASSESSMENT OF EFFECTS OF INJECTED T-CELLS

The effect of injected T-cells on the numbers of  
20 surviving optic nerve fibers was monitored by retrograde labeling of RGCs (see above) immediately after injury in order to assess primary degeneration and two weeks later in order to assess secondary degeneration. Five days after dye (4-Di-10-Asp) application, the retinas were excised, whole  
25 mounted and their RGCs were counted. The counting was done in five randomly selected fields in each retina (all located at approximately the same distance from the optic disc). In all cases the dye was applied 2 ml distally to the site of the prior insert. Using this lengthening approach, only  
30 those RGCs whose axons were still viable could be labeled. The numbers of RGCs in each group of injured nerves treated with PBS only were injected with T<sub>MBP</sub> or T<sub>OVA</sub> cells. Results were expressed as percentage of axons, out of those which survived the primary insult (42% the axons remained after the  
35 primary insult).

### 7.1.6 CLINICAL EVALUATION OF EAE

Clinical disease was scored every 1 to 2 days according to the following neurological scale: 0, no abnormality; 1, tail atony; 2, hind limb paralysis; 3, paralysis extending to 5 thoracic spine; 4, front limb paralysis; 5, moribound state.

## 7.2 RESULTS

### 7.2.1 ACCUMULATION OF NS-SPECIFIC ATCS

The injured optic nerve was analyzed for T-cell  
10 accumulation. As shown in Fig. 7, in the uninjured optic  
nerves of control rats injected with phosphate-buffered  
saline (PBS) no T-cells could be detected. Small but  
significant numbers of T-cells were observed in the uninjured  
optic nerves of rats injected with anti-MBP T-cells (primed  
15 against a peptide comprising amino acids 51-70 of MBP "P51-  
70" known to be capable of inducing experimental autoimmune  
encephalomyelitis (EAE) under these experimental conditions),  
but not of rats injected with anti-OVA T-cells. Crush injury  
of the optic nerve was accompanied by a small but significant  
20 accumulation of endogenous T-cells, possibly reflecting a  
response to self antigens triggered by the injury. In the  
injured optic nerves, T-cell accumulation was significantly  
increased by 5- to 6-fold) in rats injected with anti-OVA,  
anti-hsp60, or anti-MBP T-cells. These observations  
25 confirmed our previous finding that axonal injury in the CNS  
is accompanied by the accumulation of endogenous T-cells and  
that this accumulation is augmented by systemic injection of  
activated T-cells irrespective of their antigenic  
specificity.

30

### 7.2.2 PROTECTION OF SECONDARY NERVE DEGENERATION BY MBP SPECIFIC T-CELLS

The course of secondary degeneration as a result of the  
injected T-cells was then examined. Previous studies have  
35 shown that a time lapse of 2 weeks between a crush injury (of  
similar severity to the present one) and dye application is  
optimal for demonstrating differences (in terms of the

numbers of still-viable, i.e. labeled, neurons) in degeneration with and without neuroprotection. As shown in Fig. 8, in retinas of injured nerves that were subjected to dye application 2 weeks after injury and excised a week  
5 later, the number of labeled ganglion cells (reflecting still-viable axons) was about 2.5-fold greater in animals injected at the time of injury, with T-cells specific to MBP (primed against P51-70) than with PBS. In contrast, labeled ganglion cells in the retinas of rats injected with anti-OVA  
10 or anti-hsp60 T-cells were not significantly more numerous than in the retinas of rats injected with PBS. Fig. 9 represents micrographs of retrogradeably labeled retinas of injured optic nerves of rats injected with PBS, anti-hsp60 T-cells, or anti-MBP T-cells.

15 Since only the anti-MBP T-cells showed a neuroprotective effect, and as hsp60, like MBP, is a self antigen which is expressed in injured tissues including EAE lesions, it was interesting to find out whether the protective effect of the anti-MBP T-cells is a function of their aggressiveness in  
20 causing an autoimmune disease. If so, this would explain the lack of a protective effect by hsp60, which is also a self antigen, but, unlike MBP, is not restricted to the CNS and the T-cells specific to it do not cause a disease. To explore the possibility of a connection between the observed  
25 neuroprotective effect and autoimmune disease, the effect of T-cells generated against an epitope in MBP (P51-70) that does not cause an autoimmune disease was examined. As shown in Fig. 10, the neuroprotective effect of these non-aggressive anti-MBP T-cells was similar to that of the anti-  
30 MBP T-cells that cause autoimmune diseases. It thus seems that the observed beneficial effect of the T-cells on secondary degeneration is not common to all self antigens, but in this study is restricted to NS-specific antigens. Furthermore, T-cells activated with a fragment of a NS-  
35 specific antigen that does not cause autoimmune disease were substantially as effective in inhibiting secondary

degeneration as T-cells activated with full-length NS-specific antigen that does cause autoimmune disease.

### 7.2.3 CLINICAL SEVERITY OF EAE

5        Animals were injected i.p. with  $10^7$  T<sub>MBP</sub> cells with or without concurrent optic nerve crush injury. The clinical course of the rats injected with the T<sub>MBP</sub> cells was evaluated according to the neurological paralysis scale. Each group contained 5-9 rats. As can be seen in Fig. 11, the course  
10 and degree of the EAE was not affected by whether or not the rats had been subjected to an optic nerve crush.

### 7.2.4 SURVIVAL OF RGCs IN NON-INJURED NERVES

Animals were injected i.p. with  $10^7$  T<sub>MBP</sub> cells or PBS.  
15 Two weeks later, 4-Di-10-Asp was applied to the optic nerves. After five days the retinas were excised and flat mounted. Labeled RGCs from five fields, in each retina were counted and their average number per mm<sup>2</sup> was calculated.

As can be seen in Fig. 12, there is no difference in the  
20 number of surviving RGCs in non-injured optic nerves of rats injected with anti-MBP T-cells compared to rats injected with PBS.

## 25 8. EXAMPLE: NEUROPROTECTIVE EFFECTS OF NS-SPECIFIC ANTIGEN

### 8.1 MATERIALS AND METHODS

Animals, crush injury of rat optic nerve, and retrograde labeling are described above in Sections 6 and 7. A peptide based on amino acids 35-55 of myelin/oligodendrocyte  
30 glycoprotein (MOG p35-55) was chemically synthesized at the Weizmann Institute, Israel.

#### 8.1.1 INHIBITION OF SECONDARY DEGENERATION

Rats were injected intradermally in the footpads with  
35 MOG p35-55 (50 µg/animal) and IFA, or PBS ten days prior to optic nerve crush injury. Retinal ganglion cells were assessed two weeks after injury using retrograde labeling as

described above. The number of RGCs in rats injected with PBS or MOG p35-55 was expressed as a percentage of the total number of neurons in rats injected with MOG p35-55 in the absence of crush injury.

5

## 8.2 RESULTS

As shown in Fig. 13, the number of labeled ganglion cells (indicating viable axons) was about 12.5 fold greater in animals injected with MOG p35-55 compared to animals receiving PBS.

10

## 9. EXAMPLE: NEUROPROTECTIVE EFFECTS OF MBP ADMINISTERED ORALLY

### 9.1 MATERIALS AND METHODS

Animals, crush injury of rat optic nerve, and retrograde labeling of RGCs are described above in Sections 6 and 7.

15

#### 9.1.1 INHIBITION OF SECONDARY DEGENERATION

Bovine MBP (Sigma, Israel) (1 mg/dose) was administered to rats by gavage using a blunt needle. MBP was administered 5 times, every third day, beginning 2 weeks prior to optic nerve crush injury. The number of RGCs in treated animals was expressed as a percentage of the total number of neurons in animals subjected to optic nerve crush injury but which did not receive MBP.

20

25

## 9.2 RESULTS

As shown in Fig. 14, the number of labeled RGCs was about 1.3 fold greater in animals treated with MBP compared to untreated animals.

30

## 10. DISCUSSION

The results of the experiments described in Sections 6 and 7 show that activated T-cells accumulate at a site of injury in the CNS. Furthermore, the results also demonstrate that the accumulation of T-cells at the site of injury is a non-specific process, i.e., T-cells which accumulated at the

35

site of injury included both T-cells which are activated by exposure to an antigen present at the site of injury as well as T-cells which are activated by an antigen not normally present in the individual.

5       The results of experiments described in Section 7 demonstrate that the beneficial effects of T-cells in ameliorating damage due to injury in the CNS are associated with a NS-specific self-antigen as illustrated by MBP. More specifically, the administration of non-recombinant T-cells  
10 which were activated by exposure to an antigen which causes autoimmune disease ( $T_{MBP}$ ), rather than aggravating the injury, led to a significant degree of protection from secondary degeneration. Thus, activating T-cells by exposure to a fragment of a NS-specific antigen was beneficial in limiting  
15 the spread of injury in the CNS. The present findings show that secondary degeneration can be inhibited by the transfer into the individual of T-cells which recognize a NS-specific self antigen which is present at a site of injury.

20       In addition, the studies described in Sections 8 and 9 show that activation of T-cells by administering an immunogenic antigen (e.g. MBP) or immunogenic epitope of an antigen (e.g. MOG p35-55), may be used for preventing or inhibiting secondary CNS degeneration following injury.

25       The present application claims priority benefits of Israeli patent application IL 124550, filed May 19, 1998, the disclosure of which is incorporated herein by reference in its entirety.

30       The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and  
35 accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.



All publications cited herein are incorporated by reference in their entirety.

5

10

15

20

25

30

35

WHAT IS CLAIMED IS:

1. A method for delivering a therapeutic or detectable substance to a site of injury or disease of the central nervous system (CNS), comprising administering activated T-cells that do not recognize a nervous system specific (NS-specific) antigen in which the activated T-cells contain or express a therapeutic or detectable substance to a mammal.

10

2. The method according to claim 1 in which said activated T-cells are generated by exposing T-cells to a cognate non-self antigen or a mitogen.

15

3. The method according to claim 1 in which said activated T-cells endogenously produce said substance.

4. The method according to claim 1 in which said activated T-cells are T-cells that have been genetically-engineered to express said therapeutic substance or to express an enzyme which catalyzes production of said therapeutic substance or to express a regulatory product, that induces production of said therapeutic substance.

20

5. The method according to claim 1 in which said injury comprises blunt trauma, penetrating trauma, hemorrhagic stroke, or ischemic stroke.

6. The method according to claim 1 in which said disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, glaucoma, Huntington's disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.

25

7. A recombinant T-cell comprising a promoter operably linked to a nucleotide sequence that encodes a protein that ameliorates the effects of an injury or disease

of the central nervous system (CNS) wherein the recombinant T-cells do not recognize a nervous system specific (NS-specific) antigen.

5                   8. A method for delivering a substance to a site of injury or disease of the CNS, comprising administering to a mammal the recombinant T-cell of claim 7.

9. The method according to claim 1 or 8 in which  
10 said mammal is a human.

10. The method according to claim 8 in which said recombinant T-cell is produced using an autologous T-cell.

15                   11. A method for detecting a site of injury or disease of the central nervous system (CNS) in a mammal, comprising:

- 20                   a) administering to a mammal an effective amount of labeled activated T-cells that do not recognize a nervous system specific (NS-specific) antigen; and
- 25                   b) detecting in the mammal the labeled activated T-cells that have accumulated at said site of injury or disease, in which step (b) is performed after an interval sufficient to permit said labeled activated T-cells administered in step (a) to accumulate at said site of injury or disease.

30                   12. The method according to claim 11 in which the mammal is a human.

13. The method according to claim 1, 8 or 11 in which the activated T-cells recognize a non-self antigen.

35                   14. The method according to claim 11 in which the detectable substance is detected in vivo.

15. The method of claim 11 in which the labeled activated T-cells are labeled with a radioisotope or a contrast agent.

5           16. The method of claim 1, 8 or 11 in which the labeled activated T-cells are administered intravenously or intraperitoneally.

10           17. A method for preventing or inhibiting degeneration in the central nervous system (CNS) of a mammal comprising administering non-recombinant, NS-specific antiseft activated T-cells in which said activated T-cells ameliorate the effects of injury or disease.

15           18. A method for preventing or inhibiting degeneration in the central nervous system (CNS) of a mammal comprising administering an effective amount of a NS-specific antigen.

20           19. The method according to claim 18 in which said NS-specific antigen activates T-cells *in vivo* resulting in a population of T-cells that accumulate at a site of injury or disease of the CNS.

25           20. The method according to claim 18 in which said NS-specific antigen is administered intravenously, intraperitoneally, orally, nasally or buccally.

30           21. The method according to claim 2 in which said T-cells are autologous.

35           22. A pharmaceutical composition comprising isolated, activated T-cells that do not recognize a nervous system specific (NS-specific) antigen in which the activated T-cells contain an exogenously added detectable substance or contain a therapeutic substance or express a recombinant

substance having a therapeutic effect when administered in vivo to a mammal; and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a  
5 therapeutically effective amount of an isolated, NS-specific antigen; and a pharmaceutically acceptable carrier.

24. Use of an active ingredient comprising non-recombinant NS-specific antiseif T-cells or a NS-specific  
10 antigen, for the preparation of a pharmaceutical composition for the treatment of a human condition or disease of the CNS.

25. Use according to claim 24 in which the untreated human condition or disease results in central  
15 nervous system degeneration.

26. Use of an active ingredient comprising recombinant, activated T-cells that do not recognize a nervous system specific (NS-specific) antigen, for the  
20 preparation of a pharmaceutical composition for the treatment of a human condition or disease of the CNS.

25

30

35

## AMENDED CLAIMS

[received by the International Bureau on 21 December 1998 (21.12.98);  
original claims 1-26 replaced by new claims 1-32 (5 pages)]

1. A method for delivering a therapeutic or detectable substance to a site of injury or disease of the central nervous system (CNS), comprising administering to a mammal activated T-cells that do not recognize a nervous system specific (NS-specific) antigen in which the activated T-cells contain or express a therapeutic or detectable substance.
2. The method according to claim 1 in which said activated T-cells are generated by exposing T-cells to a non-self antigen or a mitogen.
3. The method according to claim 1 in which said activated T-cells endogenously produce said therapeutic substance.
4. The method according to claim 1 in which said activated T-cells are T-cells that have been genetically-engineered to express said therapeutic substance or to express an enzyme which catalyzes production of said therapeutic substance or to express a regulatory product, that induces production of said therapeutic substance.
5. The method according to claim 4 in which the genetically engineered T-cells express said therapeutic substance or enzyme or regulatory product under the control of necessary elements for transcription or translation continuously or after induction.
6. The method according to claim 1 in which said injury comprises blunt trauma, penetrating trauma, trauma sustained during a neurosurgical operation, hemorrhagic stroke, or ischemic stroke.
7. The method according to claim 1 in which said disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, glaucoma, optic nerve injury accompanying optic neuropathy, Huntington's disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.

8. A recombinant T-cell comprising a promoter operably linked to a nucleotide sequence that encodes a protein that ameliorates the effects of an injury or disease of the central nervous system (CNS) wherein the recombinant T-cells do not recognize a nervous system specific (NS-specific) antigen.

5

9. The recombinant T-cell according to claim 8 in which the protein is a therapeutic substance or an enzyme which catalyzes production of said therapeutic substance or a regulatory product, that induces production of a therapeutic substance.

10

10. A method for delivering a substance to a site of injury or disease of the CNS, comprising administering to a mammal the recombinant T-cell of claim 8.

11. The method according to claim 1 or 10 in which said mammal is a human.

15

12. The method according to claim 10 in which said recombinant T-cell is produced using an autologous T-cell.

20

13. A method for detecting a site of injury or disease of the central nervous system (CNS) in a mammal, comprising:

a) administering to a mammal an effective amount of labeled activated T-cells that do not recognize a nervous system specific (NS-specific) antigen; and

25

b) detecting in the mammal the labeled activated T-cells that have accumulated at said site of injury or disease, in which step (b) is performed after an interval sufficient to permit said labeled activated T-cells administered in step (a) to accumulate at said site of injury or disease.

30

14. The method according to claim 13 in which the mammal is a human.

15. The method according to claim 1, 10 or 13 in which the activated T-cells recognize a non-self antigen.

16. The method of claim 13 in which the labeled activated T-cells are  
5 labeled with a radioisotope, a contrast agent or fluorescence-emitting metal.

17. The method of claim 1, 10 or 13 in which the activated T-cells are administered intravenously, intraperitoneally, intramuscularly or subcutaneously.

10 18. The method according to claim 2 in which said T-cells are autologous.

19. A pharmaceutical composition comprising isolated, activated T-cells that do not recognize a nervous system specific (NS-specific) antigen for use to deliver a  
15 therapeutic or detectable substance in which the activated T-cells contain a therapeutic substance or express a recombinant substance having a therapeutic effect or contain an exogenously added detectable substance when administered *in vivo* to a mammal; and a pharmaceutically acceptable carrier.

20 20. The pharmaceutical composition according to claim 19 in which said activated T-cells are generated by exposing T-cells to a non-self antigen or a mitogen.

21. The pharmaceutical composition according to claim 19 in which said activated T-cells endogenously produce said therapeutic substance.  
25

22. The pharmaceutical composition according to claim 19 in which said activated T-cells are T-cells that have been genetically-engineered to express said therapeutic substance or to express an enzyme which catalyzes production of said therapeutic substance or a regulatory product, that induces production of said therapeutic  
30 substance.



23. The pharmaceutical composition according to claim 19 in which said activated T-cells express said therapeutic substance or enzyme or regulatory product under the control of necessary elements for transcription or translation continuously or after induction.

5

24. The pharmaceutical composition according to claim 19 in which said activated T-cells are used to treat injury comprising blunt trauma, penetrating trauma, penetrating trauma, trauma sustained during a neurosurgical operation, hemorrhagic stroke, or ischemic stroke.

10

25. The pharmaceutical composition according to claim 19 in which said activated T-Cells are used to treat disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, glaucoma, optic nerve injury accompanying optic neuropathy, Huntington's disease, amyotrophic lateral sclerosis, and Creutzfeldt-

15 Jakob disease.

26. Use of an active ingredient comprising activated T-cells that do not recognize a nervous system specific (NS-specific) antigen, for the preparation of a pharmaceutical composition for the treatment or detection of a human condition or disease of the CNS.

20

27. The use according to claim 26 in which said activated T-cells are generated by exposing T-cells to a non-self antigen or a mitogen.

25

28. The use according to claim 26 in which said activated T-cells endogenously product said therapeutic substance.

30

29. The use according to claim 26 in which said activated T-cells are T-cells that have been genetically-engineered to express said therapeutic substance or to express an enzyme which catalyzes production of said therapeutic substance or to express a regulatory product, that induces production of said therapeutic substance.

30. The use according to claims 26 in which said activated T-cells express said therapeutic substance or enzyme or regulatory product under the control of necessary elements for transcription or translation continuously or after induction.

5 31. The use according to claim 26 in which said activated T-cells are used to treat injury comprising blunt trauma, penetrating trauma, trauma sustained during a neurosurgical operation, hemorrhagic stroke, or ischemic stroke.

10 32. The use according to claim 26 in which said activated T-cells are used to treat disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, glaucoma, optic nerve injury accompanying optic neuropathy, Huntington's disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease.

15

20

25

30

1/13




FIG.1




FIG.2

2/13



FIG.3

3/13




FIG. 4

4/13





FIG.5

5/13



6/13




FIG.7



7/13





FIG.8

8/13



160 μm

FIG. 9C



FIG. 9B




FIG. 9A




FIG.10

10/13




FIG.11

11/13




FIG.12

12/13




FIG. 13

13/13




FIG.14

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/14715

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 39/35, 45/00; A01N 63/00

US CL :424/184.1, 93.1, 93.2, 93.71, 278.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 93.1, 93.2, 93.71, 278.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, CAPLUS, WPIDS, APS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LOHSE ET AL. Control of Experimental Autoimmune Encephalomyelitis by T Cells Responding to Activated T Cells. Science. 19 May 1989, Vol. 244, pages 820-822, see entire document.	1-26
Y	YUEN ET AL. Immunoregulatory CD8+ Cells Recognize Antigen-Activated CD4+ Cells in Myasthenia Gravis Patients and in Healthy Controls. J. Immunol. 1995, Vol. 154, No. 3, pages 1508-1520, see entire document.	1-26
Y	LOHSE ET AL. Inhibition of the Mixed Lymphocyte Reaction by T Cell Vaccination. Eur. J. Immunol. November 1990, Vol. 20, pages 2521-2524, see entire document.	1-26

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 SEPTEMBER 1998

Date of mailing of the international search report

22 OCT 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EVELYN RABIN

Telephone No. (703) 308-0196



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/14715

## C. (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LOHSE ET AL. Induction of the Anti-ergotype Response. International Immunology. May 1993, Vol. 5, No. 5, pages 533-539, see entire document.	1-26
Y	BROD ET AL. Autologous T-T Cell Activation Mediated by Cell Adhesion Molecules. FASEB J. 1989, Vol. 3, No. 3, page A514, see entire abstract.	1-26